US20030232082A1 - Modified release dosage forms - Google Patents
Modified release dosage forms Download PDFInfo
- Publication number
- US20030232082A1 US20030232082A1 US10/393,638 US39363803A US2003232082A1 US 20030232082 A1 US20030232082 A1 US 20030232082A1 US 39363803 A US39363803 A US 39363803A US 2003232082 A1 US2003232082 A1 US 2003232082A1
- Authority
- US
- United States
- Prior art keywords
- shell
- core
- dosage form
- active ingredient
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/02—Apparatus specially adapted for manufacture or treatment of sweetmeats or confectionery; Accessories therefor
- A23G3/04—Sugar-cookers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/50—Cocoa products, e.g. chocolate; Substitutes therefor characterised by shape, structure or physical form, e.g. products with an inedible support
- A23G1/54—Composite products, e.g. layered laminated, coated, filled
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/0002—Processes of manufacture not relating to composition and compounding ingredients
- A23G3/0004—Processes specially adapted for manufacture or treatment of sweetmeats or confectionery
- A23G3/0019—Shaping of liquid, paste, powder; Manufacture of moulded articles, e.g. modelling, moulding, calendering
- A23G3/0025—Processes in which the material is shaped at least partially in a mould in the hollows of a surface, a drum, an endless band, or by a drop-by-drop casting or dispensing of the material on a surface, e.g. injection moulding, transfer moulding
- A23G3/0029—Moulding processes for hollow products, e.g. opened shell
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
- A23G3/54—Composite products, e.g. layered, coated, filled
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/005—Coating of tablets or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2873—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B30—PRESSES
- B30B—PRESSES IN GENERAL
- B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
- B30B11/02—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using a ram exerting pressure on the material in a moulding space
- B30B11/08—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using a ram exerting pressure on the material in a moulding space co-operating with moulds carried by a turntable
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B30—PRESSES
- B30B—PRESSES IN GENERAL
- B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
- B30B11/34—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses for coating articles, e.g. tablets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B30—PRESSES
- B30B—PRESSES IN GENERAL
- B30B15/00—Details of, or accessories for, presses; Auxiliary measures in connection with pressing
- B30B15/30—Feeding material to presses
- B30B15/302—Feeding material in particulate or plastic state to moulding presses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
Definitions
- This invention relates to modified release dosage forms such as modified release pharmaceutical compositions, and methods of providing predetermined active ingredient concentrations, which may be substantially constant or substantially non-constant, over an extended period of time, using such dosage forms. More particularly, this invention relates to modified release dosage forms for delivering one or more active ingredients in a controlled or delayed manner upon contacting of the dosage form with a liquid medium.
- the dosage form contains at least one active ingredient, and has a core and a shell. At least a portion of the shell is semipermeable to a liquid medium such as the gastro-intestinal (GI) fluids of a patient, such that the liquid medium diffuses through the semipermeable shell or shell portion to the core, for example due to osmosis.
- the shell or shell portion also provides for delivery of active ingredient to the liquid medium outside of the dosage form after the dosage form is contacted with the liquid medium.
- GI gastro-intestinal
- Modified release pharmaceutical dosage forms have long been used to optimize drug delivery and enhance patient compliance, especially by reducing the number of doses of medicine the patient must take in a day.
- the rate at which an orally delivered pharmaceutical active ingredient reaches its site of action in the body depends on a number of factors, including the rate and extent of drug absorption through the GI mucosa.
- the drug To be absorbed into the circulatory system (blood), the drug must first be dissolved in the GI fluids.
- diffusion across the GI membranes is relatively rapid compared to dissolution.
- the dissolution of the active ingredient is the rate limiting step in drug absorption, and controlling the rate of dissolution allows the formulator to control the rate of drug absorption into the circulatory system of a patient.
- modified release dosage forms provide a desired blood concentration versus time (pharmacokinetic, or PK) profile for the drug.
- PK profile for a drug is governed by the rate of absorption of the drug into the blood, and the rate of elimination of the drug from the blood.
- the type of PK profile desired depends, among other factors, on the particular active ingredient, and physiological condition being treated.
- a particularly desirable PK profile for a number of drugs and conditions is one in which the level of drug in the blood is maintained essentially constant (i.e. the rate of drug absorption is approximately equal to the rate of drug elimination) over a relatively long period of time.
- Such systems have the benefit of reducing the frequency of dosing, improving patient compliance, as well as minimizing side effects while maintaining full therapeutic efficacy.
- a dosage form which provides a “zero-order,” or constant release rate of the drug is useful for this purpose. Since zero-order release systems are difficult to achieve, systems which approximate a constant release rate, such as for example first-order and square root of time profiles are often used to provide sustained (e.g. prolonged, extended, or retarded) release of a drug.
- Another particularly desirable PK profile is an “ascending blood level” profile. This is achieved when the rate of absortion of drug into the blood (circulation) exceeds its rate of elimination from the blood for a period of time, producing an increasing blood level ofer the course of the dosing interval or a portion thereof.
- This type of PK profile is exemplified in PCT Publication No. WO99/62946.
- Another particularly desirable PK profile is achieved by a dosage form that delivers a delayed release dissolution profile, in which the release of one or more doses of drug from the dosage form is delayed for a pre-determined time after contact with a liquid medium, e.g. ingestion by the patient.
- the delay period (“lag time”) can be followed either by prompt release of the active ingredient (“delayed burst”), or by sustained (prolonged, extended, or retarded) release of the active ingredient (“delayed then sustained”).
- One particularly desirable type of delayed release PK profile is a “pulsatile” profile, in which for example, a first dose of a first drug is delivered, followed by a delay period during which there is substantially no release of the first drug from the dosage form, followed by either prompt or sustained release of a subsequent dose of the same drug.
- the first dose is released essentially immediately upon contacting of the dosage form with a liquid medium.
- the delay period corresponds approximately to the time during which a therapeutic concentration of the first dose is maintained in the blood.
- Pulsatile delivery systems are particularly useful for applications where a continuous release of drug is not ideal. Examples of this are drugs exhibiting first pass metabolism by the liver, drugs that induce biological tolerance (i.e. the therapeutic effect decreases with continuous presence of the drug at the site of action), and drugs whose efficacy is influenced by circadian rhythms of body functions or diseases.
- a pharmaceutical dosage form it is also particularly desirable for a pharmaceutical dosage form to deliver more than one drug at a modified rate. Because the onset and duration of the therapeutic efficacy of drugs vary widely, as do their absorption, distribution, metabolism, and elimination, it is often desirable to modify the release of different drugs in different ways, or to have a first active ingredient immediately released from the dosage form, while a second drug is released in a delayed, controlled, sustained, prolonged, extended, or retarded manner.
- Well known mechanisms by which a dosage form (or drug delivery system) can deliver drug at a controlled rate include diffusion, erosion, and osmosis.
- One classic diffusion-controlled release system comprises a “reservoir” containing the active ingredient, surrounded by a “membrane” through which the active ingredient must diffuse to be absorbed into the bloodstream of the patient.
- the rate of drug release, dM/dt depends on the area (A) of the membrane, the diffusional pathlength (1), the concentration gradient (AC) of the drug across the membrane, the partition coefficient (K) of the drug into the membrane, and the diffusion coefficient (D) according to the following equation:
- diffusion-controlled systems generally deliver a non-constant release rate.
- rate of drug release from diffusion-controlled release systems typically follows first order kinetics.
- Another common type of diffusion-controlled release system comprises active ingredient, distributed throughout an insoluble porous matrix through which the active ingredient must diffuse to be absorbed into the bloodstream of the patient.
- the amount of drug release (M) at a given time at sink conditions i.e. drug concentration at the matrix surface is much greater than drug concentration in the bulk solution
- the amount of drug release (M) at a given time at sink conditions depends on the area (A) of the matrix, the diffusion coefficient (D), the porosity (E) and tortuosity (T) of the matrix, the drug solubility (Cs) in the dissolution medium, time (t) and the drug concentration (Cp) in the dosage form according to the following equation:
- the amount of drug released is generally proportional to the square root of time. Assuming factors such as matrix porosity and tortuosity are constant within the dosage form, a plot of amount of drug released versus the square root of time should be linear.
- a commonly used erosion-controlled release system comprises a “matrix” throughout which the drug is distributed.
- the matrix typically comprises a material which swells at the surface, and slowly dissolves away layer by layer, liberating drug as it dissolves.
- the rate of drug release (dM/dt) in these systems depends on the rate of erosion (dx/dt) of the matrix, the concentration profile in the matrix, and the surface area (A) of the system according to the following equation:
- Another type of erosion controlled delivery system employs materials which swell and dissolve slowly by surface erosion to provide a delayed release of pharmaceutical active ingredient. Delayed release is useful, for example in pulsatile or repeat action delivery systems, in which an immediate release dose is delivered, followed by a pre-determined lag time before a subsequent dose is delivered from the system.
- the lag time (T 1 ) depends on the thickness (h) of the erodible layer, and the rate of erosion (dx/dt) of the matrix, which in turn depends on the swelling rate and solubility of the matrix components according to the following equation:
- dM/dt is generally described by either the diffusion-controlled or erosion-controlled equations above, and T 1 is the lag time.
- the modified release dosage forms of this invention act as osmotically controlled drug delivery systems.
- osmotically controlled drug delivery systems offer a number of advantages over conventional controlled release delivery systems.
- the basic principle of operation of osmotic drug delivery systems employs the difference in osmotic pressure between the exterior and interior of a dosage form which contains active ingredient.
- an active ingredient together with a suitable osmotic solute is contained within a core such as a compressed tablet, which is coated at least in part with a semipermeable membrane or shell having a small orifice therein.
- a core such as a compressed tablet
- a semipermeable membrane or shell having a small orifice therein.
- U.S. Pat. No. 3,995,631 discloses a system in which a semipermeable membrane houses a solution of an osmotically effective solute and a flexible bag of relatively impervious material which contains active ingredient.
- the flexible bag is provided with dispensing means for dispensing active ingredient out of the flexible bag when liquid permeates the membrane and exerts mechanical compressing or deflating force on the bag.
- U.S. Pat. No. 4,111,202 discloses a dosage form having a semipermeable wall which surrounds an active ingredient compartment and an osmagent compartment. The two compartments are separated by a moveable film which is impermeable to the active ingredient and osmagent.
- the semipermeable wall has a passageway therethrough for delivering active ingredient from its compartment. The system operates by having fluid imbibe through the wall into the osmagent compartment and causing the osmagent compartment to expand in volume and move the film, thereby diminishing the volume of the active ingredient compartment and delivering the active ingredient through the passageway.
- U.S. Pat. No. 4,327,725 discloses a system having a semipermeable outer wall which contains an active agent compartment and a fluid swellable hydrogel compartment.
- the semipermeable wall has a passageway therethrough for delivering active ingredient in solution from its compartment when the hydrogel absorbs fluid passing through the outer wall and the hydrogel swells.
- a precipitate forms at the interface of the hydrogel and active ingredient to restrict the passage of active ingredient into the hydrogel, and to act as an in situ formed membrane to apply pressure against the active ingredient in solution.
- U.S. Pat. No. 4,449,983 discloses a system in which a semipermeable wall contains first and second compartments which each contain a different active ingredient. Each of the compartments has an orifice which permits delivery of the active ingredient from each compartment, and the two compartments are separated by a hydrogel partition. The hydrogel absorbs fluid and swells, causing delivery of a solution of active ingredient through the respective compartment orifices.
- U.S. Pat. No. 4,627,971 discloses a device in which a semipermeable wall which surrounds a compartment containing a first layer containing an active ingredient and a second layer containing a hydrogel and means for sealing or closing a passageway by forming a film under the influence of thermo laser energy.
- a first passageway permits delivery of the active ingredient out of the compartment, and a second passageway formed during the manufacture of the device is adjacent to the hydrogel layer.
- Upon exposure of the means to thermo laser energy a film is formed and the second passageway is sealed.
- the hydrogel absorbs fluid and swells, causing delivery of a solution of active ingredient through the first passageway.
- U.S. Pat. No. 5,830,501 discloses a dosage form having a semipermeable wall which surrounds an internal compartment.
- the semipermeable wall contains at least one exit means such as a passageway, and the internal compartment contains an active ingredient, a flocculating hydrophilic polymer, a dehydrating agent, a surfactant, a swellable hydrophilic polymer, a lubricant, and an osmagent.
- the flocculating polymer precipitates and forms a floc containing the active ingredient.
- the swellable polymer and osmagent act as a push member to deliver the floc through the exit means.
- the floe lessens the tackiness and/or irritation of the mucosal tissue of the patient.
- U.S. Pat. No. 6,342,249 discloses a dosage form having a semipermeable wall with an exit orifice, in which the wall defines a cavity containing an active ingredient layer adjacent to the orifice and an expandable “push” layer remote from the orifice.
- the active ingredient layer contains a liquid active ingredient formulation absorbed in porous particles.
- a placebo layer to delay onset of delivery of the active ingredient may optionally be placed between the active ingredient layer and the exit orifice. When fluid permeates the semipermeable wall, the push layer expands to deliver the placebo (if employed) and particles containing active ingredient through the orifice.
- European Patent Publication No. 0384642 discloses a device for releasing active ingredient in a pulsed manner.
- the device comprises a water permeable or impermeable capsule containing an active ingredient and a water swellable material, in which the capsule has an opening which is closed by a water permeable plug.
- the water swellable material expands to eject the plug and deliver the active ingredient through the opening.
- the capsule may be made of a water impermeable material.
- the modified release dosage forms of this invention employ a core and a shell, which may optionally comprise multiple portions having different compositions and/or functions.
- the dosage forms of this invention are prepared by a novel method which enables at least portion of the shell to be semipermeable.
- current core-shell systems are limited by the available methods for manufacturing them, as well as the materials that are suitable for use with the current methods.
- a shell, or coating, which confers modified release properties is typically applied via conventional methods, such as for example, spray-coating in a coating pan. Pan-coating produces a single shell which essentially surrounds the core. The single shell is inherently limited in its functionality.
- pan-coating it is possible via pan-coating to apply multiple concentric shells, each with a different functionality, however such systems are limited in that the outer shell must first dissolve before the functionality conferred by each successive layer can be realized. It is also known, via pan coating, to deliver a first dose of active ingredient from a coating, and a second dose of active ingredient from a core. Dosage forms having sprayed coatings which provide delayed release are described, for example, in Maffione et al., “High-Viscosity HPMC as a Film-Coating Agent,” Drug Development and Industrial Pharmacy (1993) 19(16), pp. 2043-2053. U.S. Pat. No.
- 4,576,604 discloses an osmotic device (dosage form) comprising a drug compartment surrounded by a wall (coating) in which the coating may comprise an immediate release dose of drug, and the inner drug compartment may comprise a sustained release dose of drug.
- the coating compositions that can be applied via spraying are limited by their viscosity. High viscosity solutions are difficult or impractical to pump and deliver through a spray nozzle. Spray coating methods suffer the further limitations of being time-intensive and costly. Several hours of spraying may be required to spray an effective amount of coating to control the release of an active ingredient. Coating times of 8 to 24 hours are not uncommon.
- the invention provides a dosage form comprising (a) at least one active ingredient; (b) a core having an outer surface having an outer surface; and (c) a shell which resides upon at least a portion of the core outer surface, wherein at least a portion of the shell is semipermeable, at least about 30% of the cross-sectional area of the semipermeable shell portion is non-striated, and the shell comprises means for providing the active ingredient to a liquid medium outside the shell after contacting of the dosage form with the liquid medium.
- the invention also provides a dosage from comprising (a) at least one active ingredient; (b) a core having an outer surface; and (c) a shell which resides upon at least a portion of the core outer surface, wherein the shell comprises a first shell portion which is semipermeable to the liquid medium, and a second shell portion which is compositionally different than the first shell portion, the first and second shell portions each are substantially in contact with the core outer surface, and the shell comprises means for providing the active ingredient to a liquid medium outside the shell after contacting of the dosage form with the liquid medium.
- the invention further provides a dosage form comprising: (a) at least one active ingredient; (b) a core having an outer surface, a first core portion, a second core portion, and a third core portion located between the first and second core portions, wherein the third core portion comprises an osmopolymer; (c) and a shell which resides upon at least a portion of the core outer surface, in which the shell comprises a first shell portion which is semipermeable to the liquid medium, and a second shell portion which is compositionally different than the first shell portion, the first and second shell portions each are substantially in contact with the core outer surface, and at least one of the first or second shell portions has at least one passageway therein extending to the core outer surface.
- the invention also provides a dosage form comprising (a) at least one active ingredient; (b) a core having an outer surface; (c) and a shell which resides upon at least a portion of the core outer surface, in which the shell comprises a first shell portion which is semipermeable to the liquid medium, and a second shell portion which is compositionally different than the first shell portion, the first and second shell portions each are substantially in contact with the core outer surface, and the shell and core have a continuous cavity therein defining an interior surface, wherein neither the first shell portion nor the second shell portion extend substantially upon the interior surface.
- the invention further provides a dosage form comprising: (a) at least one active ingredient; (b) a core having an outer surface, a first core portion, a second core portion, and a third core portion located between the first and second core portions, wherein the third core portion comprises a osmopolymer; and (c) a shell which resides upon at least a portion of the core outer surface, in which the shell comprises a first shell portion which is semipermeable to the liquid medium, and a second shell portion which is compositionally different than the first shell portion, the first and second shell portions each are substantially in contact with the core outer surface, and the shell and core have a continuous cavity therein defining an interior surface, wherein neither the first shell portion nor the second shell portion extend substantially upon the interior surface.
- FIG. 1A depicts a cross-sectional side view of one embodiment of the dosage form of this invention.
- FIG. 1B depicts a cross-sectional side view of another embodiment of the dosage form of this invention.
- FIG. 2 depicts a cross-sectional side view of another embodiment of the dosage form of this invention.
- FIG. 3 depicts a cross-sectional side view of another embodiment of the dosage form of this invention.
- FIG. 4 depicts a cross-sectional side view of another embodiment of the dosage form of this invention.
- FIG. 5 depicts a cross-sectional side view of another embodiment of the dosage form of this invention.
- FIG. 6 depicts a cross-sectional side view of another embodiment of the dosage form of this invention.
- FIGS. 7A and 7B depict cross-sectional micrographs of a prior art coated composition.
- FIGS. 8A and 8B depict cross-sectional micrographs of an embodiment of this invention.
- FIG. 9 depicts the release profile of active ingredient for the dosage form of this invention described in Example 1 herein.
- the term “dosage form” applies to any solid object, semi-solid, or liquid composition designed to contain a specific pre-determined amount (dose) of a certain ingredient, for example an active ingredient as defined below.
- Suitable dosage forms include pharmaceutical drug delivery systems, including those for oral administration, buccal administration, rectal administration, topical or mucosal delivery, or subcutaneous implants, or other implanted drug delivery systems; or compositions for delivering minerals, vitamins and other nutraceuticals, oral care agents, flavorants, and the like.
- the dosage forms of the present invention are considered to be solid, however they may contain liquid or semi-solid components.
- the dosage form is an orally administered system for delivering a pharmaceutical active ingredient to the GI tract of a human.
- the dosage forms of this invention exhibit modified release of one or more active ingredients contained therein.
- the active ingredient or ingredients may be found within the core, the shell, or a portion or combination thereof.
- the term “modified release” shall apply to dosage forms, coatings, shells, cores, portions thereof, or compositions that alter the release of an active ingredient in any manner.
- the active ingredient or ingredients that are released in a modified manner may be contained within the coating, shell, core, composition, or portion thereof providing the modification.
- the modified release active ingredient may be contained in a different portion of the dosage form from the coating, shell, core, composition, or portion thereof providing the modification; for example the modified release active ingredient may be contained in a core portion, and the modification may be provided by the overlaying shell portion.
- Types of modified release include controlled, prolonged, sustained, extended, delayed, pulsatile, repeat action, and the like. Suitable mechanisms for achieving these types of modified release include diffusion, erosion, surface area control via geometry and/or impermeable barriers, or other mechanisms known in the art. Moreover, the modified release properties of the dosage form may be achieved through design of the core or a portion thereof, or the shell or portion thereof, or a combination of two or more of these parts of the dosage form.
- the dissolution profile of each active ingredient from the dosage form may be governed by a sum of contributions from the properties of the various portions. Additionally, a single portion, for example a core portion may possess a combination of erosional and diffusional properties. In any case, the dissolution rate of a particular active ingredient from the dosage form will be the sum of the contributions from all the various mechanisms contributed by the various portions of the dosage form which effect the release of that particular active ingredient
- the dosage forms of the present invention are designed to release substantially all (i.e. at least about 80%, or at least about 90%, say at least about 95%) of the active ingredient contained therein, within a specified amount of time.
- the total amount of time required for substantially all of the active ingredient(s) to be released from the dosage form shall be referred to as the “dosing interval.”
- the amount of drug released is typically measured at several time points.
- time interval shall refer to periods of time during the dosing interval, over which a periodic rate of release may be measured.
- the time interval may be the entire dosing interval, or a portion thereof.
- a drug “release rate” refers to the quantity of drug released from a dosage form per unit time, e.g., milligrams of drug released per hour (mg/hr). Drug release rates are calculated under in vitro dosage form dissolution testing conditions known in the art. As used herein, a drug release rate obtained at a specified time “following administration” refers to the in vitro drug release rate obtained at the specified time following implementation of an appropriate dissolution test.
- a “periodic release rate” refers to the quantity per unit time of drug released from a dosage form during a specified periodic interval as determined at the end of that specified periodic interval, i.e., at each periodic interval when a determination is made, the quantity per unit time of drug released represents the periodic release rate during that periodic interval.
- a “constant release rate” is obtained over a given time interval when the periodic release rates determined during two or more portions of the time interval are substantially the same, i.e. not more than 6% different.
- “non-constant release rate” shall mean two or more periodic release rates are not the same, i.e. more than 6% different, over the entire duration of the specified interval.
- sending blood level refers to the PK profile obtained when the rate of release of drug from the dosage form, and also its absorption into the bloodstream, exceeds its reate of elimination from the blood of a mammal for a period of time, producing an increasing blood level ofer the course of the dosing interval or a portion thereof.
- a “burst release” profile refers to a release profile which meets immediate release criteria during a specified interval.
- the specified interval may optionally follow a pre-determined lag time.
- FIG. 1A is a cross-sectional view of a dosage form 2 which comprises a core 4 and a shell 5 .
- shell 5 may reside upon a portion of core 4 without surrounding core 4 .
- shell 5 is semipermeable to a liquid medium, and at least about 30% of the cross-sectional area of the semipermeable shell 5 is non-striated as is discussed further herein.
- Core 4 contains at least one active ingredient, and shell 5 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained within core 4 .
- shell 5 contains passageway 12 which extends from the outer surface of shell 5 to the outer surface of core 4 , as shown.
- a plurality of passageways may be employed. Accordingly, upon contacting of dosage form 2 with a liquid medium, the liquid medium permeates shell 5 , reaches core 4 (where active ingredient, and optionally osmagent or osmopolymer, are contained), and liquid medium containing active ingredient is osmotically “pumped” through passageway 12 and out of dosage form 2 into the surrounding liquid medium.
- FIG. 11B is a cross-sectional view of a dosage form 22 which comprises a core 24 , a first shell portion 25 and a second shell portion 26 , which in this embodiment surround core 24 .
- first shell portion 25 or second shell portion 26 may reside upon a portion of core 24 without surrounding core 24 .
- First shell portion 25 is semipermeable to a liquid medium and second shell portion 26 is compositionally different than first shell portion 25 .
- second shell portion 26 is diffusible.
- Core 24 contains at least one active ingredient, and first shell portion 25 and/or second shell portion 26 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained within core 24 . Accordingly, upon contacting of dosage form 22 with a liquid medium, the liquid medium permeates first shell portion 25 , reaches core 24 (where active ingredient is contained), and liquid medium containing active ingredient is osmotically “pumped” through diffusible second shell portion 26 and out of dosage form 22 into the surrounding liquid medium.
- second shell portion 26 may be erodible, thereby permitting active ingredient to be released from the core 24 as second shell portion 26 erodes to expose core 24 to the liquid medium.
- FIG. 2 is a cross-sectional side view of a dosage form 202 which comprises a core 204 and a shell 206 having a first shell portion 208 which is semipermeable to the liquid medium, and a second shell portion 210 which is compositionally different than first shell portion 208 .
- second shell portion 210 may be diffusible, impermeable or erodible.
- Core 204 contains at least one active ingredient
- shell 206 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained within core 204 .
- first shell portion 208 contains passageway 212 which extends from the outer surface of first shell portion 208 to the outer surface of core 204 , as shown.
- first shell portion 208 may contain a plurality of passageways.
- first shell portion 208 is semipermeable, and second shell portion 210 is impermeable. Accordingly, upon contacting of dosage form 202 with a liquid medium, the liquid medium permeates first shell portion 208 , reaches core 204 (where active ingredient, and optionally osmagent or osmopolymer are contained), and liquid medium containing active ingredient is osmotically “pumped” through passageway 212 and out of dosage form 202 into the surrounding liquid medium.
- second shell portion 210 may contain at least one passageway which extends from the outer surface of second shell portion 210 to the outer surface of core 204 , or both first shell portion 208 and second shell portion 210 may each contain at least one passageway which extends from the outer surface of first shell portion 208 and second shell portion 210 , respectively, to the outer surface of core 204 .
- FIG. 3 is a cross-sectional side view of a dosage form 302 which comprises a core 304 having first core portion 303 and second core portion 305 , and shell 306 having a plurality of passageways 312 therein which extend from the outer surface of shell 306 to the outer surfaces of first and second core portions 303 and 305 .
- shell 306 may have a single passageway.
- Core 304 contains at least one active ingredient
- shell 306 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained within core 304 .
- At least a portion of shell 306 is semipermeable to a liquid medium, and at least about 30% of the cross-sectional area of the semipermeable portion of the shell is non-striated.
- the liquid medium permeates shell 306 , reaches first and second core portions 303 and 305 , respectively, (where active ingredient or ingredients, and optionally osmagent or osmopolymer are contained), and liquid medium containing active ingredient or ingredients is osmotically “pumped” through passageways 312 and out of dosage form 302 into the surrounding liquid medium.
- first core portion 303 contains a first active ingredient and second core portion 305 contains a second active ingredient which may be the same or different than the first active ingredient.
- first and second core portions 303 and 305 each contain a different dose or concentration of first and second active ingredients, which may be the same or different active ingredients.
- passageways 312 in shell 306 may expose different surface areas of the underlying core portions 303 and 305 , respectively, thereby permitting either different release rates for the first and second active ingredients, or the same release rate for the first and second active ingredients, if the first and second active ingredients have different solubilities.
- FIG. 4 is a cross-sectional side view of a dosage form 402 which comprises a core 404 having first core portion 403 , second core portion 405 , and third core portion 407 , and shell 406 comprising first and second shell portions 408 and 410 , respectively.
- a plurality of passageways 412 extend from the outer surface of shell 406 to the outer surfaces of first and second core portions 403 and 405 .
- shell 406 may have a single passageway located in either first shell portion 408 or second shell portion 410 .
- first shell portion 408 and second shell portion 410 are each semipermeable to a liquid medium.
- Second shell portion 410 may be compositionally different than first shell portion 408 .
- first shell portion 408 may be semipermeable, and second shell portion 410 may be diffusible, impermeable or erodible.
- Core 404 contains at least one active ingredient, and shell 406 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained within core 404 .
- FIG. 4 depicted in FIG.
- first core portion 403 contains a first active ingredient
- second core portion 405 contains a second active ingredient which may be the same or different than the first active ingredient
- third core portion 407 contains an osmopolymer which provides osmotic pressure upon contact with the liquid medium to push the active ingredients through the passageways 412 to the surface of shell 406 .
- the liquid medium permeates the first and second shell portions 408 and 410 , reaches first and second core portions 403 and 405 , respectively (where active ingredient or ingredients are contained), as well as third core portion 407 containing the osmopolymer (which swells and compresses against first and second core portions 403 and 405 ), and liquid medium containing active ingredient is osmotically “pumped” through passageways 412 and out of dosage form 402 into the surrounding liquid medium.
- passageways 412 in first and second shell portions 408 and 410 may expose different surface areas of the underlying core portions 403 and 405 , respectively, thereby permitting either different release rates for the first and second active ingredients, or the same release rate for the first and second active ingredients, if the first and second active ingredients have different solubilities.
- FIG. 5 is a cross-sectional side view of a dosage form 502 which comprises a core 504 and a shell 506 having a first shell portion 508 which is semipermeable to the liquid medium, and a second shell portion 510 which is compositionally different than first shell portion 508 .
- second shell portion 510 may be semipermeable, diffusible, impermeable or erodible, although in this embodiment second shell portion 510 is semipermeable.
- Core 504 contains at least one active ingredient
- shell 506 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained within core 504 .
- FIG. 5 is a cross-sectional side view of a dosage form 502 which comprises a core 504 and a shell 506 having a first shell portion 508 which is semipermeable to the liquid medium, and a second shell portion 510 which is compositionally different than first shell portion 508 .
- second shell portion 510 may be semipermeable, diffusible, impermeable
- cavity 501 extends through core 504 , first shell portion 508 and second shell portion 510 .
- the interior surface 513 of core 504 is defined by cavity 501 , and neither first shell portion 508 nor second shell portion 510 substantially extend upon interior surface 513 , thereby permitting active ingredient contained within core 504 to be released only through interior surface 513 .
- the diameter of the continuous cavity is preferably in the range of about 15 to about 90 percent of the thickness of the dosage form, and the diameter of the continuous cavity is preferably in the range of about 5 to about 30 percent of the core diameter.
- the length of the continuous cavity is typically about the same as the thickness of the dosage form, and the length of the continuous cavity is preferably about 25 to about 40 percent of the diameter of the dosage form.
- the liquid medium Upon contacting of dosage form 502 with a liquid medium, the liquid medium permeates interior surface 513 , as well as first and second shell portions 508 and 510 , reaches core 504 (where active ingredient is contained), and liquid medium containing active ingredient passes through interior surface 513 into central cavity 501 and out of dosage form 502 into the surrounding liquid medium.
- the predominant mechanism for drug release is erosion.
- FIG. 6 is a cross-sectional side view of a dosage form 602 which comprises a core 604 having first core portion 603 , second core portion 605 , and third core portion 607 , and a shell 606 having a first shell portion 608 which is semipermeable to the liquid medium, and a second shell portion 610 which is compositionally different than first shell portion 608 .
- second shell portion 610 may be semipermeable, diffusible, impermeable or erodible, although in this embodiment second shell portion 610 is semipermeable.
- Core 604 contains at least one active ingredient, and shell 606 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained within core 604 .
- cavity 601 extends through core 604 , first shell portion 608 and second shell portion 610 .
- the interior surface 613 of core 604 is defined by cavity 601 , and neither first shell portion 608 nor second shell portion 610 substantially extend upon interior surface 613 , thereby permitting active ingredient contained within core 604 to be released only through interior surface 613 .
- first core portion 603 contains a first active ingredient
- second core portion 605 contains a second active ingredient which may be the same or different than the first active ingredient
- third core portion 607 contains a osmopolymer which provides osmotic pressure upon contact with the liquid medium to push the active ingredients through the interior surface 613 and into the liquid medium.
- the diameter of the continuous cavity is preferably in the range of about 15 to about 90 percent of the thickness of the dosage form, and the diameter of the continuous cavity is preferably in the range of about 5 to about 30 percent of the core diameter.
- the length of the continuous cavity is typically about the same as the thickness of the dosage form, and the length of the continuous cavity is preferably about 25 to about 40 percent of the diameter of the dosage form.
- the liquid medium Upon contacting of dosage form 602 with the liquid medium, the liquid medium permeates interior surface 613 , as well as the first and second shell portions 608 and 610 , respectively, reaches first core portion and second core portions 603 and 605 , respectively, (where active ingredient or ingredients are contained) as well as third core portion 607 containing the osmopolymer (which swells and compresses against first core portion 603 and second core portion 605 ), and liquid medium containing the active ingredient or ingredients passes through interior surface 613 into central cavity 601 and out of dosage form 602 into the surrounding liquid medium.
- the predominant mechanism for drug release is erosion.
- each shell portion must be substantially in contact with the outer surface of the core, as depicted, for example, in FIGS. 1B, 2, 4 , 5 and 6 . Accordingly, in such embodiments, the inner surface of any shell portion does not reside upon the outer surface of any other shell portion.
- Suitable active ingredients for use in this invention include for example pharmaceuticals, minerals, vitamins and other nutraceuticals, oral care agents, flavorants and mixtures thereof.
- suitable pharmaceuticals include analgesics, anti-inflammatory agents, antiarthritics, anesthetics, antihistamines, antitussives, antibiotics, anti-infective agents, antivirals, anticoagulants, antidepressants, antidiabetic agents, antiemetics, antiflatulents, antifungals, antispasmodics, appetite suppressants, bronchodilators, cardiovascular agents, central nervous system agents, central nervous system stimulants, decongestants, oral contraceptives, diuretics, expectorants, gastrointestinal agents, migraine preparations, motion sickness products, mucolytics, muscle relaxants, osteoporosis preparations, polydimethylsiloxanes, respiratory agents, sleep-aids, urinary tract agents and mixtures thereof.
- Suitable oral care agents include breath fresheners, tooth whiteners, antimicrobial agents, tooth mineralizers, tooth decay inhibitors, topical anesthetics, mucoprotectants, and the like.
- Suitable flavorants include menthol, peppermint, mint flavors, fruit flavors, chocolate, vanilla, bubblegum flavors, coffee flavors, liqueur flavors and combinations and the like.
- Suitable gastrointestinal agents include antacids such as calcium carbonate, magnesium hydroxide, magnesium oxide, magnesium carbonate, aluminum hydroxide, sodium bicarbonate, dihydroxyaluminum sodium carbonate; stimulant laxatives, such as bisacodyl, cascara sagrada, danthron, senna, phenolphthalein, aloe, castor oil, ricinoleic acid, and dehydrocholic acid, and mixtures thereof; H2 receptor antagonists, such as famotadine, ranitidine, cimetadine, nizatidine; proton pump inhibitors such as omeprazole or lansoprazole; gastrointestinal cytoprotectives, such as sucraflate and misoprostol; gastrointestinal prokinetics, such as prucalopride, antibiotics for H.
- antacids such as calcium carbonate, magnesium hydroxide, magnesium oxide, magnesium carbonate, aluminum hydroxide, sodium bicarbonate, dihydroxyaluminum
- pylori such as clarithromycin, amoxicillin, tetracycline, and metronidazole; antidiarrheals, such as diphenoxylate and loperamide; glycopyrrolate; antiemetics, such as ondansetron, analgesics, such as mesalamine.
- the active ingredient may be selected from bisacodyl, famotadine, ranitidine, cimetidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, antacids, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
- the active ingredient is selected from analgesics, anti-inflammatories, and antipyretics, e.g. non-steroidal anti-inflammatory drugs (NSAIDs), including propionic acid derivatives, e.g. ibuprofen, naproxen, ketoprofen and the like; acetic acid derivatives, e.g. indomethacin, diclofenac, sulindac, tolmetin, and the like; fenamic acid derivatives, e.g. mefenamic acid, meclofenamic acid, flufenamic acid, and the like; biphenylcarbodylic acid derivatives, e.g.
- NSAIDs non-steroidal anti-inflammatory drugs
- the active ingredient is selected from propionic acid derivative NSAID, e.g. ibuprofen, naproxen, flurbiprofen, fenbufen, fenoprofen, indoprofen, ketoprofen, fluprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, and pharmaceutically acceptable salts, derivatives, and combinations thereof.
- NSAID e.g. ibuprofen, naproxen, flurbiprofen, fenbufen, fenoprofen, indoprofen, ketoprofen, fluprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, and pharmaceutically acceptable salts, derivatives, and combinations thereof.
- the active ingredient may be selected from acetaminophen, acetyl salicylic acid, ibuprofen, naproxen, ketoprofen, flurbiprofen, diclofenac, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
- the active ingredient may be selected from pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, astemizole, terfenadine, fexofenadine, loratadine, desloratadine, cetirizine, mixtures thereof and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
- Suitable polydimethylsiloxanes which include, but are not limited to dimethicone and simethicone, are those disclosed in U.S. Pat. Nos. 4,906,478, 5,275,822, and 6,103,260, the contents of each is expressly incorporated herein by reference.
- simethicone refers to the broader class of polydimethylsiloxanes, including but not limited to simethicone and dimethicone.
- the active ingredient is present in the dosage form in a therapeutically effective amount, which is an amount that produces the desired therapeutic response upon oral administration and can be readily determined by one skilled in the art. In determining such amounts, the particular active ingredient being administered, the bioavailability characteristics of the active ingredient, the dosing regimen, the age and weight of the patient, and other factors must be considered, as known in the art.
- the dosage form comprises about 2 to about 75 weight percent, for example, the dosage form may comprise about 5 to about 50 weight percent, say about 7 to about 25 weight percent of a combination of one or more active ingredients.
- the core comprises a total of at least about 25 weight percent, e.g. about 25 to about 75 weight percent (based on the weight of the core) of one or more active ingredients.
- the active ingredient may be present in the dosage form in any form.
- the active ingredient may be dispersed at the molecular level, e.g. melted or dissolved, within the dosage form, or may be in the form of particles, which in turn may be coated or uncoated.
- the particles typically have an average particle size of about 1-2000 microns. In one embodiment, such particles are crystals having an average particle size of about 1-300 microns. In another embodiment, the particles ate granules or pellets having an average particle size of about 50-2000 microns, preferably about 50-1000 microns, most preferably about 100-800 microns.
- the core may contain coated particles of one or more active ingredients, in which the particle coating confers a release modifying function, as is well known in the art.
- suitable release modifying coatings for particles are described in U.S. Pat. Nos. 4,173,626; 4,863,742; 4,980,170; 4,984,240; 5,286,497; 5,912,013; 6,270,805; and 6,322,819.
- Commercially available modified release coated active particles may also be employed. Accordingly, all or a portion of one or more active ingredients in the core may be coated with a release-modifying material.
- the active ingredient or ingredients are preferably capable of dissolution upon contact with a fluid such as water, gastric fluid, intestinal fluid or the like.
- a fluid such as water, gastric fluid, intestinal fluid or the like.
- the dissolution characteristics of one or more active ingredients are modified: e.g. controlled, sustained, extended, retarded, prolonged, delayed and the like.
- the modified release active ingredient or ingredients are contained in the core.
- the dosage form releases one or more active ingredients contained in the core at a substantially constant rate over a specified time interval.
- the dissolution characteristics of at least one active ingredient meets USP specifications for immediate release tablets containing the active ingredient.
- USP 24 specifies that in pH 5.8 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released therefrom within 30 minutes after dosing
- USP 24 specifies that in pH 7.2 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the ibuprofen contained in the dosage form is released therefrom within 60 minutes after dosing. See USP 24, 2000 Version, 19-20 and 856 (1999).
- the immediately released active ingredient is preferably contained in the shell or on the surface of the shell, e.g. in a further coating surrounding at least a portion of the shell.
- the core or core portions function as an eroding matrix from which dispersed active ingredient is liberated by the dissolution of successive layers of the matrix surface.
- the rate of active ingredient release from the core or core portion will depend on the dissolution rate of the matrix material.
- Particularly useful eroding matrix materials for providing surface erosion include those which first absorb liquid, then swell and/or gel prior to dissolving.
- the eroding matrix core or core portion preferably comprises a release-modifying compressible or moldable excipient selected from swellable erodible hydrophilic materials, pH-dependent polymers, insoluble edible materials, and combinations thereof.
- the core or core portions function as a diffusional matrix.
- the core portion preferably comprises active ingredient, distributed throughout an insoluble porous matrix, which contains pores or channels through which fluids can enter the core or core portion, and the active ingredient must diffuse to be released from the dosage form.
- the rate of active ingredient release from the core or core portion will depend upon the area (A) of the matrix, the diffusion coefficient (D), the porosity (E) and tortuosity (T) of the matrix, the drug solubility (Cs) in the dissolution medium, and the drug concentration (Cp) in the dosage form.
- the release of the active ingredient from the core or core portion may be described as controlled, prolonged, sustained, or extended.
- the contribution to active ingredient dissolution from the subject core portion may follow zero-order, first-order, or preferably square-root of time kinetics.
- the diffusional matrix core or core portion preferably comprises a pore former.
- the release of active ingredient may be further modified by the function of the surrounding shell or shell portion, as described above.
- the release of the active ingredient from the dosage form will be governed by the sum of all the contributions acting upon it, e.g. from the relevant core or core portion and shell or shell portions, and may be described as controlled, prolonged, sustained, extended, delayed, or pulsatile.
- the dissolution of active ingredient from the dosage form may follow zero-order, first-order, or square-root of time kinetics.
- the portions may comprise different materials, or be prepared by different methods, or both.
- a first core portion may be prepared by compression, and a second core portion may be prepared by molding.
- the core comprises multiple portions, which comprise different active ingredients or have different release-modifying properties, or both; and the shell comprises a corresponding number of multiple portions, which each cover a specific core portion in order to modify or further modify the release of one or more active ingredients contained within the respective core portion.
- the orientation of the components of the dosage forms of the present invention can be precisely controlled, when manufactured using the thermal cycle or thermal setting apparatus and described below.
- the dosage form comprises a core comprising a first core portion and a second core portion which are compositionally different, wherein at least one of the first or second core portions comprises an active ingredient; and a shell which surrounds the core and comprises a first shell portion and a second shell portion which are compositionally different, wherein at least one of the first or second shell portions confers a modification to the release of an active ingredient contained in the underlying core portion.
- the core or core portion of the present invention may be prepared by any suitable method, including for example compression and molding, and depending on the method by which it is made, typically comprises active ingredient and a variety of excipients (inactive ingredients which may be useful for conferring desired physical properties to the core).
- suitable excipients include fillers, binders, disintegrants, lubricants, glidants, and the like, as known in the art.
- the core preferably further comprises a release-modifying compressible excipient.
- Suitable fillers for use in making the core, or a portion thereof, by compression include water-soluble compressible carbohydrates such as sugars, which include dextrose, sucrose, maltose, and lactose, sugar-alcohols, which include mannitol, sorbitol, maltitol, xylitol, starch hydrolysates, which include dextrins, and maltodextrins, and the like, water soluble plastically deforming materials such as microcrystalline cellulose or other cellulosic derivatives, water-insoluble brittle fracture materials such as dicalcium phosphate, tricalcium phosphate and the like and mixtures thereof.
- water-soluble compressible carbohydrates such as sugars, which include dextrose, sucrose, maltose, and lactose
- sugar-alcohols which include mannitol, sorbitol, maltitol, xylitol
- starch hydrolysates which include dextrins, and
- Suitable binders for making the core, or a portion thereof, by compression include dry binders such as polyvinyl pyrrolidone, hydroxypropylmethylcellulose, and the like; wet binders such as water-soluble polymers, including hydrocolloids such as acacia, alginates, agar, guar gum, locust bean, carrageenan, carboxymethylcellulose, tara, gum arabic, tragacanth, pectin, xanthan, gellan, gelatin, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, inulin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, polyvinyl pyrrolidone, cellulosics, sucrose, starches, and the like; and derivatives and mixtures thereof.
- dry binders such as polyvinyl pyrrol
- Suitable disintegrants for making the core, or a portion thereof, by compression include sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, starches, microcrystalline cellulose, and the like.
- Suitable lubricants for making the core, or a portion thereof, by compression include long chain fatty acids and their salts, such as magnesium stearate and stearic acid, talc, glycerides and waxes.
- Suitable glidants for making the core, or a portion thereof, by compression include colloidal silicon dioxide, and the like.
- Suitable release-modifying compressible excipients for making the core, or a portion thereof, by compression include swellable erodible hydrophillic materials, insoluble edible materials, pH-dependent polymers, and the like.
- Suitable swellable erodible hydrophilic materials for use as release-modifying excipients for making the core, or a portion thereof, by compression include: water swellable cellulose derivatives, polyalkalene glycols, thermoplastic polyalkalene oxides, acrylic polymers, hydrocolloids, clays, gelling starches, and swelling cross-linked polymers, and derivatives, copolymers, and combinations thereof.
- suitable water swellable cellulose derivatives include sodium carboxymethylcellulose, cross-linked hydroxypropylcellulose, hydroxypropyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyisopropylcellulose, hydroxybutylcellulose, hydroxyphenylcellulose, hydroxyethylcellulose (HEC), hydroxypentylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, hydroxypropylethylcellulose.
- suitable polyalkalene glycols include polyethylene glycol.
- suitable thermoplastic polyalkalene oxides include poly (ethylene oxide).
- acrylic polymers include potassium methacrylatedivinylbenzene copolymer, polymethylmethacrylate, CARBOPOL (high-molecular weight cross-linked acrylic acid homopolymers and copolymers), and the like.
- suitable hydrocolloids include alginates, agar, guar gum, locust bean gum, kappa carrageenan, iota carrageenan, tara, gum arabic, tragacanth, pectin, xanthan gum, gellan gum, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, gelatin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan.
- Suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof.
- suitable gelling starches include acid hydrolyzed starches, swelling starches such as sodium starch glycolate, and derivatives thereof.
- suitable swelling cross-linked polymers include cross-linked polyvinyl pyrrolidone, cross-linked agar, and cross-linked carboxymethylcellose sodium.
- Suitable insoluble edible materials for use as release-modifying excipients for making the core, or a portion thereof, by compression include water-insoluble polymers, and low-melting hydrophobic materials.
- suitable water-insoluble polymers include ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers; and the like and derivatives, copolymers, and combinations thereof.
- Suitable low-melting hydrophobic materials include fats, fatty acid esters, phospholipids, and waxes.
- suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts.
- suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GLYCOWAX-932, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides.
- Suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid.
- suitable waxes include carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; and the like.
- Suitable pH-dependent polymers for use as release-modifying excipients for making the core, or a portion thereof, by compression include enteric cellulose derivatives, for example hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate; natural resins such as shellac and zein; enteric acetate derivatives such as for example polyvinylacetate phthalate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate; and enteric acrylate derivatives such as for example polymethacrylate-based polymers such as poly(methacrylic acid, methyl methacrylate) 1:2, which is commercially available from Rohm Pharma GmbH under the tradename EUDRAGIT S, and poly(methacrylic acid, methyl methacrylate) 1:1, which is commercially available from Rohm Pharma GmbH under the tradename EUDRAGIT L, and the like, and derivatives, salts, copolymers, and combinations thereof.
- Suitable pharmaceutically acceptable adjuvants for making the core, or a portion thereof, by compression include, preservatives; high intensity sweeteners such as aspartame, acesulfame potassium, sucralose, and saccharin; flavorants; colorants; antioxidants; surfactants; wetting agents; and the like and mixtures thereof
- the core or a portion thereof comprises at least one osmagent, an osmotically effective solute or osmotically effective compound that can be blended homogeneously or heterogeneously with the core constituents to form a push member, acting as osmotically effective solutes that are soluble in liquid medium imbibed into the core, and exhibit an osmotic pressure gradient across the semipermeable shell or shell portion against an exterior liquid medium.
- Osmagents useful in the present invention include compounds disclosed at col. 8, lines 18-35 of U.S. Pat. No. 5,830,501, which is incorporated herein by reference.
- the core or a portion thereof comprises at least one osmopolymer.
- the osmopolymer if employed, exhibits fluid absorbing and or fluid imbibing properties.
- the osmopolymer comprises a hydrophilic polymer that can interact with water and aqueous biological fluids and then swell or expand to an equilibrium state. The osmopolymer exhibits the ability to retain a significant portion of the imbibed or absorbed fluid.
- osmopolymers include poly(hydroxyalkyl methacrylate) having a molecular weight of 20,000 to 5,000,000; poly(vinylpyrrolidone) having a molecular weight of about 10,000 to 360,000; poly(vinylalcohol) having a low acetate content and lightly cross-linked with glyoxal, formaldehyde, or glutaraidehyde and having a degree of polymerization from 2,000 to 30,000; poly(ethylene oxide) having a molecular weight from 10,000 to 7,800,000; acidic carboxy polymers known as carboxypolymethylene or as carboxyvinyl polymers, a polymer consisting of acrylic acid lightly cross-linked with polyallylsucrose and sold under the trade name CARBOPOL, acidic carboxy polymer having a molecular weight of 200,000 to 6,000,000, including sodium acidic carboxyvinyl hydrogel and potassium acidic carboxyvinyl hydrogel; CYANAMER polyacrylamide; and the like.
- a dry blending i.e. direct compression
- wet granulation process may be employed.
- a dry blending (direct compression) method the active ingredient or ingredients, together with the excipients, are blended in a suitable blender, than transferred directly to a compression machine for pressing into tablets.
- a wet granulation method the active ingredient or ingredients, appropriate excipients, and a solution or dispersion of a wet binder (e.g. an aqueous cooked starch paste, or solution of polyvinyl pyrrolidone) are mixed and granulated.
- a wet binder e.g. an aqueous cooked starch paste, or solution of polyvinyl pyrrolidone
- a dry binder may be included among the excipients, and the mixture may be granulated with water or other suitable solvent.
- suitable equipment for wet granulation are known in the art, including low shear, e.g. planetary mixers; high shear mixers; and fluid beds, including rotary fluid beds.
- the resulting granulated material is dried, and optionally dry-blended with further ingredients, e.g. adjuvants and/or excipients such as for example lubricants, colorants, and the like.
- the final dry blend is then suitable for compression.
- Methods for direct compression and wet granulation processes are known in the art, and are described in detail in, for example, Lachman, et al., The Theory and Practice of Industrial Pharmacy , Chapter 11 (3rd ed. 1986).
- the dry-blended, or wet granulated, powder mixture is typically compacted into tablets using a rotary compression machine as known in the art, such as for example those commercially available from Fette America Inc. (Rockaway, N.J.), or Manesty Machines LTD (Liverpool, UK).
- a rotary compression machine a metered volume of powder is filled into a die cavity, which rotates as part of a “die table” from the filling position to a compaction position where the powder is compacted between an upper and a lower punch to an ejection position, where the resulting tablet is pushed from the die cavity by the lower punch and guided to an ejection chute by a stationary “take-off” bar.
- the core or core portion may be prepared by the compression methods and apparatus described in copending U.S. patent application Ser. No. 09/966,509, pages 16-27, the disclosure of which is incorporated herein by reference.
- the core is made using a rotary compression module comprising a fill zone, insertion zone, compression zone, ejection zone, and purge zone in a single apparatus having a double row die construction as shown in FIG. 6 of U.S. patent application Ser. No. 09/966,509.
- the dies of the compression module are preferably filled using the assistance of a vacuum, with filters located in or near each die.
- the purge zone of the compression module includes an optional powder recovery system to recover excess powder from the filters and return the powder to the dies.
- the core, or the shell, or a portion thereof is prepared by molding.
- the core, the shell or a portion of either one may be made by solvent-based or solvent-free molding.
- the core, or the shell, or a portion thereof is made from a flowable material optionally comprising an active ingredient.
- the flowable material may be any edible material that is flowable at a temperature between about 37° C. and 250° C., and that is solid, semi-solid, or can form a gel at a temperature between about ⁇ 10° C. and about 35° C.
- the flowable material may comprise a dispersed, dissolved, or molten component, and optionally a solvent such as for example water or organic solvents, or combinations thereof.
- the solvent may be partially or substantially removed by drying.
- solvent-based or solvent-free molding is performed via thermal setting molding using the method and apparatus described in copending U.S. patent application Ser. No. 09/966,450, pages 57-63, the disclosure of which is incorporated herein by reference.
- a core, shell, or portion thereof is formed by injecting flowable form into a molding chamber.
- the flowable material preferably comprises a thermal setting material at a temperature above its melting point but below the decomposition temperature of any active ingredient contained therein.
- the flowable material is cooled and solidifies in the molding chamber into a shaped form (i.e., having the shape of the mold).
- the flowable material may comprise solid particles suspended in a molten matrix, for example a polymer matrix.
- the flowable material may be completely molten or in the form of a paste.
- the flowable material may comprise an active ingredient dissolved in a molten material in the case of solvent-based molding.
- the flowable material may be made by dissolving a solid in a solvent, which solvent is then evaporated after the molding step in the case of solvent-based molding.
- solvent-based or solvent-free molding is performed by thermal cycle molding using the method and apparatus described in copending U.S. patent application Ser. No. 09/966,497, pages 27-51, the disclosure of which is incorporated herein by reference.
- Thermal cycle molding is performed by injecting a flowable material into a heated molding chamber.
- the flowable material may comprise active ingredient and a thermoplastic material at a temperature above the set temperature of the thermoplastic material but below the decomposition temperature of active ingredient.
- the flowable material is cooled and solidifies in the molding chamber into a shaped form (i.e., having the shape of the mold).
- thermal cycle molding module 200 comprises a rotor 202 around which a plurality of mold units 204 are disposed.
- the thermal cycle molding module includes a reservoir 206 (see FIG. 4) for holding flowable material to make the core.
- the thermal cycle molding module is provided with a temperature control system for rapidly heating and cooling the mold units.
- FIGS. 55 and 56 depict the temperature control system 600 .
- the mold units may comprise center mold assemblies 212 , upper mold assemblies 214 , and lower mold assemblies 210 , as shown in FIGS. 26 - 28 , which mate to form mold cavities having a desired shape, for instance of a core or a shell surrounding a core.
- center mold assemblies 212 upper mold assemblies 214
- lower mold assemblies 210 lower mold assemblies 210 , as shown in FIGS. 26 - 28 , which mate to form mold cavities having a desired shape, for instance of a core or a shell surrounding a core.
- Flowable material which is heated to a flowable state in reservoir 206 , is injected into the resulting mold cavities.
- the temperature of the flowable material is then decreased, hardening the flowable material.
- the mold assemblies open and eject the finished product.
- the shell is applied to the dosage form using a thermal cycle molding apparatus of the general type shown in FIGS. 28 A-C of copending U.S. application Ser. No. 09/966,497 comprising rotatable center mold assemblies 212 , lower mold assemblies 210 and upper mold assemblies 214 . Cores are continuously fed to the mold assemblies. Shell flowable material, which is heated to a flowable state in reservoir 206 , is injected into the mold cavities created by the closed mold assemblies holding the cores. The temperature of the shell flowable material is then decreased, hardening it around the cores. The mold assemblies open and eject the finished dosage forms. Shell coating is performed in two steps, each half of the dosage forms being coated separately as shown in the flow diagram of FIG. 28B of copending U.S. application Ser. No. 09/966,939 via rotation of the center mold assembly.
- a preferred method for making the shell or a shell portion by solvent-based molding comprises: (a) preparing a flowable dispersion of the film former, release-modifying excipient, and other shell materials in a suitable solvent, e.g. water, organic solvents such as alcohols or acetone, or combinations of water and organic solvents, such as acetone; (b) injecting the flowable dispersion (which may be heated in a heated feed tank) into a mold cavity (at room temp or below) containing a core such that the flowable dispersion surrounds a first portion of the core within the mold cavity; (c) rapidly changing the temperature of the mold cavity to induce thermal setting of the flowable dispersion around at first portion of the core; (d) opening the mold cavity and rotating the portion of the mold containing the core to expose a second portion of the core; (e) closing the mold cavity; (f) injecting heated, flowable dispersion into the mold cavity such that the flowable dispersion surrounds the second portion of the core within the mold cavity
- a preferred method for making the shell or a shell portion by solvent-free molding comprises: (a) melting a thermal reversible carrier, adding and mixing a release-modifying excipient and any other desired ingredients for the shell into the thermal reversible carrier to form a flowable shell material; (b) injecting the flowable shell material (which is heated in a heated feed tank) into a mold cavity (heated to allow the flowable shell material to flow) containing a core such that the flowable shell material surrounds a first portion of the core within the mold cavity; (c) rapidly lowering the temperature of the mold cavity to induce thermal setting of the flowable shell material surrounding the first portion of the core; (d) opening the mold cavity and rotating the portion of the mold containing the core to expose a second portion of the core; (e) closing the mold cavity; (f) injecting heated, flowable shell material into the mold cavity (also heated) such that the flowable shell material surrounds the second portion of the core within the mold cavity; (g) rapidly lowering the temperature of the mold cavity to
- the compression module of copending U.S. patent application Ser. No. 09/966,509, pp. 16-27 may be employed to make cores.
- the shell may be made applied to these cores using a thermal cycle molding module as described above.
- a transfer device as described in U.S. patent application Ser. No. 09/966,414, pp. 51-57, the disclosure of which is incorporated herein by reference, may be used to transfer the cores from the compression module to the thermal cycle molding module.
- Such a transfer device may have the structure shown as 300 in FIG. 3 of copending U.S. application Ser. No. 09/966,939. It comprises a plurality of transfer units 304 attached in cantilever fashion to a belt 312 as shown in FIGS.
- Transfer devices 304 comprise retainers 330 for holding cores as they travel around the transfer device.
- Suitable materials for use in or as the flowable material include those comprising thermoplastic materials; film formers; thickeners such as gelling polymers or hydrocolloids; low melting hydrophobic materials such as fats and waxes; non-crystallizable carbohydrates; and the like.
- Suitable molten components of the flowable material include thermoplastic materials, low melting hydrophobic materials, and the like.
- Suitable dissolved components for the flowable material include film formers, thickeners such as gelling polymers or hydrocolloids, non-crystallizable carbohydrates, and the like.
- Suitable dispersed components include insoluble edible materials.
- Suitable thermoplastic materials can be molded and shaped when heated, and include both water soluble and water insoluble polymers that are generally linear, not crosslinked, nor strongly hydrogen bonded to adjacent polymer chains.
- suitable thermoplastic materials include: thermoplastic water swellable cellulose derivatives, thermoplastic water insoluble cellulose derivatives, thermoplastic vinyl polymers, thermoplastic starches, thermoplastic polyalkalene glycols, thermoplastic polyalkalene oxides, and amorphous sugar-glass, and the like, and derivatives, copolymers, and combinations thereof.
- suitable thermoplastic water swellable cellulose derivatives include hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC).
- suitable water insoluble cellulose derivatives include cellulose acetate (CA), ethyl cellulose (EC), cellulose acetate butyrate (CAB), cellulose propionate.
- suitable thermoplastic vinyl polymers include polyvinyl alcohol (PVA) and polyvinyl pyrrolidone (PVP).
- suitable thermoplastic starches are disclosed for example in U.S. Pat. No. 5,427,614.
- suitable thermoplastic polyalkalene glycols include polyethylene glycol.
- suitable thermoplastic polyalkalene oxides include polyethylene oxide having a molecular weight from about 100,000 to about 900,000 Daltons.
- Other suitable thermoplastic materials include sugar in the form on an amorphous glass such as that used to make hard candy forms.
- any film former known in the art is suitable for use in the flowable material of the present invention.
- suitable film formers include, but are not limited to, film-forming water soluble polymers, film-forming proteins, film-forming water insoluble polymers, and film-forming pH-dependent polymers.
- the film-former for making the core or shell or portion thereof by molding may be selected from cellulose acetate, ammonio methacrylate copolymer type B, shellac, hydroxypropylmethylcellulose, and polyethylene oxide, and combinations thereof.
- Suitable film-forming water soluble polymers include water soluble vinyl polymers such as polyvinylalcohol (PVA); water soluble polycarbohydrates such as hydroxypropyl starch, hydroxyethyl starch, pullulan, methylethyl starch, carboxymethyl starch, pre-gelatinized starches, and film-forming modified starches; water swellable cellulose derivatives such as hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC), hydroxyethylmethylcellulose (HEMC), hydroxybutylmethylcellulose (HBMC), hydroxyethylethylcellulose (HEEC), and hydroxyethylhydroxypropylmethyl cellulose (HEMPMC); water soluble copolymers such as methacrylic acid and methacrylate ester copolymers, polyvinyl alcohol and polyethylene glycol copolymers, polyethylene oxide and polyvinylpyrrolidone copolymers; and derivatives such as
- Suitable film-forming proteins may be natural or chemically modified, and include gelatin, whey protein, myofibrillar proteins, coaggulatable proteins such as albumin, casein, caseinates and casein isolates, soy protein and soy protein isolates, zein; and polymers, derivatives and mixtures thereof.
- Suitable film-forming water insoluble polymers include for example ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers; and the like and derivatives, copolymers, and combinations thereof.
- Suitable film-forming pH-dependent polymers include enteric cellulose derivatives, such as for example hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate; natural resins, such as shellac and zein; enteric acetate derivatives such as for example polyvinylacetate phthalate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate; and enteric acrylate derivatives such as for example polymethacrylate-based polymers such as poly(methacrylic acid, methyl methacrylate) 1:2, which is commercially available from Rohm Pharma GmbH under the tradename, EUDRAGIT S, and poly(methacrylic acid, methyl methacrylate) 1:1, which is commercially available from Rohm Pharma GmbH under the tradename, EUDRAGIT L, and the like, and derivatives, salts, copolymers, and combinations thereof.
- enteric cellulose derivatives such as for example hydroxypropyl methylcellulose
- HPMC 2910 is a cellulose ether having a degree of substitution of about 1.9 and a hydroxypropyl molar substitution of 0.23, and containing, based upon the total weight of the compound, from about 29% to about 30% methoxyl groups and from about 7% to about 12% hydroxylpropyl groups.
- HPMC 2910 is commercially available from the Dow Chemical Company under the tradename METHOCEL E.
- METHOCEL E5 which is one grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 4 to 6 cps (4 to 6 millipascal-seconds) at 20° C.
- METHOCEL E6 which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 5 to 7 cps (5 to 7 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer.
- METHOCEL E15 which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 15000 cps (15 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer.
- degree of substitution shall mean the average number of substituent groups attached to a anhydroglucose ring
- hydroxypropyl molar substitution shall mean the number of moles of hydroxypropyl per mole anhydroglucose.
- polyvinyl alcohol and polyethylene glycol copolymer are commercially available from BASF Corporation under the tradename KOLLICOAT IR.
- modified starches include starches that have been modified by crosslinking, chemically modified for improved stability or optimized performance, or physically modified for improved solubility properties or optimized performance.
- chemically-modified starches are well known in the art and typically include those starches that have been chemically treated to cause replacement of some of its hydroxyl groups with either ester or ether groups.
- Crosslinking as used herein, may occur in modified starches when two hydroxyl groups on neighboring starch molecules are chemically linked.
- pre-gelatinized starches or “instantized starches” refers to modified starches that have been pre-wetted, then dried to enhance their cold-water solubility.
- Suitable modified starches are commercially available from several suppliers such as, for example, A. E. Staley Manufacturing Company, and National Starch & Chemical Company.
- One suitable film forming modified starch includes the pre-gelatinized waxy maize derivative starches that are commercially available from National Starch & Chemical Company under the tradenames PURITY GUM and FILMSET, and derivatives, copolymers, and mixtures thereof.
- Such waxy maize starches typically contain, based upon the total weight of the starch, from about 0 percent to about 18 percent of amylose and from about 100% to about 88% of amylopectin.
- Another suitable film forming modified starch includes the hydroxypropylated starches, in which some of the hydroxyl groups of the starch have been etherified with hydroxypropyl groups, usually via treatment with propylene oxide.
- hydroxypropyl starch that possesses film-forming properties is available from Grain Processing Company under the tradename, PURE-COTE B790.
- Suitable tapioca dextrins for use as film formers include those available from National Starch & Chemical Company under the tradenames CRYSTAL GUM or K-4484, and derivatives thereof such as modified food starch derived from tapioca, which is available from National Starch and Chemical under the tradename PURITY GUM 40, and copolymers and mixtures thereof.
- any thickener known in the art is suitable for use in the flowable material of the present invention.
- thickeners include but are not limited to hydrocolloids (also referred to herein as gelling polymers), clays, gelling starches, and crystallizable carbohydrates, and derivatives, copolymers and mixtures thereof.
- hydrocolloids also referred to herein as gelling polymers
- suitable hydrocolloids such as alginates, agar, guar gum, locust bean, carrageenan, tara, gum arabic, tragacanth, pectin, xanthan, gellan, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan.
- Suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof.
- suitable gelling starches include acid hydrolyzed starches, and derivatives and mixtures thereof.
- Additional suitable thickening hydrocolloids include low-moisture polymer solutions such as mixtures of gelatin and other hydrocolloids at water contents up to about 30%, such as for example those used to make “gummi” confection forms.
- Suitable thickeners include crystallizable carbohydrates, and the like, and derivatives and combinations thereof.
- Suitable crystallizable carbohydrates include the monosaccharides and the oligosaccharides.
- the aldohexoses e.g., the D and L isomers of allose, altrose, glucose, mannose, gulose, idose, galactose, talose
- the ketohexoses e.g., the D and L isomers of fructose and sorbose along with their hydrogenated analogs: e.g., glucitol (sorbitol), and mannitol are preferred.
- the 1,2-disaccharides sucrose and trehalose the 1,4-disaccharides maltose, lactose, and cellobiose, and the 1,6-disaccharides gentiobiose and melibiose, as well as the trisaccharide raffinose are preferred along with the isomerized form of sucrose known as isomaltulose and its hydrogenated analog isomalt.
- Other hydrogenated forms of reducing disaccharides such as maltose and lactose
- maltitol and lactitol are also preferred.
- the hydrogenated forms of the aldopentoses e.g., D and L ribose, arabinose, xylose, and lyxose and the hydrogenated forms of the aldotetroses: e.g., D and L erythrose and threose are preferred and are exemplified by xylitol and erythritol, respectively.
- the flowable material comprises gelatin as a gelling polymer.
- Gelatin is a natural, thermogelling polymer. It is a tasteless and colorless mixture of derived proteins of the albuminous class which is ordinarily soluble in warm water.
- Type A gelatin is a derivative of acid-treated raw materials.
- Type B gelatin is a derivative of alkali-treated raw materials.
- Bloom is defined as the weight in grams required to move a half-inch diameter plastic plunger 4 mm into a 6.67% gelatin gel that has been held at 10° C. for 17 hours.
- the flowable material is an aqueous solution comprising 20% 275 Bloom pork skin gelatin, 20% 250 Bloom Bone Gelatin, and approximately 60% water.
- Suitable xanthan gums include those available from C. P. Kelco Company under the tradenames KELTROL 1000, XANTROL 180, or K9B310
- Suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof.
- Acid-hydrolyzed starch is one type of modified starch that results from treating a starch suspension with dilute acid at a temperature below the gelatinization point of the starch. During the acid hydrolysis, the granular form of the starch is maintained in the starch suspension, and the hydrolysis reaction is ended by neutralization, filtration and drying once the desired degree of hydrolysis is reached. As a result, the average molecular size of the starch polymers is reduced. Acid-hydrolyzed starches (also known as “thin boiling starches”) tend to have a much lower hot viscosity than the same native starch as well as a strong tendency to gel when cooled.
- Gelling starches include those starches that, when combined with water and heated to a temperature sufficient to form a solution, thereafter form a gel upon cooling to a temperature below the gelation point of the starch.
- Examples of gelling starches include, but are not limited to, acid hydrolyzed starches such as that available from Grain Processing Corporation under the tradename PURE-SET B950; hydroxypropyl distarch phosphate such as that available from Grain Processing Corporation under the tradename, PURE-GEL B990, and mixtures thereof.
- Suitable low-melting hydrophobic materials include fats, fatty acid esters, phospholipids, and waxes.
- suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts.
- Suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GLYCOWAX-932, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides.
- suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid.
- suitable waxes include camauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; and the like.
- Suitable non-crystallizable carbohydrates include non-crystallizable sugars such as polydextrose, and starch hydrolysates, e.g. glucose syrup, corn syrup, and high fructose corn syrup; and non-crystallizable sugar-alcohols such as maltitol syrup.
- Suitable solvents for optional use as components of the flowable material for making the core, or the shell, or a portion thereof by molding include water; polar organic solvents such as methanol, ethanol, isopropanol, acetone, and the like; and non-polar organic solvents such as methylene chloride, and the like; and mixtures thereof.
- the flowable material for making the core or the shell or a portion thereof by molding may optionally comprise adjuvants or excipients, which may comprise up to about 30% by weight of the flowable material.
- adjuvants or excipients include plasticizers, detackifiers, humectants, surfactants, anti-foaming agents, colorants, flavorants, sweeteners, opacifiers, and the like.
- Suitable plasticizers for making the core, the shell, or a portion thereof, by molding include, but not be limited to polyethylene glycol; propylene glycol; glycerin; sorbitol; triethyl citrate; tribuyl citrate; dibutyl sebecate; vegetable oils such as castor oil, rape oil, olive oil, and sesame oil; surfactants such as polysorbates, sodium lauryl sulfates, and dioctyl-sodium sulfosuccinates; mono acetate of glycerol; diacetate of glycerol; triacetate of glycerol; natural gums; triacetin; acetyltributyl citrate; diethyloxalate; diethylmalate; diethyl fumarate; diethylmalonate; dioctylphthalate; dibutylsuccinate; glyceroltributyrate; hydrogenated castor oil; fatty acids
- the flowable material comprises less than 5% humectants, or alternately is substantially free of humectants, such as glycerin, sorbitol, maltitol, xylitol, or propylene glycol.
- Humectants have traditionally been included in pre-formed films employed in enrobing processes, such as that disclosed in U.S. Pat. Nos. 5,146,730 and 5,459,983, assigned to Banner Gelatin Products Corp., to ensure adequate flexibility or plasticity and bondability of the film during processing. Humectants function by binding water and retaining it in the film. Pre-formed films used in enrobing processes can typically comprise up to 45% water. Disadvantageously, the presence of humectant prolongs the drying process, and can adversely affect the stability of the finished dosage form.
- the core, shell, or portions thereof may comprise active ingredient contained within an excipient matrix.
- the matrix, or the core, or the shell, or portions thereof typically comprises at least about 30 percent, e.g. at least about 45 weight percent of a thermal-reversible carrier, and optionally up to about 30 weight percent of various adjuvants such as for example plasticizers, gelling agents, strengthening agents, colorants, stabilizers, preservatives, and the like as known in the art.
- the matrix or the core, or the shell, or portions thereof may optionally further comprise up to about 55 weight percent of one or more release-modifying moldable excipients as described below.
- Solvent-free molding may be used to obtain semipermeable, impermeable, or diffusible shells or shell portions.
- the core may be in a variety of different shapes.
- the core may be shaped as a polyhedron, such as a cube, pyramid, prism, or the like; or may have the geometry of a space figure with some non-flat faces, such as a cone, truncated cone, cylinder, sphere, torus, or the like.
- the core has one or more major faces.
- the core surface typically has two opposing major faces formed by contact with the upper and lower punch faces in the compression machine.
- the core surface typically further comprises a “belly-band” located between the two major faces, and formed by contact with the die walls in the compression machine.
- Exemplary core shapes which may be employed include tablet shapes formed from compression tooling shapes described by “The Elizabeth Companies Tablet Design Training Manual” (Elizabeth Carbide Die Co., Inc., p. 7 (McKeesport, Pa.) (incorporated herein by reference) as follows (the tablet shape corresponds inversely to the shape of the compression tooling):
- FIG. 8 /Bar Bell.
- the core comprises multiple portions, for example a first portion and a second portion.
- the portions may be prepared by the same or different methods, such as the thermal cycle molding or thermal setting molding methods described herein, and mated using various techniques.
- the first and second portions may both be made by compression, or both may be made by molding.
- one portion may be made by compression and the other by molding.
- the same or different active ingredient may be present in the first and second portions of the core.
- one or more core portions may be substantially free of active ingredients.
- the core comprises first, second and third portions, each comprising the same or different active ingredient.
- the core comprises first, second and third portions, and the third portion (located between the first and second portions) has a higher concentration of active ingredient, thereby causing a particularly desired release profile for at least one active ingredient from the dosage form.
- release of at least one active ingredient from the dosage form may have a substantially constant release rate, substantially non-constant release rate, or an ascending release rate.
- the core comprises first, second, and third portions, and the third portion (located between the first and second portions) is substantially free of active ingredient, and may contain osmagent or osmopolymer, or may serve as a barrier to the passage of active ingredient between the first and second core portions.
- the core or a portion thereof may function to confer modified release properties to at least one active ingredient contained therein.
- the core or core portion is made by compression, as previously noted, the core preferably comprises a release-modifying compressible excipient.
- the core or core portion is made by molding, as previously noted, the core preferably comprises a release-modifying moldable excipient.
- the core portion preferably comprises a release-modifying compressible or moldable excipient selected from swellable erodible hydrophilic agents, pH-dependent polymers, and combinations thereof.
- the core portion preferably comprises a release-modifying excipient selected from combinations of insoluble edible materials and pore formers.
- a thermal-reversible carrier may be included in the core portion and may function by dissolving and forming pores or channels through which the active ingredient may be liberated.
- the term “semipermeable” means permeable to the passage of water but not permeable to the passage of active ingredient therethrough.
- the semipermeable shell or shell portion allows water to be absorbed therethrough and into the core of the dosage form from the environment, such as the dissolution media or gastro-intestinal fluids.
- the semipermeable shell portion functions as a barrier to the passage of active ingredient from the underlying core portion, forcing the active ingredient to be released from the dosage form via a different avenue, such as an orifice or passageway, or through a diffusible shell portion.
- the semipermeable shell or shell portions are non-erodible, and they are insoluble in fluids.
- the semipermeable shell or shell portion is made using a flowable material.
- Suitable dissolved or molten components for the flowable material for forming the semi-permeable shell or shell portion may include thermoplastic film-formers selected from cellulose esters, cellulose ethers, and cellulose ester-ethers. These cellulosic polymers have a degree of substitution (D.S.) on the anhydroglucose unit, from greater than 0 up to 3 inclusive.
- degree of substitution as used herein it is meant the average number of hydroxyl groups originally present on the anhydroglucose unit comprising the cellulose polymer that are replaced by a substituting group.
- Representative materials include those selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, mono-, di-, and tricellulose alkanylates, nono-, di-, and tricellulose aroylates, and the like.
- Exemplary polymers include cellulose acetate having a D.S. up to 1 and an acetyl content up to 21%; cellulose acetate having an acetyl content of 32 to 39.8%; cellulose acetate having a D.S. of 1 to 2 and an acetyl content of 21 to 35%; cellulose acetate having a D.S.
- More specific cellulosic polymers include cellulose propionate having a D.S. of 1.8 and a propyl content of 39.2 to 45% and a hydroxyl content of 2.8 to 5.4%; cellulose acetate butyrate having a D.S. of 1.8, an acetyl content of 13 to 15% and a butyryl content of 34 to 39%; cellulose acetate butyrate having an acetyl content of 2 to 29%, a butyryl content of 17 to 53% and a hydroxyl content of 0.5 to 4.7%; cellulose triacylates having a D.S.
- cellulose diacylates having a D.S. of 2.2 to 2.6, such as cellulose disuccinate, cellulose dipalmitate, cellulose dioctanoate, cellulose dipentanoate, co-esters of cellulose, such as cellulose acetate butyrate and cellulose acetate propionate.
- Additional polymers useful for manufacturing the semipermeable shell or shell portion include ethyl cellulose of various degree of etherification with ethoxy content of from about 40 to 55%, acetaldehyde demethylcellulose acetate, cellulose acetate ethyl carbamate, cellulose acetate methyl carbamate, cellulose acetate diethyl aminoacetate, semipermeable polyamides; semipermeable polyurethanes; semipermeable sulfonated polystyrenes; semipermeable cross-linked selective polymers formed by the coprecipitation of a polyanion and a polycation as disclosed in U.S. Pat. Nos.
- the dissolved or molten components for the flowable material for forming the semi-permeable shell or shell portion comprise a polymer exhibiting a 8,500 to 4,000,000 molecular weight, and is present in the shell portion at a level from about 15 to about 85 weight percent of the shell portion.
- Polymeric materials which may be used include non-ionic water-soluble polymers, cellulose ether nonionic with its solutions unaffected by cations, hydroxyalkylcellulose, hydroxyalkylalkylcellulose, hydroxypropylcellulose, phenylellulose, benzylcellulose, nonionic cellulose ester with its solutions unaffected by cations, benzhydrylcellulose, hydroxyethyloctylcellulose, diphenylmethylcellulose, hydroxyethylcellulose, tritylcellulose and polymercompositions that delay water flux up to 7.0 hours, and more preferably, up to 4.5 hours.
- At least about 30% of the cross-sectional area of the semipermeable shell or semipermeable shell portion used in dosage forms of this invention is non-striated. In other embodiments, at least about 50% of the cross-sectional area of the semipermeable shell or semipermeable shell portion is non-striated. In yet other embodiments, at least about 80% of the cross-sectional area of the semipermeable shell or semipermeable shell portion is non-striated.
- “non-striated” means homogeneous with respect to appearance, and with respect to the internal structure of the shell or shell portion when viewed under any magnification and lighting conditions. For example a cross-section of the shell or shell portion is free of striations, and uniform with respect to refractive properties when observed utilizing a light microscope at a magnification of about 50 to about 400 times.
- the shell or shell portion of the present invention may advantageously be applied to a core directly by a molding process, yielding a uniform and homogeneous layer in 5 minutes or less, e.g. 60 seconds or less, or 30 seconds or less, or 10 seconds or less, and in certain embodiments, say 1 second or less. As such, at least about 30% of the cross-sectional area of the shell or shell portion in certain embodiments of the present invention is non-striated.
- FIGS. 7A and 7B show prior art spray coated compositions having striations which are thus distinguishable from certain embodiments of the present invention.
- FIG. 7A is a micrographic cross-section (121 ⁇ magnification) of a prior art PROCARDIA XL tablet (commercially available from Pfizer Labs) and
- FIG. 7B is a micrographic cross-section (800 ⁇ magnification) of the same tablet.
- This prior art product clearly had striations.
- FIGS. 8A and 8B show a dosage form of this invention (at 124 ⁇ and 800 ⁇ magnifications, respectively). As shown, this embodiment of the invention had no striations.
- the shell or shell portion of the present invention has a cross-sectional area in the range of about 1 to 900 sq. mm, preferably about 25 to 600 sq. mm, most preferably about 50 to about 500 sq. mm.
- the shell comprises two parts that abut one another, thereby forming a shell that completely surrounds the core.
- a portion of the shell contains active ingredient which is released essentially immediately upon ingestion of the dosage form.
- the shell or shell portion preferably comprises materials which exhibit rapid dissolution in gastro-intestinal fluids.
- the shell or shell portion employed in this invention also provides for delivery of active ingredient from the core or core portion to the liquid medium outside the dosage form after the dosage form is contacted with the liquid medium. In one embodiment, this is accomplished by having at least one aperture or passageway within the shell or shell portion to permit liquid medium containing active ingredient within the dosage form to pass through the shell or shell portion and out of the dosage form.
- the shell comprises a diffusible shell or shell portion, and active ingredient diffuses therethrough to the liquid medium outside of the dosage form.
- the shell or shell portion has at least a portion which is extremely thin (e.g.
- the shell or shell portion has a seam, and internal pressure within the shell or shell portion causes a breach or mechanical failure of the seam, thereby delivering active ingredient from the core to the liquid medium outside of the dosage form.
- a portion of the shell functions as a diffusional membrane which contains pores through which liquid medium containing active ingredient within the dosage form can be released through the diffusible shell portion in a sustained, extended, prolonged or retarded manner.
- the rate of release of active ingredient from the underlying core or core portion will depend upon the total pore area in the shell or shell portion, the pathlength of the pores, and the solubility and diffusivity of the active ingredient (in addition to its rate of release from the core or core portion itself).
- the release of the active ingredient from the dosage form may be described as controlled, prolonged, sustained or extended.
- the contribution to active ingredient dissolution from the shell or shell portion may follow zero-order, first-order, or square-root of time kinetics.
- the diffusional membrane shell or shell portion preferably comprises a release-modifying excipient such as a combination of a pore former and an insoluble edible material such as for example a film forming water insoluble polymer.
- the thermal-reversible carrier may function by dissolving and forming pores or channels through which the active ingredient may be liberated.
- a portion of the shell functions as an eroding matrix from which active ingredient dispersed in the shell portion is liberated by the dissolution of successive layers of the shell or shell portion surface.
- the rate of active ingredient release will depend on the dissolution rate of the matrix material in the shell or shell portion.
- Particularly useful matrix materials for providing surface erosion include those which first absorb liquid, then swell and/or gel prior to dissolving.
- the eroding matrix shell or shell portion preferably comprises a swellable erodible hydrophilic material.
- one or more shell portions function as a barrier to prevent release therethrough of an active ingredient contained in the underlying core or core portion.
- active ingredient is typically released from a portion of the core which is not covered by the barrier shell portion. Typically, this is achieved by having at least one passageway in the shell or shell portion to permit active ingredient to reach the liquid medium outside the dosage form.
- Such embodiments advantageously allow for control of the surface area for release of the active ingredient.
- the surface area for release of active ingredient can be maintained substantially constant over time.
- the release of at least one active ingredient follows substantially zero-order kinetics.
- the barrier shell portion preferably comprises a water insoluble material such as for example a water insoluble polymer.
- the shell or portion thereof functions as a delayed release coating to delay release of an active ingredient which is contained in the core or a portion thereof.
- the lag-time for onset of active ingredient release may be governed by erosion of the coating or diffusion through the coating or a combination thereof.
- the eroding matrix shell or shell portion preferably comprises a swellable erodible hydrophilic material.
- the thickness of the shell or shell portion is critical to the release properties of the dosage form.
- the dosage forms of the invention can be made with precise control over shell thickness.
- the shell or one or more shell portions function to modify the release of an active ingredient which is contained in the core or the subject shell or shell portion
- the shell or shell portion is made by the thermal cycle or thermal setting molding methods and apparatus described below.
- the dosage form of the invention comprises at least one active ingredient; a core; a shell or shell portion which resides upon at least a portion of the core; and an outer coating which covers at least a portion of the shell or shell portion.
- the outer coating may for example cover a portion of the first shell portion, or the second shell portion, or both, or may surround the entire shell.
- the outer coating comprises an active ingredient, which is released immediately (i.e.
- the dosage form is a pulsatile drug delivery system, in which one or more shell portions provides for delayed release of a second dose of active ingredient, which is contained in an underlying core portion.
- the first and second shell portions may comprise different levels of the same ingredients, e.g. colorants, opacifiers, film-formers, etc.
- the first and second shell portions may be visually distinct from one another, for example the visually distinct portions may be of different colors, hues, glosses, reflective qualities, brightness, depth, shades, chroma, opacity, etc.
- the shell may have a red portion and a yellow portion, or a flat finish portion and a glossy portion, or an opaque portion and a translucent portion.
- the first and second shell portions may have different thickness.
- the first and second shell portions may have different functionalities.
- the first and second shell portions may confer different release properties to an active ingredient contained in either the subject shell portion, or in a corresponding underlying core portion.
- the first shell portion may function as a diffusional membrane which contains pores through which fluids can enter the dosage form, and dissolved active ingredient can be released from an underlying core portion; and the second shell portion, may function as an eroding matrix from which active ingredient dispersed in the second shell portion is liberated by the dissolution of successive layers of the shell portion surface.
- the shell or shell portions will typically comprise at least about 30 percent, e.g. at least about 45 percent by weight of a thermal-reversible carrier.
- the shell or shell portion or portions may optionally further comprise up to about 55 weight percent of a release-modifying excipient.
- the shell or shell portion or portions may optionally further comprise up to about 30 weight percent total of various plasticizers, adjuvants and excipients.
- the release modifying excipient is preferably selected from swellable, erodible hydrophilic materials.
- the shell or shell portion or portions will typically comprise at least about 10 weight percent, e.g. at least about 12 weight percent or at least about 15 weight percent or at least about 20 weight percent or at least about 25 weight percent of a film-former.
- the solvent-molded shell or shell portion or portions may optionally further comprise up to about 55 weight percent of a release-modifying excipient.
- the solvent-molded shell or shell portion or portions may again also optionally further comprise up to about 30 weight percent total of various plasticizers, adjuvants, and excipients.
- the shell or shell portion or portions of the present invention are substantially free of pores having a diameter of 0.5-5.0 microns.
- substantially free means that the shell or shell portion or portions have a pore volume of less than about 0.02 cc/g, preferably less than about 0.01 cc/g, more preferably less than about 0.005 cc/g in the pore diameter range of 0.5 to 5.0 microns.
- typical compressed materials have pore volumes of more than about 0.02 cc/g in this diameter range.
- the core is a molded core and the core or core portions are substantially free of pores having a diameter of 0.5-5.0 microns.
- Shell or shell portions may be tested for surface gloss using an instrument available from TriCor Systems Inc. (Elgin, IL) under the tradename TRI-COR MODEL 805A/806H SURFACE ANALYSIS SYSTEM and generally in accordance with the procedure described in “TriCor Systems WGLOSS 3.4 Model 805A/806H Surface Analysis System Reference Manual” (1996), which is incorporated by reference herein, except as modified below.
- TriCor Systems Inc. Elgin, IL
- TRI-COR MODEL 805A/806H SURFACE ANALYSIS SYSTEM and generally in accordance with the procedure described in “TriCor Systems WGLOSS 3.4 Model 805A/806H Surface Analysis System Reference Manual” (1996), which is incorporated by reference herein, except as modified below.
- This instrument uses a CCD camera detector, a flat diffuse light source, compares tablet samples to a reference standard, and determines average gloss values at a 60 degree incident angle. During its operation, the instrument generates a gray-scale image, wherein the occurrence of brighter pixels indicates the presence of more gloss at that given location.
- the instrument also incorporates software that uses a grouping method to quantify gloss: i.e., pixels with similar brightness which are grouped together for averaging purposes.
- the “percent full scale” or “percent ideal” setting (also referred to as the “percent sample group” setting), is specified by the user to designate the portion of the brightest pixels above the threshold that will be considered as one group and averaged within that group.
- “Threshold,” as used herein, is defined as the maximum gloss value that will not be included in the average gloss value calculation. Thus, the background, or the non-glossy areas of a sample are excluded from the average gloss value calculations.
- the method disclosed in K. Fegley and C. Vesey, “The Effect of Tablet Shape on the Perception of High Gloss Film Coating Systems,” which is available at www.colorcon.com as of Mar. 18, 2002 and incorporated by reference herein, is used to minimize the effects resulting from different tablet shapes, and to report a metric that was comparable across the industry. (The 50% sample group setting is selected as the setting which best approximates analogous data from tablet surface roughness measurements.)
- a standard surface gloss measurement is created.
- a standard surface gloss was obtained using gel-coated caplets available from McNEIL-PPC, Inc. under the tradename, EXTRA STRENGTH TYLENOL GELCAPS. The average gloss value for a sample of 112 of such gel-coated caplets was then determined, while employing the 25 mm full view mask (190-280), and configuring the instrument to the following settings:
- the total weight of the shell or shell portion or portions is preferably about 20 percent to about 400 percent of the weight of the core.
- the total weight of the shell or shell portion or portions is typically from about 50 percent to about 400 percent, e.g. from about 75 percent to about 400 percent, or about 100 percent to about 200 percent of the weight of the core.
- the shell portion or portions are prepared by a solvent-based molding process, the total weight of the shell or shell portion or portions is typically from about 20 percent to about 100 percent of the weight of the core.
- Typical shell or shell portion thicknesses which may be employed in this invention are about 10 to about 1000 microns. In certain preferred embodiments, the shell or shell portion has a thickness of less than 800 microns. In embodiments wherein the shell or shell portion is prepared by a solvent-free molding process, the shell or shell portion typically has a thickness of about 500 to about 4000 microns, e.g. about 500 to about 2000 microns, say about 500 to about 800 microns, or about 800 to about 1200 microns. In embodiments wherein the shell or shell portion is prepared by a solvent-based molding process, the shell or shell portion typically has a thickness of less than about 800 microns, e.g.
- the semi-permeable shell or shell portion typically has a thickness from about 20 to about 400 microns, e.g. about 20 to about 200 microns, say about 40 to about 100 microns.
- the flowable material may comprise a thermal-reversible carrier.
- Suitable thermal-reversible carriers are thermoplastic materials typically having a melting point below about 110° C., more preferably between about 20 and about 100° C.
- suitable thermal-reversible carriers for solvent-free molding include thermoplastic polyalkalene glycols, thermoplastic polyalkalene oxides, low melting hydrophobic materials, thermoplastic polymers, thermoplastic starches, and the like.
- Preferred thermal-reversible carriers include polyethylene glycol and polyethylene oxide.
- Suitable thermoplastic polyalkylene glycols for use as thermal-reversible carriers include polyethylene glycol having molecular weight from about 100 to about 20,000, e.g.
- Suitable thermoplastic polyalkalene oxides include polyethylene oxide having a molecular weight from about 100,000 to about 900,000 Daltons.
- Suitable low-melting hydrophobic materials for use as thermal-reversible carriers include fats, fatty acid esters, phospholipids, and waxes which are solid at room temperature, fat-containing mixtures such as chocolate; and the like.
- suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts.
- Suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GLYCOWAX-932, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides.
- suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid.
- suitable waxes which are solid at room temperature include carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax.
- suitable thermoplastic polymers for use as thermal-reversible carriers include thermoplastic water swellable cellulose derivatives, thermoplastic water insoluble polymers, thermoplastic vinyl polymers, thermoplastic starches, and thermoplastic resins, and combinations thereof.
- Suitable thermoplastic water swellable cellulose derivatives include hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC), carboxymethylcellulose (CMC), cross-linked hydroxypropylcellulose, hydroxypropyl cellulose (HPC), hydroxybutylcellulose (HBC), hydroxyethylcellulose (HEC), hydroxypropylethylcellulose, hydroxypropylbutylcellulose, hydroxypropylethylcellulose, and salts, derivatives, copolymers, and combinations thereof.
- HPMC hydroxypropylmethyl cellulose
- MC methyl cellulose
- CMC carboxymethylcellulose
- HPC hydroxypropyl cellulose
- HBC hydroxybutylcellulose
- HEC hydroxyethylcellulose
- thermoplastic water insoluble polymers include ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers, and the like and derivatives, copolymers, and combinations thereof.
- Suitable thermoplastic vinyl polymers include polyvinylacetate, polyvinyl alcohol, and polyvinyl pyrrolidone (PVP). Examples of suitable thermoplastic starches for use as thermal-reversible carriers are disclosed for example in U.S. Pat. No. 5,427,614.
- thermoplastic resins for use as thermal-reversible carriers include dammars, mastic, rosin, shellac, sandarac, and glcerol ester of rosin.
- the thermal-reversible carrier for making the core, or a portion thereof, by molding is selected from polyalkylene glycols, polyalkaline oxides, and combinations thereof.
- Suitable release-modifying excipients for making the core, or the shell, or a portion thereof, by solvent free or solvent based molding include but are not limited to swellable erodible hydrophilic materials, pH-dependent polymers, pore formers, and insoluble edible materials.
- suitable release-modifying excipients for making the core, or the shell, or a portion thereof, by molding include hydroxypropylmethylcellulose, polyethylene oxide, ammonio methacrylate copolymer type B, and shellac, and combinations thereof.
- Suitable swellable erodible hydrophilic materials for use as release-modifying excipients for making the core, or the shell, or a portion thereof by a solvent-free molding process include water swellable cellulose derivatives, polyalkalene glycols, thermoplastic polyalkalene oxides, acrylic polymers, hydrocolloids, clays, gelling starches, and swelling cross-linked polymers, and derivatives, copolymers, and combinations thereof.
- suitable water swellable cellulose derivatives include sodium carboxymethylcellulose, cross-linked hydroxypropylcellulose, hydroxypropyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyisopropylcellulose, hydroxybutylcellulose, hydroxyphenylcellulose, hydroxyethylcellulose (HEC), hydroxypentylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, hydroxypropylethylcellulose.
- suitable polyalkalene glycols include polyethylene glycol.
- suitable thermoplastic polyalkalene oxides include poly (ethylene oxide).
- acrylic polymers include potassium methacrylatedivinylbenzene copolymer, polymethylmethacrylate, CARBOPOL (high-molecular weight cross-linked acrylic acid homopolymers and copolymers), and the like.
- suitable hydrocolloids include alginates, agar, guar gum, locust bean gum, kappa carrageenan, iota carrageenan, tara, gum arabic, tragacanth, pectin, xanthan gum, gellan gum, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, gelatin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan.
- Suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof.
- suitable gelling starches include acid hydrolyzed starches, swelling starches such as sodium starch glycolate, and derivatives thereof.
- suitable swelling cross-linked polymers include cross-linked polyvinyl pyrrolidone, cross-linked agar, and cross-linked carboxymethylcellose sodium.
- Suitable pH-dependent polymers for use as release-modifying moldable excipients for making the molded core or molded shell or a portion thereof by molding include enteric cellulose derivatives, for example hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate; natural resins such as shellac and zein; enteric acetate derivatives such as for example polyvinylacetate phthalate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate; and enteric acrylate derivatives such as for example polymethacrylate-based polymers such as poly(methacrylic acid, methyl methacrylate) 1:2, which is commercially available from Rohm Pharma GmbH under the tradename EUDRAGIT S, and poly(methacrylic acid, methyl methacrylate) 1:1, which is commercially available from Rohm Pharma GmbH under the tradename EUDRAGIT L, and the like, and derivatives, salts, copolymers,
- Suitable insoluble edible materials for use as release-modifying excipients making the core, or the shell, or a portion thereof by molding include water-insoluble polymers, and low-melting hydrophobic materials.
- suitable water-insoluble polymers include ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers; and the like and derivatives, copolymers, and combinations thereof.
- Suitable low-melting hydrophobic materials include fats, fatty acid esters, phospholipids, and waxes.
- suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts.
- suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GLYCOWAX-932, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides.
- Suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid.
- suitable waxes include carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; and the like.
- Suitable pore formers for use as release-modifying excipients for making the molded core, the shell, or a portion thereof by molding include water-soluble organic and inorganic materials.
- the pore former is hydroxypropylmethylcellulose.
- suitable water-soluble organic materials include water soluble polymers including water soluble cellulose derivatives such as hydroxypropylmethylcellulose, and hydroxypropylcellulose; water soluble carbohydrates such as sugars, and starches; water soluble polymers such as polyvinylpyrrolidone and polyethylene glycol, and insoluble swelling polymers such as microcrystalline cellulose.
- suitable water soluble inorganic materials include salts such as sodium chloride and potassium chloride and the like and/or mixtures thereof.
- the shell or shell portion is preferably prepared via the solvent-free molding method described above.
- the thermal-reversible carrier is preferably selected from polyethylene glycol with weight average molecular weight from about 1450 to about 20000, polyethylene oxide with weight average molecular weight from about 100,000 to about 900,000, and the like.
- the shell or shell portion in the core, the shell or both, typically comprises at least one release modifying agent as described above.
- the dosage form may function for example as a multi-compartment, e.g. a four-compartment pulsatile release delivery system.
- each of the compartments may comprise a dose of the same active ingredient, to be release at a desired time or rate.
- the corresponding first core portion and first shell portions may comprise a dose of the same first active ingredient to be released at a desired time or rate, while the second core portion and second shell portion may comprise a dose of the same second active ingredient to be released at a desired time or rate.
- each compartment comprises inactive materials which enable the desired functionality of that particular core portion or shell portion.
- the dosage form may further comprise a water-impermeable barrier layer between the first and second core portions.
- the water-impermeable barrier layer may be made by any method, for example compression or molding, and preferably comprises at least one water-insoluble material selected from water-insoluble polymers, insoluble edible materials, pH-dependent polymers, and mixtures thereof.
- At least one active ingredient contained within the dosage form exhibits a non-constant release rate.
- At least one active ingredient contained within the dosage form exhibits a delayed burst release profile.
- delayed burst release profile it is meant that the release of that particular active ingredient from the dosage form is delayed for a pre-determined time after ingestion by the patient, and the delay period (“lag time”) is followed by prompt (immediate) release of that active ingredient.
- At least one shell portion of the present invention provides for the delay period and is preferably substantially free of the active ingredient to be released in a delayed burst manner.
- the delayed burst active ingredient is typically contained within the corresponding underlying core portion.
- the core portion may be prepared by compression or molding, and is formulated for immediate release, as is known in the art, so that the core portion is readily soluble upon contact with the dissolution medium.
- the core portion preferably comprises a disintegrant, and optionally comprises additional excipients such as fillers or thermoplastic materials selected from water-soluble or low-melting materials, and surfactants or wetting agents.
- additional excipients such as fillers or thermoplastic materials selected from water-soluble or low-melting materials, and surfactants or wetting agents.
- USP 24 specifies that in pH 5.8 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released therefrom within 30 minutes after dosing, and for ibuprofen tablets, USP 24 specifies that in pH 7.2 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the ibuprofen contained in the dosage form is released therefrom within 60 minutes after dosing. (See USP 24, 2000 Version, 19-20 and 856 (1999)).
- At least one active ingredient contained within the dosage form exhibits a delayed and sustained release profile.
- delayed then sustained release profile it is meant that the release of that particular active ingredient from the dosage form is delayed for a pre-determined time after ingestion by the patient, and the delay period (“lag time”) is followed by sustained (prolonged, extended, or retarded) release of that active ingredient.
- At least one shell portion of the present invention provides for the delay period, and is preferably substantially free of the active ingredient to be released in a delayed then sustained manner.
- the delayed then sustained release active ingredient is preferably contained within the corresponding underlying core portion.
- the core portion may function for example as an eroding matrix or a diffusional matrix, or an osmotic pump.
- the core portion preferably comprises a release-modifying excipient selected from combinations of insoluble edible materials and pore-formers.
- the thermal-reversible carrier may function by dissolving and forming pores or channels through which the active ingredient may be liberated.
- the core portion functions as an eroding matrix from which dispersed active ingredient is liberated in a sustained, extended, prolonged, or retarded manner
- the core portion preferably comprises a release-modifying compressible or moldable excipient selected from swellable erodible hydrophilic materials, pH-dependent polymers, and combinations thereof.
- the core portion preferably comprises a release-modifying excipient selected from combinations of insoluble edible materials and pore formers.
- the thermal-reversible carrier may function by dissolving and forming pores or channels through which the active ingredient may be liberated.
- the release-delaying shell or shell portion preferably comprises a release modifying excipient selected from swellable erodible hydrophilic materials, insoluble edible materials, and combinations thereof.
- the shell or shell portion preferably comprises a release-modifying compressible or moldable excipient selected from swellable erodible hydrophilic materials, pH-dependent polymers, insoluble edible materials, and combinations thereof.
- the release-delaying shell or shell portion preferably provides a delay of greater than one hour, for example at least about 3 hours, or at least about 4 hours, or at least about 6 hours, or at least about 12 hours to the onset of dissolution of the active ingredient upon contacting of the dosage form with a liquid medium such as water, gastrointestinal fluid or the like.
- the delay period is typically controlled by the shell or shell portion thickness, composition, or a combination thereof. In one embodiment the delay period is independent of the pH of the dissolution media or fluid environment.
- the average lag-time for dissolution of active ingredient in 0.1 N HCl is not substantially different (i.e. within about 30 minutes, preferably within about 15 minutes) from the average lag-time for the dissolution of active ingredient in pH 5.6 buffer system.
- the release-delaying shell or shell portion preferably comprises a release modifying excipient selected from swellable erodible hydrophilic materials, insoluble edible materials, and combinations thereof.
- the shell or shell portion preferably comprises materials which exhibit rapid dissolution in gastro-intestinal fluids.
- the immediate release shell or shell portion or portions may comprise readily soluble materials selected from water soluble or water swellable thermoplastic film formers, water soluble or water swellable thickeners, crystallizable and non-crystallizable carbohydrates.
- suitable water soluble or water swellable thermoplastic film formers may be selected from water swellable cellulose derivatives, thermoplastic starches, polyalkalene glycols, polyalkalene oxides, and amorphous sugar glass, and combinations thereof.
- suitable film formers may be selected from film forming water soluble polymers such as for example water soluble vinyl polymers, water soluble polycarbohydrates, water swellable cellulose derivatives, and water soluble copolymers; film-forming proteins, and combinations thereof.
- suitable thickeners may be selected from gelling polymers or hydrocolloids; gelling starches, and crystallizable carbohydrates.
- suitable non-crystallizable carbohydrates may be selected from polydextrose, starch hydrolysates, and non-crystallizable sugar alcohols.
- the immediate release shell or shell portion will preferably be breached or dissolved within 30 minutes in 900 ml water or 0.1 N HCl, or phosphate buffer solution at 37° C. with stirring by a USP type 2 (Paddle method) at 50 or 100 rpm.
- the shell or portion thereof additionally comprises at least one active ingredient which may be the same or different than the active ingredient contained in the core.
- the release-modifying agent in the shell or shell portion preferably comprises a pore-former, and optionally a film-former.
- the shell or shell portion functions as a diffusional membrane.
- the dissolution of the active ingredient may follow “diffusion-controlled” release kinetics, as described for example in Example 1 of U.S. Pat. No. 5,286,497.
- Shells or shell portions which confer sustained, extended, or retarded release and/or function as diffusional membranes can be prepared by a solvent-free method, or a solvent-based method, as described above.
- the release-modifying agent in the shell or shell portion preferably comprises a swellable erodible hydrophilic material, and may optionally comprise a secondary gelling agent such as for example cross-linked carboxymethylcellulose, cross-linked polyvinylpyrrolidone, or sodium starch glycolate.
- the release-modifying agent is preferably selected from swellable erodible hydrophilic materials.
- the shell or shell portions which confer delayed release can be prepared by a solvent-free method, or a solvent-based method, as described above.
- the shell or shell portion is preferably prepared via a solvent-free molding method, as described above.
- the thermal-reversible carrier is preferably selected from waxes, such as for example camuba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; hydrogenated vegetable oils such as for example cocoa butter, hydrogenated castor oil; other waxy materials such as for example glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate; thermal-reversible polymers such as for example polycaprolactones and polyvinyl acetate.
- an impermeable barrier can be formed which consists essentially of the thermal reversible carrier.
- an additional release-modifying agent is not necessary.
- the release-modifying agent is preferably selected from water insoluble polymers such as cellulose acetate, acrylates, acrylic acid copolymers, cellulose acetate, cellulose acetate propionate, cellulose acetate propionate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate, cellulose acetate ethyl carbamate, cellulose acetate methyl carbamate, cellulose acetate diethyl aminoacetate, ethylcellulose, methacrylates, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, and the like, and mixtures thereof.
- the shell or shell portion may optionally further comprise a liquid carrier such as for example mineral oil, propylene
- Dosage forms according to the invention comprising a core having a first core portion and a second core portion within a shell having a first shell portion and a second shell portion were prepared as follows.
- the pseudoephedrine HCl crystal, hydroxypropyl methylcellulose, and PEO were first mixed in a plastic bag for 1-2 minutes. This powder mixture was added into the 5 qt. bowl of a planetary mixer (available from Hobart Corp., Dayton, Ohio). The alcohol was added to the powder mixture while mixing at low speed. The ingredients were mixed for 10 minutes. The resulting granulation was removed from the bowl and dried at room temperature for 12 to 16 hours to remove all residual solvent. The granulation was screened through a #20 mesh screen and put into a plastic bag. Magnesium stearate was added to the dry granules, followed by mixing for 3 minutes to form the second core portion.
- Cores were made from two different portions (by weight) of the first and second core portions as follows.
- a model M hydraulic Carver Laboratory Press (available from Fred S. Carver, Inc., Hydraulic Equipment, Summit, N.J.) was employed.
- a round, concave punch and die unit having a 0.4375′′ diameter was used for compression.
- the osmotic layer granulation (186 mg) for the first core portion was fed into the cavity mold of the press and was gently tapped. Then the pseudoephedrine HCl granulation (434 mg) for the second core portion was fed into the cavity overlying the osmotic granulation.
- the granulations were pressed into a solid two-portion core using 1600 lb/sq. in. of compression force.
- the cellulose acetate was added to a beaker containing acetone and mixed using a mixer until all powder was dissolved. An agitating speed of 500 rpm was used. PEO, which was screened through a #40 mesh screen, was added to the cellulose acetate solution, which was again mixed until all powder was dispersed. The shell portion material was provided in flowable form.
- a laboratory scale thermal cycle molding unit was used to apply the first and second shell portions to the core, and comprised a single mold assembly made from an upper mold assembly portion comprising an upper mold cavity, and a lower mold assembly portion comprising a lower mold cavity.
- the lower mold assembly portion was first cycled to a cold stage at 5° C. for 30 seconds.
- the shell portion material was added to the lower mold cavity.
- a two-portion core as described above was inserted into the lower mold cavity such that the first core portion, containing osmotic layer granules, was inserted into the lower mold cavity.
- a blank upper mold assembly portion was mated the lower mold assembly portion.
- the mold assembly was then cycled to a hot stage at 85° C. for 2 minutes. Next, the assembly was cycled to a cold stage at 5° C. for 1 minute to harden the first shell portion.
- the blank upper mold assembly portion was then removed from the lower mold assembly portion.
- the upper mold assembly portion was next cycled to a cold stage at 5° C. for 30 seconds.
- the shell portion material was added to the upper mold cavity.
- the half-coated core, with the first shell portion, was inserted into the upper mold cavity such that the uncoated core portion containing pseudoephedrine HCl sustained release granules rested within the upper mold cavity.
- the lower mold assembly portion which had been maintained at 5° C., was then mated with the upper mold assembly portion.
- the upper mold assembly portion was then cycled to a hot stage at 85° C. for 2 minutes, followed by a cold stage at 5° C. for 1 minute to harden the second shell portion.
- the lower mold assembly portion was removed and the finished dosage form, a two-portion core coated with the same shell portion, was ejected form the upper mold cavity.
- the weight gain due to the shell portion i.e. the difference in weights of the finished dosage form and the uncoated core, was recorded.
- the finished dosage form was dried at room temperature for 12 hours to remove all residual solvent.
- a 0.55 mm aperture was manually drilled on the pseudophedrine HCl layer side of the dosage form by using a pin of diameter of 0.55 mm.
Abstract
A dosage form comprises: (a) at least one active ingredient; (b) a core having an outer surface; and (c) a shell which resides upon at least a portion of the core outer surface, wherein at least a portion of the shell is semipermeable, such that the liquid medium diffuses through the semipermeable shell or shell portion to the core due to osmosis. The shell also provides for delivery of the active ingredient to a liquid medium outside the shell after contacting of the dosage form with the liquid medium. The dosage form delivers one or more active ingredients in a controlled manner upon contacting of the dosage form with a liquid medium. The dosage form may be employed to provide a burst release of the active ingredient, or to provide release of the active ingredient at an ascending release rate over an extended time period upon contacting of the dosage form with a liquid medium.
Description
- This is a continuation-in-part of PCT Application Nos. PCT/IUS02/31129, filed Sep. 28, 2002; PCT/US02/31117, filed Sep. 28, 2002; PCT/US02/31062, filed Sep. 28, 2002; PCT/US02/31024, filed Sep. 28, 2002; and PCT/US02/31163, filed Sep. 28, 2002, which are each continuations-in-part of U.S. Ser. No. 09/966,939, filed Sep. 28, 2001; U.S. Ser. No. 09/966,509, filed Sep. 28, 2001; U.S. Ser. No. 09/966,497, filed Sep. 28, 2001; U.S. Ser. No. 09/967,414, filed Sep. 28, 2001; and U.S. Ser. No. 09/966,450, filed September 28, the disclosures of all of the above being incorporated herein by reference in their entirety.
- 1. Field of the Invention
- This invention relates to modified release dosage forms such as modified release pharmaceutical compositions, and methods of providing predetermined active ingredient concentrations, which may be substantially constant or substantially non-constant, over an extended period of time, using such dosage forms. More particularly, this invention relates to modified release dosage forms for delivering one or more active ingredients in a controlled or delayed manner upon contacting of the dosage form with a liquid medium. The dosage form contains at least one active ingredient, and has a core and a shell. At least a portion of the shell is semipermeable to a liquid medium such as the gastro-intestinal (GI) fluids of a patient, such that the liquid medium diffuses through the semipermeable shell or shell portion to the core, for example due to osmosis. The shell or shell portion also provides for delivery of active ingredient to the liquid medium outside of the dosage form after the dosage form is contacted with the liquid medium.
- 2. Background Information
- Modified release pharmaceutical dosage forms have long been used to optimize drug delivery and enhance patient compliance, especially by reducing the number of doses of medicine the patient must take in a day. For this purpose, it is often desirable to modify the rate of release of a drug (one particularly preferred type of active ingredient) from a dosage form into the GI fluids of a patient, especially to slow the release to provide prolonged action of the drug in the body.
- The rate at which an orally delivered pharmaceutical active ingredient reaches its site of action in the body depends on a number of factors, including the rate and extent of drug absorption through the GI mucosa. To be absorbed into the circulatory system (blood), the drug must first be dissolved in the GI fluids. For many drugs, diffusion across the GI membranes is relatively rapid compared to dissolution. In these cases, the dissolution of the active ingredient is the rate limiting step in drug absorption, and controlling the rate of dissolution allows the formulator to control the rate of drug absorption into the circulatory system of a patient.
- An important objective of modified release dosage forms is to provide a desired blood concentration versus time (pharmacokinetic, or PK) profile for the drug. Fundamentally, the PK profile for a drug is governed by the rate of absorption of the drug into the blood, and the rate of elimination of the drug from the blood. The type of PK profile desired depends, among other factors, on the particular active ingredient, and physiological condition being treated.
- A particularly desirable PK profile for a number of drugs and conditions is one in which the level of drug in the blood is maintained essentially constant (i.e. the rate of drug absorption is approximately equal to the rate of drug elimination) over a relatively long period of time. Such systems have the benefit of reducing the frequency of dosing, improving patient compliance, as well as minimizing side effects while maintaining full therapeutic efficacy. A dosage form which provides a “zero-order,” or constant release rate of the drug is useful for this purpose. Since zero-order release systems are difficult to achieve, systems which approximate a constant release rate, such as for example first-order and square root of time profiles are often used to provide sustained (e.g. prolonged, extended, or retarded) release of a drug.
- Another particularly desirable PK profile is an “ascending blood level” profile. This is achieved when the rate of absortion of drug into the blood (circulation) exceeds its rate of elimination from the blood for a period of time, producing an increasing blood level ofer the course of the dosing interval or a portion thereof. This type of PK profile is exemplified in PCT Publication No. WO99/62946.
- Another particularly desirable PK profile is achieved by a dosage form that delivers a delayed release dissolution profile, in which the release of one or more doses of drug from the dosage form is delayed for a pre-determined time after contact with a liquid medium, e.g. ingestion by the patient. The delay period (“lag time”) can be followed either by prompt release of the active ingredient (“delayed burst”), or by sustained (prolonged, extended, or retarded) release of the active ingredient (“delayed then sustained”).
- One particularly desirable type of delayed release PK profile, is a “pulsatile” profile, in which for example, a first dose of a first drug is delivered, followed by a delay period during which there is substantially no release of the first drug from the dosage form, followed by either prompt or sustained release of a subsequent dose of the same drug. In one particularly desirable type of pulsatile drug delivery system, the first dose is released essentially immediately upon contacting of the dosage form with a liquid medium. In another particularly desirable type of pulsatile drug delivery system, the delay period corresponds approximately to the time during which a therapeutic concentration of the first dose is maintained in the blood. Pulsatile delivery systems are particularly useful for applications where a continuous release of drug is not ideal. Examples of this are drugs exhibiting first pass metabolism by the liver, drugs that induce biological tolerance (i.e. the therapeutic effect decreases with continuous presence of the drug at the site of action), and drugs whose efficacy is influenced by circadian rhythms of body functions or diseases.
- It is also particularly desirable for a pharmaceutical dosage form to deliver more than one drug at a modified rate. Because the onset and duration of the therapeutic efficacy of drugs vary widely, as do their absorption, distribution, metabolism, and elimination, it is often desirable to modify the release of different drugs in different ways, or to have a first active ingredient immediately released from the dosage form, while a second drug is released in a delayed, controlled, sustained, prolonged, extended, or retarded manner.
- Well known mechanisms by which a dosage form (or drug delivery system) can deliver drug at a controlled rate (e.g. sustained, prolonged, extended or retarded/release) include diffusion, erosion, and osmosis.
- One classic diffusion-controlled release system comprises a “reservoir” containing the active ingredient, surrounded by a “membrane” through which the active ingredient must diffuse to be absorbed into the bloodstream of the patient. The rate of drug release, dM/dt depends on the area (A) of the membrane, the diffusional pathlength (1), the concentration gradient (AC) of the drug across the membrane, the partition coefficient (K) of the drug into the membrane, and the diffusion coefficient (D) according to the following equation:
- dM/dt={ADKΔC}/1
- Since one or more of the above terms, particularly the diffusional pathlength, and concentration gradient tend to be non-constant, diffusion-controlled systems generally deliver a non-constant release rate. In general, the rate of drug release from diffusion-controlled release systems typically follows first order kinetics.
- Another common type of diffusion-controlled release system comprises active ingredient, distributed throughout an insoluble porous matrix through which the active ingredient must diffuse to be absorbed into the bloodstream of the patient. The amount of drug release (M) at a given time at sink conditions (i.e. drug concentration at the matrix surface is much greater than drug concentration in the bulk solution) depends on the area (A) of the matrix, the diffusion coefficient (D), the porosity (E) and tortuosity (T) of the matrix, the drug solubility (Cs) in the dissolution medium, time (t) and the drug concentration (Cp) in the dosage form according to the following equation:
- M=A(DE/T(2Cp−ECs)(Cs)t)1/2
- It will be noted in the above relationship that the amount of drug released is generally proportional to the square root of time. Assuming factors such as matrix porosity and tortuosity are constant within the dosage form, a plot of amount of drug released versus the square root of time should be linear.
- A commonly used erosion-controlled release system comprises a “matrix” throughout which the drug is distributed. The matrix typically comprises a material which swells at the surface, and slowly dissolves away layer by layer, liberating drug as it dissolves. The rate of drug release (dM/dt) in these systems depends on the rate of erosion (dx/dt) of the matrix, the concentration profile in the matrix, and the surface area (A) of the system according to the following equation:
- dM/dt=A{dx/dt}{f(C)}
- Again, variation in one or more terms, such as surface area, typically lead to a non-constant release rate of drug. In general, the rate of drug release from erosion-controlled release systems typically follows first order kinetics.
- Another type of erosion controlled delivery system employs materials which swell and dissolve slowly by surface erosion to provide a delayed release of pharmaceutical active ingredient. Delayed release is useful, for example in pulsatile or repeat action delivery systems, in which an immediate release dose is delivered, followed by a pre-determined lag time before a subsequent dose is delivered from the system. In these systems, the lag time (T1) depends on the thickness (h) of the erodible layer, and the rate of erosion (dx/dt) of the matrix, which in turn depends on the swelling rate and solubility of the matrix components according to the following equation:
- T 1 =h(dx/dt)
- The cumulative amount of drug (M) released from these systems at a given time generally follows the equation:
- M=(dM/dt)(t−T 1)
- where dM/dt is generally described by either the diffusion-controlled or erosion-controlled equations above, and T1 is the lag time.
- It is often practical to design dosage forms which use a combination of the above mechanisms to achieve a particularly desirable release profile for a particular active ingredient. It will be readily recognized by those skilled in the art that a dosage form construct which offers multiple compartments, such as for example multiple core portions and/or multiple shell portions, is particularly advantageous for its flexibility in providing a number of different mechanisms for controlling the release of one or more active ingredients.
- In various embodiments of this invention, the modified release dosage forms of this invention act as osmotically controlled drug delivery systems. As discussed, for example, in Verma et al., “Osmotically Controlled Oral Drug Delivery,”Drug Development and Industrial Pharmacy, 26(7), pp. 695-708 (2000), osmotically controlled drug delivery systems offer a number of advantages over conventional controlled release delivery systems. The basic principle of operation of osmotic drug delivery systems employs the difference in osmotic pressure between the exterior and interior of a dosage form which contains active ingredient. For example, as discussed by Verna et al., in an elementary osmotic pump (EOP) system, an active ingredient, together with a suitable osmotic solute is contained within a core such as a compressed tablet, which is coated at least in part with a semipermeable membrane or shell having a small orifice therein. When this dosage form contacts a liquid medium such as the aqueous environment of the GI tract, the active ingredient draws liquid through the semipermeable membrane due to the osmotic pressure gradient and forms a saturated solution of active ingredient within the dosage form. Hydrostatic pressure thus develops within the dosage form, and is relieved by the flow of saturated solution through the orifice and out of the dosage form, thereby delivering the active ingredient to the patient until the pressures inside and outside the dosage form are equal. Such a system is exemplified in U.S. Pat. No. 3,845,770, which discloses (see FIG. 1 of U.S. Pat. No. 3,845,770) a device having a semipermeable wall which surrounds a compartment containing active ingredient. A passageway communicates with the compartment and the exterior of the device. Fluid permeates the wall into the compartment and produces a solution of active ingredient which is released through the passageway.
- Various improvements have also been made in the design of osmotic drug delivery systems. For example, U.S. Pat. No. 3,995,631 discloses a system in which a semipermeable membrane houses a solution of an osmotically effective solute and a flexible bag of relatively impervious material which contains active ingredient. The flexible bag is provided with dispensing means for dispensing active ingredient out of the flexible bag when liquid permeates the membrane and exerts mechanical compressing or deflating force on the bag.
- U.S. Pat. No. 4,111,202 discloses a dosage form having a semipermeable wall which surrounds an active ingredient compartment and an osmagent compartment. The two compartments are separated by a moveable film which is impermeable to the active ingredient and osmagent. The semipermeable wall has a passageway therethrough for delivering active ingredient from its compartment. The system operates by having fluid imbibe through the wall into the osmagent compartment and causing the osmagent compartment to expand in volume and move the film, thereby diminishing the volume of the active ingredient compartment and delivering the active ingredient through the passageway.
- U.S. Pat. No. 4,327,725 discloses a system having a semipermeable outer wall which contains an active agent compartment and a fluid swellable hydrogel compartment. The semipermeable wall has a passageway therethrough for delivering active ingredient in solution from its compartment when the hydrogel absorbs fluid passing through the outer wall and the hydrogel swells. A precipitate forms at the interface of the hydrogel and active ingredient to restrict the passage of active ingredient into the hydrogel, and to act as an in situ formed membrane to apply pressure against the active ingredient in solution.
- U.S. Pat. No. 4,449,983 discloses a system in which a semipermeable wall contains first and second compartments which each contain a different active ingredient. Each of the compartments has an orifice which permits delivery of the active ingredient from each compartment, and the two compartments are separated by a hydrogel partition. The hydrogel absorbs fluid and swells, causing delivery of a solution of active ingredient through the respective compartment orifices.
- U.S. Pat. No. 4,627,971 discloses a device in which a semipermeable wall which surrounds a compartment containing a first layer containing an active ingredient and a second layer containing a hydrogel and means for sealing or closing a passageway by forming a film under the influence of thermo laser energy. A first passageway permits delivery of the active ingredient out of the compartment, and a second passageway formed during the manufacture of the device is adjacent to the hydrogel layer. Upon exposure of the means to thermo laser energy, a film is formed and the second passageway is sealed. The hydrogel absorbs fluid and swells, causing delivery of a solution of active ingredient through the first passageway.
- U.S. Pat. No. 5,830,501 discloses a dosage form having a semipermeable wall which surrounds an internal compartment. The semipermeable wall contains at least one exit means such as a passageway, and the internal compartment contains an active ingredient, a flocculating hydrophilic polymer, a dehydrating agent, a surfactant, a swellable hydrophilic polymer, a lubricant, and an osmagent. When the dosage form is in a biological environment of use, the flocculating polymer precipitates and forms a floc containing the active ingredient. When fluid permeates the semipermeable wall, the swellable polymer and osmagent act as a push member to deliver the floc through the exit means. The floe lessens the tackiness and/or irritation of the mucosal tissue of the patient.
- U.S. Pat. No. 6,342,249 discloses a dosage form having a semipermeable wall with an exit orifice, in which the wall defines a cavity containing an active ingredient layer adjacent to the orifice and an expandable “push” layer remote from the orifice. The active ingredient layer contains a liquid active ingredient formulation absorbed in porous particles. A placebo layer to delay onset of delivery of the active ingredient may optionally be placed between the active ingredient layer and the exit orifice. When fluid permeates the semipermeable wall, the push layer expands to deliver the placebo (if employed) and particles containing active ingredient through the orifice.
- European Patent Publication No. 0384642 discloses a device for releasing active ingredient in a pulsed manner. The device comprises a water permeable or impermeable capsule containing an active ingredient and a water swellable material, in which the capsule has an opening which is closed by a water permeable plug. When fluid permeates into the capsule, the water swellable material expands to eject the plug and deliver the active ingredient through the opening. If the flux of liquid through the plug is sufficient to achieve the desired pulsed release of active ingredient, the capsule may be made of a water impermeable material.
- The modified release dosage forms of this invention employ a core and a shell, which may optionally comprise multiple portions having different compositions and/or functions. The dosage forms of this invention are prepared by a novel method which enables at least portion of the shell to be semipermeable. In contrast, current core-shell systems are limited by the available methods for manufacturing them, as well as the materials that are suitable for use with the current methods. A shell, or coating, which confers modified release properties is typically applied via conventional methods, such as for example, spray-coating in a coating pan. Pan-coating produces a single shell which essentially surrounds the core. The single shell is inherently limited in its functionality. It is possible via pan-coating to apply multiple concentric shells, each with a different functionality, however such systems are limited in that the outer shell must first dissolve before the functionality conferred by each successive layer can be realized. It is also known, via pan coating, to deliver a first dose of active ingredient from a coating, and a second dose of active ingredient from a core. Dosage forms having sprayed coatings which provide delayed release are described, for example, in Maffione et al., “High-Viscosity HPMC as a Film-Coating Agent,”Drug Development and Industrial Pharmacy (1993) 19(16), pp. 2043-2053. U.S. Pat. No. 4,576,604, for example, discloses an osmotic device (dosage form) comprising a drug compartment surrounded by a wall (coating) in which the coating may comprise an immediate release dose of drug, and the inner drug compartment may comprise a sustained release dose of drug. The coating compositions that can be applied via spraying are limited by their viscosity. High viscosity solutions are difficult or impractical to pump and deliver through a spray nozzle. Spray coating methods suffer the further limitations of being time-intensive and costly. Several hours of spraying may be required to spray an effective amount of coating to control the release of an active ingredient. Coating times of 8 to 24 hours are not uncommon.
- It is one object of this invention to provide a modified release dosage form in which at least one active ingredient contained therein exhibits a modified release profile upon contacting of the dosage form with a liquid medium. It is one feature of the dosage form of this invention that it has a semipermeable shell or shell portion. It is another feature of this invention that the semipermeable shell or shell portion allows the liquid medium to diffuse through the shell or shell portion to the core, for example due to osmosis and permeate into the core. It is another feature of this invention that the shell provides for delivery of liquid medium carrying active ingredient out of the dosage form. Other objects, features and advantages of the invention will be apparent to those skilled in the art from the detailed description set forth below.
- The invention provides a dosage form comprising (a) at least one active ingredient; (b) a core having an outer surface having an outer surface; and (c) a shell which resides upon at least a portion of the core outer surface, wherein at least a portion of the shell is semipermeable, at least about 30% of the cross-sectional area of the semipermeable shell portion is non-striated, and the shell comprises means for providing the active ingredient to a liquid medium outside the shell after contacting of the dosage form with the liquid medium.
- The invention also provides a dosage from comprising (a) at least one active ingredient; (b) a core having an outer surface; and (c) a shell which resides upon at least a portion of the core outer surface, wherein the shell comprises a first shell portion which is semipermeable to the liquid medium, and a second shell portion which is compositionally different than the first shell portion, the first and second shell portions each are substantially in contact with the core outer surface, and the shell comprises means for providing the active ingredient to a liquid medium outside the shell after contacting of the dosage form with the liquid medium.
- The invention further provides a dosage form comprising: (a) at least one active ingredient; (b) a core having an outer surface, a first core portion, a second core portion, and a third core portion located between the first and second core portions, wherein the third core portion comprises an osmopolymer; (c) and a shell which resides upon at least a portion of the core outer surface, in which the shell comprises a first shell portion which is semipermeable to the liquid medium, and a second shell portion which is compositionally different than the first shell portion, the first and second shell portions each are substantially in contact with the core outer surface, and at least one of the first or second shell portions has at least one passageway therein extending to the core outer surface.
- The invention also provides a dosage form comprising (a) at least one active ingredient; (b) a core having an outer surface; (c) and a shell which resides upon at least a portion of the core outer surface, in which the shell comprises a first shell portion which is semipermeable to the liquid medium, and a second shell portion which is compositionally different than the first shell portion, the first and second shell portions each are substantially in contact with the core outer surface, and the shell and core have a continuous cavity therein defining an interior surface, wherein neither the first shell portion nor the second shell portion extend substantially upon the interior surface.
- The invention further provides a dosage form comprising: (a) at least one active ingredient; (b) a core having an outer surface, a first core portion, a second core portion, and a third core portion located between the first and second core portions, wherein the third core portion comprises a osmopolymer; and (c) a shell which resides upon at least a portion of the core outer surface, in which the shell comprises a first shell portion which is semipermeable to the liquid medium, and a second shell portion which is compositionally different than the first shell portion, the first and second shell portions each are substantially in contact with the core outer surface, and the shell and core have a continuous cavity therein defining an interior surface, wherein neither the first shell portion nor the second shell portion extend substantially upon the interior surface.
- FIG. 1A depicts a cross-sectional side view of one embodiment of the dosage form of this invention.
- FIG. 1B depicts a cross-sectional side view of another embodiment of the dosage form of this invention.
- FIG. 2 depicts a cross-sectional side view of another embodiment of the dosage form of this invention.
- FIG. 3 depicts a cross-sectional side view of another embodiment of the dosage form of this invention.
- FIG. 4 depicts a cross-sectional side view of another embodiment of the dosage form of this invention.
- FIG. 5 depicts a cross-sectional side view of another embodiment of the dosage form of this invention.
- FIG. 6 depicts a cross-sectional side view of another embodiment of the dosage form of this invention.
- FIGS. 7A and 7B depict cross-sectional micrographs of a prior art coated composition.
- FIGS. 8A and 8B depict cross-sectional micrographs of an embodiment of this invention.
- FIG. 9 depicts the release profile of active ingredient for the dosage form of this invention described in Example 1 herein.
- As used herein, the term “dosage form” applies to any solid object, semi-solid, or liquid composition designed to contain a specific pre-determined amount (dose) of a certain ingredient, for example an active ingredient as defined below. Suitable dosage forms include pharmaceutical drug delivery systems, including those for oral administration, buccal administration, rectal administration, topical or mucosal delivery, or subcutaneous implants, or other implanted drug delivery systems; or compositions for delivering minerals, vitamins and other nutraceuticals, oral care agents, flavorants, and the like. Preferably the dosage forms of the present invention are considered to be solid, however they may contain liquid or semi-solid components. In a particularly preferred embodiment, the dosage form is an orally administered system for delivering a pharmaceutical active ingredient to the GI tract of a human.
- The dosage forms of this invention exhibit modified release of one or more active ingredients contained therein. The active ingredient or ingredients may be found within the core, the shell, or a portion or combination thereof. As used herein, the term “modified release” shall apply to dosage forms, coatings, shells, cores, portions thereof, or compositions that alter the release of an active ingredient in any manner. The active ingredient or ingredients that are released in a modified manner may be contained within the coating, shell, core, composition, or portion thereof providing the modification. Alternatively the modified release active ingredient may be contained in a different portion of the dosage form from the coating, shell, core, composition, or portion thereof providing the modification; for example the modified release active ingredient may be contained in a core portion, and the modification may be provided by the overlaying shell portion. Types of modified release include controlled, prolonged, sustained, extended, delayed, pulsatile, repeat action, and the like. Suitable mechanisms for achieving these types of modified release include diffusion, erosion, surface area control via geometry and/or impermeable barriers, or other mechanisms known in the art. Moreover, the modified release properties of the dosage form may be achieved through design of the core or a portion thereof, or the shell or portion thereof, or a combination of two or more of these parts of the dosage form.
- The dissolution profile of each active ingredient from the dosage form may be governed by a sum of contributions from the properties of the various portions. Additionally, a single portion, for example a core portion may possess a combination of erosional and diffusional properties. In any case, the dissolution rate of a particular active ingredient from the dosage form will be the sum of the contributions from all the various mechanisms contributed by the various portions of the dosage form which effect the release of that particular active ingredient
- The dosage forms of the present invention are designed to release substantially all (i.e. at least about 80%, or at least about 90%, say at least about 95%) of the active ingredient contained therein, within a specified amount of time. As used herein, the total amount of time required for substantially all of the active ingredient(s) to be released from the dosage form shall be referred to as the “dosing interval.” During the dosing interval, the amount of drug released is typically measured at several time points.
- As used herein, the term “time interval” shall refer to periods of time during the dosing interval, over which a periodic rate of release may be measured. The time interval may be the entire dosing interval, or a portion thereof.
- As used herein, a drug “release rate” refers to the quantity of drug released from a dosage form per unit time, e.g., milligrams of drug released per hour (mg/hr). Drug release rates are calculated under in vitro dosage form dissolution testing conditions known in the art. As used herein, a drug release rate obtained at a specified time “following administration” refers to the in vitro drug release rate obtained at the specified time following implementation of an appropriate dissolution test.
- As used herein, a “periodic release rate” refers to the quantity per unit time of drug released from a dosage form during a specified periodic interval as determined at the end of that specified periodic interval, i.e., at each periodic interval when a determination is made, the quantity per unit time of drug released represents the periodic release rate during that periodic interval. For example, the quantity of drug released per hour (h) determined as the difference in quantity released between t=0 and t=2h divided by the time interval of 2 hours represents the periodic release rate during the first two hours following administration, the quantity of drug released per hour as determined from t=2h to t=4h represents the periodic release rate from two to four hours following administration, etc.
- As used herein, a “constant release rate” is obtained over a given time interval when the periodic release rates determined during two or more portions of the time interval are substantially the same, i.e. not more than 6% different. As used herein, “non-constant release rate” shall mean two or more periodic release rates are not the same, i.e. more than 6% different, over the entire duration of the specified interval.
- As used herein, an “ascending release rate” refers to a periodic release rate that is increased over the immediately preceding periodic release rate. For example, when the quantity of drug released from a dosage form is measured at hourly intervals and the quantity of drug released during the fifth hour following administration is greater than the quantity of drug released from the dosage form during the fourth hour following administration, an ascending release rate from the fourth hour to the fifth hour has occurred. It will be appreciated that the first periodic release rate measured, e.g., the periodic release rate at t=1 hour (unless equal to 0), will always be greater than the release rate during the preceding period, e.g., the hour before the dosage form was administered, and thus, the first periodic release rate always constitutes an occurrence of an ascending release rate.
- As used herein, “ascending blood level” refers to the PK profile obtained when the rate of release of drug from the dosage form, and also its absorption into the bloodstream, exceeds its reate of elimination from the blood of a mammal for a period of time, producing an increasing blood level ofer the course of the dosing interval or a portion thereof.
- As used herein, a “burst release” profile refers to a release profile which meets immediate release criteria during a specified interval. The specified interval may optionally follow a pre-determined lag time.
- A first embodiment of this invention is depicted in FIG. 1A, which is a cross-sectional view of a
dosage form 2 which comprises acore 4 and ashell 5. In other embodiments of this invention,shell 5 may reside upon a portion ofcore 4 without surroundingcore 4. In this embodiment of the invention,shell 5 is semipermeable to a liquid medium, and at least about 30% of the cross-sectional area of thesemipermeable shell 5 is non-striated as is discussed further herein.Core 4 contains at least one active ingredient, andshell 5 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained withincore 4. In this embodiment of the invention,shell 5 containspassageway 12 which extends from the outer surface ofshell 5 to the outer surface ofcore 4, as shown. In other embodiments of this invention, a plurality of passageways may be employed. Accordingly, upon contacting ofdosage form 2 with a liquid medium, the liquid medium permeatesshell 5, reaches core 4 (where active ingredient, and optionally osmagent or osmopolymer, are contained), and liquid medium containing active ingredient is osmotically “pumped” throughpassageway 12 and out ofdosage form 2 into the surrounding liquid medium. - Another embodiment of this invention is depicted in FIG. 11B, which is a cross-sectional view of a
dosage form 22 which comprises a core 24, afirst shell portion 25 and asecond shell portion 26, which in thisembodiment surround core 24. In other embodiments of this invention,first shell portion 25 orsecond shell portion 26 may reside upon a portion ofcore 24 without surroundingcore 24.First shell portion 25 is semipermeable to a liquid medium andsecond shell portion 26 is compositionally different thanfirst shell portion 25. In the embodiment depicted in FIG. 1B,second shell portion 26 is diffusible.Core 24 contains at least one active ingredient, andfirst shell portion 25 and/orsecond shell portion 26 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained withincore 24. Accordingly, upon contacting ofdosage form 22 with a liquid medium, the liquid medium permeatesfirst shell portion 25, reaches core 24 (where active ingredient is contained), and liquid medium containing active ingredient is osmotically “pumped” through diffusiblesecond shell portion 26 and out ofdosage form 22 into the surrounding liquid medium. In other embodiments,second shell portion 26 may be erodible, thereby permitting active ingredient to be released from the core 24 assecond shell portion 26 erodes to exposecore 24 to the liquid medium. - Another embodiment of this invention is depicted in FIG. 2, which is a cross-sectional side view of a
dosage form 202 which comprises acore 204 and ashell 206 having afirst shell portion 208 which is semipermeable to the liquid medium, and asecond shell portion 210 which is compositionally different thanfirst shell portion 208. For example,second shell portion 210 may be diffusible, impermeable or erodible.Core 204 contains at least one active ingredient, and shell 206 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained withincore 204. In this embodiment of the invention,first shell portion 208 containspassageway 212 which extends from the outer surface offirst shell portion 208 to the outer surface ofcore 204, as shown. In other embodiments of this invention,first shell portion 208 may contain a plurality of passageways. In this embodiment,first shell portion 208 is semipermeable, andsecond shell portion 210 is impermeable. Accordingly, upon contacting ofdosage form 202 with a liquid medium, the liquid medium permeatesfirst shell portion 208, reaches core 204 (where active ingredient, and optionally osmagent or osmopolymer are contained), and liquid medium containing active ingredient is osmotically “pumped” throughpassageway 212 and out ofdosage form 202 into the surrounding liquid medium. In other embodiments of this invention (not shown in FIG. 2),second shell portion 210 may contain at least one passageway which extends from the outer surface ofsecond shell portion 210 to the outer surface ofcore 204, or bothfirst shell portion 208 andsecond shell portion 210 may each contain at least one passageway which extends from the outer surface offirst shell portion 208 andsecond shell portion 210, respectively, to the outer surface ofcore 204. - Another embodiment of this invention is depicted in FIG. 3, which is a cross-sectional side view of a
dosage form 302 which comprises acore 304 havingfirst core portion 303 andsecond core portion 305, and shell 306 having a plurality ofpassageways 312 therein which extend from the outer surface ofshell 306 to the outer surfaces of first andsecond core portions shell 306 may have a single passageway.Core 304 contains at least one active ingredient, and shell 306 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained withincore 304. At least a portion ofshell 306 is semipermeable to a liquid medium, and at least about 30% of the cross-sectional area of the semipermeable portion of the shell is non-striated. Upon contacting ofdosage form 302 with a liquid medium, the liquid medium permeatesshell 306, reaches first andsecond core portions passageways 312 and out ofdosage form 302 into the surrounding liquid medium. In one embodiment,first core portion 303 contains a first active ingredient andsecond core portion 305 contains a second active ingredient which may be the same or different than the first active ingredient. In another preferred embodiment, first andsecond core portions passageways 312 inshell 306 may expose different surface areas of theunderlying core portions - Another embodiment of this invention is depicted in FIG. 4, which is a cross-sectional side view of a
dosage form 402 which comprises acore 404 havingfirst core portion 403,second core portion 405, andthird core portion 407, and shell 406 comprising first andsecond shell portions passageways 412 extend from the outer surface ofshell 406 to the outer surfaces of first andsecond core portions shell 406 may have a single passageway located in eitherfirst shell portion 408 orsecond shell portion 410. In this embodiment,first shell portion 408 andsecond shell portion 410 are each semipermeable to a liquid medium.Second shell portion 410 may be compositionally different thanfirst shell portion 408. For example, in other embodimentsfirst shell portion 408 may be semipermeable, andsecond shell portion 410 may be diffusible, impermeable or erodible.Core 404 contains at least one active ingredient, and shell 406 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained withincore 404. In the embodiment depicted in FIG. 4,first core portion 403 contains a first active ingredient,second core portion 405 contains a second active ingredient which may be the same or different than the first active ingredient, andthird core portion 407 contains an osmopolymer which provides osmotic pressure upon contact with the liquid medium to push the active ingredients through thepassageways 412 to the surface ofshell 406. In the embodiment depicted in FIG. 4, upon contacting ofdosage form 402 with a liquid medium, the liquid medium permeates the first andsecond shell portions second core portions third core portion 407 containing the osmopolymer (which swells and compresses against first andsecond core portions 403 and 405), and liquid medium containing active ingredient is osmotically “pumped” throughpassageways 412 and out ofdosage form 402 into the surrounding liquid medium. In addition,passageways 412 in first andsecond shell portions underlying core portions - Another embodiment of this invention is depicted in FIG. 5, which is a cross-sectional side view of a
dosage form 502 which comprises acore 504 and ashell 506 having afirst shell portion 508 which is semipermeable to the liquid medium, and asecond shell portion 510 which is compositionally different thanfirst shell portion 508. For example,second shell portion 510 may be semipermeable, diffusible, impermeable or erodible, although in this embodimentsecond shell portion 510 is semipermeable.Core 504 contains at least one active ingredient, and shell 506 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained withincore 504. As depicted in FIG. 5, cavity 501 extends throughcore 504,first shell portion 508 andsecond shell portion 510. Theinterior surface 513 ofcore 504 is defined by cavity 501, and neitherfirst shell portion 508 norsecond shell portion 510 substantially extend uponinterior surface 513, thereby permitting active ingredient contained withincore 504 to be released only throughinterior surface 513. The diameter of the continuous cavity is preferably in the range of about 15 to about 90 percent of the thickness of the dosage form, and the diameter of the continuous cavity is preferably in the range of about 5 to about 30 percent of the core diameter. The length of the continuous cavity is typically about the same as the thickness of the dosage form, and the length of the continuous cavity is preferably about 25 to about 40 percent of the diameter of the dosage form. Upon contacting ofdosage form 502 with a liquid medium, the liquid medium permeatesinterior surface 513, as well as first andsecond shell portions interior surface 513 into central cavity 501 and out ofdosage form 502 into the surrounding liquid medium. In this embodiment, the predominant mechanism for drug release is erosion. - Another embodiment of this invention is depicted in FIG. 6, which is a cross-sectional side view of a
dosage form 602 which comprises acore 604 havingfirst core portion 603,second core portion 605, and third core portion 607, and ashell 606 having afirst shell portion 608 which is semipermeable to the liquid medium, and asecond shell portion 610 which is compositionally different thanfirst shell portion 608. For example,second shell portion 610 may be semipermeable, diffusible, impermeable or erodible, although in this embodimentsecond shell portion 610 is semipermeable.Core 604 contains at least one active ingredient, and shell 606 may optionally contain at least one active ingredient which may be the same or different than the active ingredient contained withincore 604. As depicted in FIG. 6,cavity 601 extends throughcore 604,first shell portion 608 andsecond shell portion 610. Theinterior surface 613 ofcore 604 is defined bycavity 601, and neitherfirst shell portion 608 norsecond shell portion 610 substantially extend uponinterior surface 613, thereby permitting active ingredient contained withincore 604 to be released only throughinterior surface 613. In one embodiment,first core portion 603 contains a first active ingredient,second core portion 605 contains a second active ingredient which may be the same or different than the first active ingredient, and third core portion 607 contains a osmopolymer which provides osmotic pressure upon contact with the liquid medium to push the active ingredients through theinterior surface 613 and into the liquid medium. The diameter of the continuous cavity is preferably in the range of about 15 to about 90 percent of the thickness of the dosage form, and the diameter of the continuous cavity is preferably in the range of about 5 to about 30 percent of the core diameter. The length of the continuous cavity is typically about the same as the thickness of the dosage form, and the length of the continuous cavity is preferably about 25 to about 40 percent of the diameter of the dosage form. Upon contacting ofdosage form 602 with the liquid medium, the liquid medium permeatesinterior surface 613, as well as the first andsecond shell portions second core portions first core portion 603 and second core portion 605), and liquid medium containing the active ingredient or ingredients passes throughinterior surface 613 intocentral cavity 601 and out ofdosage form 602 into the surrounding liquid medium. In this embodiment, the predominant mechanism for drug release is erosion. - In embodiments of this invention in which the shell comprises at least two shell portions, the inner surface of each shell portion must be substantially in contact with the outer surface of the core, as depicted, for example, in FIGS. 1B, 2,4, 5 and 6. Accordingly, in such embodiments, the inner surface of any shell portion does not reside upon the outer surface of any other shell portion.
- Suitable active ingredients for use in this invention include for example pharmaceuticals, minerals, vitamins and other nutraceuticals, oral care agents, flavorants and mixtures thereof. Suitable pharmaceuticals include analgesics, anti-inflammatory agents, antiarthritics, anesthetics, antihistamines, antitussives, antibiotics, anti-infective agents, antivirals, anticoagulants, antidepressants, antidiabetic agents, antiemetics, antiflatulents, antifungals, antispasmodics, appetite suppressants, bronchodilators, cardiovascular agents, central nervous system agents, central nervous system stimulants, decongestants, oral contraceptives, diuretics, expectorants, gastrointestinal agents, migraine preparations, motion sickness products, mucolytics, muscle relaxants, osteoporosis preparations, polydimethylsiloxanes, respiratory agents, sleep-aids, urinary tract agents and mixtures thereof.
- Suitable oral care agents include breath fresheners, tooth whiteners, antimicrobial agents, tooth mineralizers, tooth decay inhibitors, topical anesthetics, mucoprotectants, and the like.
- Suitable flavorants include menthol, peppermint, mint flavors, fruit flavors, chocolate, vanilla, bubblegum flavors, coffee flavors, liqueur flavors and combinations and the like.
- Examples of suitable gastrointestinal agents include antacids such as calcium carbonate, magnesium hydroxide, magnesium oxide, magnesium carbonate, aluminum hydroxide, sodium bicarbonate, dihydroxyaluminum sodium carbonate; stimulant laxatives, such as bisacodyl, cascara sagrada, danthron, senna, phenolphthalein, aloe, castor oil, ricinoleic acid, and dehydrocholic acid, and mixtures thereof; H2 receptor antagonists, such as famotadine, ranitidine, cimetadine, nizatidine; proton pump inhibitors such as omeprazole or lansoprazole; gastrointestinal cytoprotectives, such as sucraflate and misoprostol; gastrointestinal prokinetics, such as prucalopride, antibiotics forH. pylori, such as clarithromycin, amoxicillin, tetracycline, and metronidazole; antidiarrheals, such as diphenoxylate and loperamide; glycopyrrolate; antiemetics, such as ondansetron, analgesics, such as mesalamine.
- In one embodiment of the invention, the active ingredient may be selected from bisacodyl, famotadine, ranitidine, cimetidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, antacids, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
- In another embodiment, the active ingredient is selected from analgesics, anti-inflammatories, and antipyretics, e.g. non-steroidal anti-inflammatory drugs (NSAIDs), including propionic acid derivatives, e.g. ibuprofen, naproxen, ketoprofen and the like; acetic acid derivatives, e.g. indomethacin, diclofenac, sulindac, tolmetin, and the like; fenamic acid derivatives, e.g. mefenamic acid, meclofenamic acid, flufenamic acid, and the like; biphenylcarbodylic acid derivatives, e.g. diflunisal, flufenisal, and the like; and oxicams, e.g. piroxicam, sudoxicam, isoxicam, meloxicam, and the like. In one particular embodiment, the active ingredient is selected from propionic acid derivative NSAID, e.g. ibuprofen, naproxen, flurbiprofen, fenbufen, fenoprofen, indoprofen, ketoprofen, fluprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, and pharmaceutically acceptable salts, derivatives, and combinations thereof. In another particular embodiment of the invention, the active ingredient may be selected from acetaminophen, acetyl salicylic acid, ibuprofen, naproxen, ketoprofen, flurbiprofen, diclofenac, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
- In another embodiment of the invention, the active ingredient may be selected from pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, astemizole, terfenadine, fexofenadine, loratadine, desloratadine, cetirizine, mixtures thereof and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
- Examples of suitable polydimethylsiloxanes, which include, but are not limited to dimethicone and simethicone, are those disclosed in U.S. Pat. Nos. 4,906,478, 5,275,822, and 6,103,260, the contents of each is expressly incorporated herein by reference. As used herein, the term “simethicone” refers to the broader class of polydimethylsiloxanes, including but not limited to simethicone and dimethicone.
- The active ingredient is present in the dosage form in a therapeutically effective amount, which is an amount that produces the desired therapeutic response upon oral administration and can be readily determined by one skilled in the art. In determining such amounts, the particular active ingredient being administered, the bioavailability characteristics of the active ingredient, the dosing regimen, the age and weight of the patient, and other factors must be considered, as known in the art. Typically, the dosage form comprises about 2 to about 75 weight percent, for example, the dosage form may comprise about 5 to about 50 weight percent, say about 7 to about 25 weight percent of a combination of one or more active ingredients. In one embodiment, the core comprises a total of at least about 25 weight percent, e.g. about 25 to about 75 weight percent (based on the weight of the core) of one or more active ingredients.
- The active ingredient may be present in the dosage form in any form. For example, the active ingredient may be dispersed at the molecular level, e.g. melted or dissolved, within the dosage form, or may be in the form of particles, which in turn may be coated or uncoated. If the active ingredient is in form of particles, the particles (whether coated or uncoated) typically have an average particle size of about 1-2000 microns. In one embodiment, such particles are crystals having an average particle size of about 1-300 microns. In another embodiment, the particles ate granules or pellets having an average particle size of about 50-2000 microns, preferably about 50-1000 microns, most preferably about 100-800 microns.
- In embodiments where an active ingredient is contained within the core, at least a portion of the active ingredient may be optionally coated with a release-modifying coating, as known in the art. This advantageously provides an additional tool for modifying the release profile of active ingredient from the dosage form. For example, the core may contain coated particles of one or more active ingredients, in which the particle coating confers a release modifying function, as is well known in the art. Examples of suitable release modifying coatings for particles are described in U.S. Pat. Nos. 4,173,626; 4,863,742; 4,980,170; 4,984,240; 5,286,497; 5,912,013; 6,270,805; and 6,322,819. Commercially available modified release coated active particles may also be employed. Accordingly, all or a portion of one or more active ingredients in the core may be coated with a release-modifying material.
- In embodiments in which it is desired for the active ingredient to be absorbed into the systemic circulation of an animal, the active ingredient or ingredients are preferably capable of dissolution upon contact with a fluid such as water, gastric fluid, intestinal fluid or the like. In one embodiment, the dissolution characteristics of one or more active ingredients are modified: e.g. controlled, sustained, extended, retarded, prolonged, delayed and the like. In one embodiment in which one or more active ingredients are released in a modified manner, the modified release active ingredient or ingredients are contained in the core. In one particular such embodiment, the dosage form releases one or more active ingredients contained in the core at a substantially constant rate over a specified time interval.
- In one embodiment, the dissolution characteristics of at least one active ingredient meets USP specifications for immediate release tablets containing the active ingredient. For example, for acetaminophen tablets,
USP 24 specifies that in pH 5.8 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released therefrom within 30 minutes after dosing, and for ibuprofen tablets,USP 24 specifies that in pH 7.2 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the ibuprofen contained in the dosage form is released therefrom within 60 minutes after dosing. SeeUSP 24, 2000 Version, 19-20 and 856 (1999). In embodiments in which at least one active ingredient is released immediately, the immediately released active ingredient is preferably contained in the shell or on the surface of the shell, e.g. in a further coating surrounding at least a portion of the shell. - In certain embodiments, the core or core portions function as an eroding matrix from which dispersed active ingredient is liberated by the dissolution of successive layers of the matrix surface. In these embodiments, the rate of active ingredient release from the core or core portion will depend on the dissolution rate of the matrix material. Particularly useful eroding matrix materials for providing surface erosion include those which first absorb liquid, then swell and/or gel prior to dissolving. In certain such embodiments, the eroding matrix core or core portion preferably comprises a release-modifying compressible or moldable excipient selected from swellable erodible hydrophilic materials, pH-dependent polymers, insoluble edible materials, and combinations thereof.
- In certain other embodiments, the core or core portions function as a diffusional matrix. In these embodiments, the core portion preferably comprises active ingredient, distributed throughout an insoluble porous matrix, which contains pores or channels through which fluids can enter the core or core portion, and the active ingredient must diffuse to be released from the dosage form. In these embodiments, the rate of active ingredient release from the core or core portion will depend upon the area (A) of the matrix, the diffusion coefficient (D), the porosity (E) and tortuosity (T) of the matrix, the drug solubility (Cs) in the dissolution medium, and the drug concentration (Cp) in the dosage form. In embodiments in which a core or core portion functions as a diffusional matrix, the release of the active ingredient from the core or core portion may be described as controlled, prolonged, sustained, or extended. In these embodiments, the contribution to active ingredient dissolution from the subject core portion may follow zero-order, first-order, or preferably square-root of time kinetics. In certain such embodiments, the diffusional matrix core or core portion preferably comprises a pore former.
- In embodiments in which the core or core portion functions to modify release of an active ingredient contained therein, the release of active ingredient may be further modified by the function of the surrounding shell or shell portion, as described above. In such embodiments, the release of the active ingredient from the dosage form will be governed by the sum of all the contributions acting upon it, e.g. from the relevant core or core portion and shell or shell portions, and may be described as controlled, prolonged, sustained, extended, delayed, or pulsatile. In these embodiments, the dissolution of active ingredient from the dosage form may follow zero-order, first-order, or square-root of time kinetics.
- In embodiments in which the core comprises multiple portions, the portions may comprise different materials, or be prepared by different methods, or both. In one particular embodiment a first core portion may be prepared by compression, and a second core portion may be prepared by molding.
- In certain embodiments, the core comprises multiple portions, which comprise different active ingredients or have different release-modifying properties, or both; and the shell comprises a corresponding number of multiple portions, which each cover a specific core portion in order to modify or further modify the release of one or more active ingredients contained within the respective core portion. For such embodiments, it is critical to have a manufacturing process which is capable of maintaining the orientation of the core prior to and during the application of the shell or each shell portion thereon. Advantageously, the orientation of the components of the dosage forms of the present invention can be precisely controlled, when manufactured using the thermal cycle or thermal setting apparatus and described below. In one such particularly preferred embodiment, the dosage form comprises a core comprising a first core portion and a second core portion which are compositionally different, wherein at least one of the first or second core portions comprises an active ingredient; and a shell which surrounds the core and comprises a first shell portion and a second shell portion which are compositionally different, wherein at least one of the first or second shell portions confers a modification to the release of an active ingredient contained in the underlying core portion.
- The core or core portion of the present invention may be prepared by any suitable method, including for example compression and molding, and depending on the method by which it is made, typically comprises active ingredient and a variety of excipients (inactive ingredients which may be useful for conferring desired physical properties to the core).
- In embodiments in which the core, or a portion thereof, is made by compression, suitable excipients include fillers, binders, disintegrants, lubricants, glidants, and the like, as known in the art. In embodiments in which the core is made by compression and additionally confers modified release of an active ingredient contained therein, the core preferably further comprises a release-modifying compressible excipient.
- Suitable fillers for use in making the core, or a portion thereof, by compression include water-soluble compressible carbohydrates such as sugars, which include dextrose, sucrose, maltose, and lactose, sugar-alcohols, which include mannitol, sorbitol, maltitol, xylitol, starch hydrolysates, which include dextrins, and maltodextrins, and the like, water soluble plastically deforming materials such as microcrystalline cellulose or other cellulosic derivatives, water-insoluble brittle fracture materials such as dicalcium phosphate, tricalcium phosphate and the like and mixtures thereof.
- Suitable binders for making the core, or a portion thereof, by compression include dry binders such as polyvinyl pyrrolidone, hydroxypropylmethylcellulose, and the like; wet binders such as water-soluble polymers, including hydrocolloids such as acacia, alginates, agar, guar gum, locust bean, carrageenan, carboxymethylcellulose, tara, gum arabic, tragacanth, pectin, xanthan, gellan, gelatin, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, inulin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, polyvinyl pyrrolidone, cellulosics, sucrose, starches, and the like; and derivatives and mixtures thereof.
- Suitable disintegrants for making the core, or a portion thereof, by compression, include sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, starches, microcrystalline cellulose, and the like.
- Suitable lubricants for making the core, or a portion thereof, by compression include long chain fatty acids and their salts, such as magnesium stearate and stearic acid, talc, glycerides and waxes.
- Suitable glidants for making the core, or a portion thereof, by compression, include colloidal silicon dioxide, and the like.
- Suitable release-modifying compressible excipients for making the core, or a portion thereof, by compression include swellable erodible hydrophillic materials, insoluble edible materials, pH-dependent polymers, and the like.
- Suitable swellable erodible hydrophilic materials for use as release-modifying excipients for making the core, or a portion thereof, by compression include: water swellable cellulose derivatives, polyalkalene glycols, thermoplastic polyalkalene oxides, acrylic polymers, hydrocolloids, clays, gelling starches, and swelling cross-linked polymers, and derivatives, copolymers, and combinations thereof. Examples of suitable water swellable cellulose derivatives include sodium carboxymethylcellulose, cross-linked hydroxypropylcellulose, hydroxypropyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyisopropylcellulose, hydroxybutylcellulose, hydroxyphenylcellulose, hydroxyethylcellulose (HEC), hydroxypentylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, hydroxypropylethylcellulose. Examples of suitable polyalkalene glycols include polyethylene glycol. Examples of suitable thermoplastic polyalkalene oxides include poly (ethylene oxide). Examples of suitable acrylic polymers include potassium methacrylatedivinylbenzene copolymer, polymethylmethacrylate, CARBOPOL (high-molecular weight cross-linked acrylic acid homopolymers and copolymers), and the like. Examples of suitable hydrocolloids include alginates, agar, guar gum, locust bean gum, kappa carrageenan, iota carrageenan, tara, gum arabic, tragacanth, pectin, xanthan gum, gellan gum, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, gelatin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan. Examples of suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof. Examples of suitable gelling starches include acid hydrolyzed starches, swelling starches such as sodium starch glycolate, and derivatives thereof. Examples of suitable swelling cross-linked polymers include cross-linked polyvinyl pyrrolidone, cross-linked agar, and cross-linked carboxymethylcellose sodium.
- Suitable insoluble edible materials for use as release-modifying excipients for making the core, or a portion thereof, by compression include water-insoluble polymers, and low-melting hydrophobic materials. Examples of suitable water-insoluble polymers include ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers; and the like and derivatives, copolymers, and combinations thereof. Suitable low-melting hydrophobic materials include fats, fatty acid esters, phospholipids, and waxes. Examples of suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts. Examples of suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GLYCOWAX-932, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides. Examples of suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid. Examples of suitable waxes include carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; and the like.
- Suitable pH-dependent polymers for use as release-modifying excipients for making the core, or a portion thereof, by compression include enteric cellulose derivatives, for example hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate; natural resins such as shellac and zein; enteric acetate derivatives such as for example polyvinylacetate phthalate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate; and enteric acrylate derivatives such as for example polymethacrylate-based polymers such as poly(methacrylic acid, methyl methacrylate) 1:2, which is commercially available from Rohm Pharma GmbH under the tradename EUDRAGIT S, and poly(methacrylic acid, methyl methacrylate) 1:1, which is commercially available from Rohm Pharma GmbH under the tradename EUDRAGIT L, and the like, and derivatives, salts, copolymers, and combinations thereof.
- Suitable pharmaceutically acceptable adjuvants for making the core, or a portion thereof, by compression include, preservatives; high intensity sweeteners such as aspartame, acesulfame potassium, sucralose, and saccharin; flavorants; colorants; antioxidants; surfactants; wetting agents; and the like and mixtures thereof
- In one embodiment, the core or a portion thereof comprises at least one osmagent, an osmotically effective solute or osmotically effective compound that can be blended homogeneously or heterogeneously with the core constituents to form a push member, acting as osmotically effective solutes that are soluble in liquid medium imbibed into the core, and exhibit an osmotic pressure gradient across the semipermeable shell or shell portion against an exterior liquid medium. Osmagents useful in the present invention include compounds disclosed at col. 8, lines 18-35 of U.S. Pat. No. 5,830,501, which is incorporated herein by reference.
- In another embodiment, the core or a portion thereof comprises at least one osmopolymer. The osmopolymer, if employed, exhibits fluid absorbing and or fluid imbibing properties. The osmopolymer comprises a hydrophilic polymer that can interact with water and aqueous biological fluids and then swell or expand to an equilibrium state. The osmopolymer exhibits the ability to retain a significant portion of the imbibed or absorbed fluid. Other osmopolymers include poly(hydroxyalkyl methacrylate) having a molecular weight of 20,000 to 5,000,000; poly(vinylpyrrolidone) having a molecular weight of about 10,000 to 360,000; poly(vinylalcohol) having a low acetate content and lightly cross-linked with glyoxal, formaldehyde, or glutaraidehyde and having a degree of polymerization from 2,000 to 30,000; poly(ethylene oxide) having a molecular weight from 10,000 to 7,800,000; acidic carboxy polymers known as carboxypolymethylene or as carboxyvinyl polymers, a polymer consisting of acrylic acid lightly cross-linked with polyallylsucrose and sold under the trade name CARBOPOL, acidic carboxy polymer having a molecular weight of 200,000 to 6,000,000, including sodium acidic carboxyvinyl hydrogel and potassium acidic carboxyvinyl hydrogel; CYANAMER polyacrylamide; and the like. Representative polymers, used for the purpose of the present invention, are known to those skilled in the art and described, for example, in Scott & Roff,Handbook of Common Polymers (published by the Chemical Company Cleveland, Ohio); Ratner & Hoffman, ACS Symposium Series, No.31, pp.1 to 36, (1976) (published by the American Chemical Society); and Schact, Recent Advances in Drug Delivery Systems, pp. 259 to 278 (published by Plenum Press, N.Y.).
- In embodiments in which the core or core portion is prepared by compression, a dry blending (i.e. direct compression), or wet granulation process may be employed. In a dry blending (direct compression) method, the active ingredient or ingredients, together with the excipients, are blended in a suitable blender, than transferred directly to a compression machine for pressing into tablets. In a wet granulation method, the active ingredient or ingredients, appropriate excipients, and a solution or dispersion of a wet binder (e.g. an aqueous cooked starch paste, or solution of polyvinyl pyrrolidone) are mixed and granulated. Alternatively a dry binder may be included among the excipients, and the mixture may be granulated with water or other suitable solvent. Suitable equipment for wet granulation are known in the art, including low shear, e.g. planetary mixers; high shear mixers; and fluid beds, including rotary fluid beds. The resulting granulated material is dried, and optionally dry-blended with further ingredients, e.g. adjuvants and/or excipients such as for example lubricants, colorants, and the like. The final dry blend is then suitable for compression. Methods for direct compression and wet granulation processes are known in the art, and are described in detail in, for example, Lachman, et al.,The Theory and Practice of Industrial Pharmacy, Chapter 11 (3rd ed. 1986).
- The dry-blended, or wet granulated, powder mixture is typically compacted into tablets using a rotary compression machine as known in the art, such as for example those commercially available from Fette America Inc. (Rockaway, N.J.), or Manesty Machines LTD (Liverpool, UK). In a rotary compression machine, a metered volume of powder is filled into a die cavity, which rotates as part of a “die table” from the filling position to a compaction position where the powder is compacted between an upper and a lower punch to an ejection position, where the resulting tablet is pushed from the die cavity by the lower punch and guided to an ejection chute by a stationary “take-off” bar.
- In one particular optional embodiment, the core or core portion may be prepared by the compression methods and apparatus described in copending U.S. patent application Ser. No. 09/966,509, pages 16-27, the disclosure of which is incorporated herein by reference. Specifically, the core is made using a rotary compression module comprising a fill zone, insertion zone, compression zone, ejection zone, and purge zone in a single apparatus having a double row die construction as shown in FIG. 6 of U.S. patent application Ser. No. 09/966,509. The dies of the compression module are preferably filled using the assistance of a vacuum, with filters located in or near each die. The purge zone of the compression module includes an optional powder recovery system to recover excess powder from the filters and return the powder to the dies.
- In certain preferred embodiments of this invention, the core, or the shell, or a portion thereof, is prepared by molding. In particular, the core, the shell or a portion of either one may be made by solvent-based or solvent-free molding. In such embodiments, the core, or the shell, or a portion thereof, is made from a flowable material optionally comprising an active ingredient. The flowable material may be any edible material that is flowable at a temperature between about 37° C. and 250° C., and that is solid, semi-solid, or can form a gel at a temperature between about −10° C. and about 35° C. When it is in the fluid or flowable state, the flowable material may comprise a dispersed, dissolved, or molten component, and optionally a solvent such as for example water or organic solvents, or combinations thereof. The solvent may be partially or substantially removed by drying.
- In one embodiment, solvent-based or solvent-free molding is performed via thermal setting molding using the method and apparatus described in copending U.S. patent application Ser. No. 09/966,450, pages 57-63, the disclosure of which is incorporated herein by reference. In this embodiment, a core, shell, or portion thereof is formed by injecting flowable form into a molding chamber. The flowable material preferably comprises a thermal setting material at a temperature above its melting point but below the decomposition temperature of any active ingredient contained therein. The flowable material is cooled and solidifies in the molding chamber into a shaped form (i.e., having the shape of the mold).
- According to this method, the flowable material may comprise solid particles suspended in a molten matrix, for example a polymer matrix. The flowable material may be completely molten or in the form of a paste. The flowable material may comprise an active ingredient dissolved in a molten material in the case of solvent-based molding. Alternatively, the flowable material may be made by dissolving a solid in a solvent, which solvent is then evaporated after the molding step in the case of solvent-based molding.
- In another embodiment, solvent-based or solvent-free molding is performed by thermal cycle molding using the method and apparatus described in copending U.S. patent application Ser. No. 09/966,497, pages 27-51, the disclosure of which is incorporated herein by reference. Thermal cycle molding is performed by injecting a flowable material into a heated molding chamber. The flowable material may comprise active ingredient and a thermoplastic material at a temperature above the set temperature of the thermoplastic material but below the decomposition temperature of active ingredient. The flowable material is cooled and solidifies in the molding chamber into a shaped form (i.e., having the shape of the mold).
- In the thermal cycle molding method and apparatus of U.S. patent application Ser. No. 09/966,497 a thermal cycle molding module having the general configuration shown in FIG. 3 therein is employed. The thermal cycle molding module200 comprises a
rotor 202 around which a plurality ofmold units 204 are disposed. The thermal cycle molding module includes a reservoir 206 (see FIG. 4) for holding flowable material to make the core. In addition, the thermal cycle molding module is provided with a temperature control system for rapidly heating and cooling the mold units. FIGS. 55 and 56 depict the temperature control system 600. - The mold units may comprise
center mold assemblies 212, upper mold assemblies 214, andlower mold assemblies 210, as shown in FIGS. 26-28, which mate to form mold cavities having a desired shape, for instance of a core or a shell surrounding a core. Asrotor 202 rotates, opposing center and upper mold assemblies or opposing center and lower mold assemblies close. Flowable material, which is heated to a flowable state inreservoir 206, is injected into the resulting mold cavities. The temperature of the flowable material is then decreased, hardening the flowable material. The mold assemblies open and eject the finished product. - In a particularly preferred embodiment of the invention, the shell is applied to the dosage form using a thermal cycle molding apparatus of the general type shown in FIGS.28A-C of copending U.S. application Ser. No. 09/966,497 comprising rotatable
center mold assemblies 212,lower mold assemblies 210 and upper mold assemblies 214. Cores are continuously fed to the mold assemblies. Shell flowable material, which is heated to a flowable state inreservoir 206, is injected into the mold cavities created by the closed mold assemblies holding the cores. The temperature of the shell flowable material is then decreased, hardening it around the cores. The mold assemblies open and eject the finished dosage forms. Shell coating is performed in two steps, each half of the dosage forms being coated separately as shown in the flow diagram of FIG. 28B of copending U.S. application Ser. No. 09/966,939 via rotation of the center mold assembly. - A preferred method for making the shell or a shell portion by solvent-based molding comprises: (a) preparing a flowable dispersion of the film former, release-modifying excipient, and other shell materials in a suitable solvent, e.g. water, organic solvents such as alcohols or acetone, or combinations of water and organic solvents, such as acetone; (b) injecting the flowable dispersion (which may be heated in a heated feed tank) into a mold cavity (at room temp or below) containing a core such that the flowable dispersion surrounds a first portion of the core within the mold cavity; (c) rapidly changing the temperature of the mold cavity to induce thermal setting of the flowable dispersion around at first portion of the core; (d) opening the mold cavity and rotating the portion of the mold containing the core to expose a second portion of the core; (e) closing the mold cavity; (f) injecting heated, flowable dispersion into the mold cavity such that the flowable dispersion surrounds the second portion of the core within the mold cavity; (g) rapidly changing the temperature of the mold cavity to induce thermal setting of the flowable dispersion surrounding the second portion of the core; (h) removing the coated core from the mold cavity; and (i) drying the coated core to remove residual solvent. The mold may be optionally heated to remove solvent, then cooled to set the shell materials. This is preferred if organic solvents are used, but is not required if the solvent used is water.
- A preferred method for making the shell or a shell portion by solvent-free molding comprises: (a) melting a thermal reversible carrier, adding and mixing a release-modifying excipient and any other desired ingredients for the shell into the thermal reversible carrier to form a flowable shell material; (b) injecting the flowable shell material (which is heated in a heated feed tank) into a mold cavity (heated to allow the flowable shell material to flow) containing a core such that the flowable shell material surrounds a first portion of the core within the mold cavity; (c) rapidly lowering the temperature of the mold cavity to induce thermal setting of the flowable shell material surrounding the first portion of the core; (d) opening the mold cavity and rotating the portion of the mold containing the core to expose a second portion of the core; (e) closing the mold cavity; (f) injecting heated, flowable shell material into the mold cavity (also heated) such that the flowable shell material surrounds the second portion of the core within the mold cavity; (g) rapidly lowering the temperature of the mold cavity to induce thermal setting of the flowable shell material surrounding the second portion of the core; (h) removing the coated core from the mold cavity. The mold may be optionally rapidly heated or cooled to facilitate removal of dosage form.
- In one embodiment, the compression module of copending U.S. patent application Ser. No. 09/966,509, pp. 16-27 may be employed to make cores. The shell may be made applied to these cores using a thermal cycle molding module as described above. A transfer device as described in U.S. patent application Ser. No. 09/966,414, pp. 51-57, the disclosure of which is incorporated herein by reference, may be used to transfer the cores from the compression module to the thermal cycle molding module. Such a transfer device may have the structure shown as300 in FIG. 3 of copending U.S. application Ser. No. 09/966,939. It comprises a plurality of
transfer units 304 attached in cantilever fashion to abelt 312 as shown in FIGS. 68 and 69 of copending U.S. application Ser. No. 09/966,939. The transfer device rotates and operates in sync with the compression module and the thermal cycle molding module to which it is coupled.Transfer units 304 comprise retainers 330 for holding cores as they travel around the transfer device. - Suitable materials for use in or as the flowable material include those comprising thermoplastic materials; film formers; thickeners such as gelling polymers or hydrocolloids; low melting hydrophobic materials such as fats and waxes; non-crystallizable carbohydrates; and the like. Suitable molten components of the flowable material include thermoplastic materials, low melting hydrophobic materials, and the like. Suitable dissolved components for the flowable material include film formers, thickeners such as gelling polymers or hydrocolloids, non-crystallizable carbohydrates, and the like. Suitable dispersed components include insoluble edible materials.
- Suitable thermoplastic materials can be molded and shaped when heated, and include both water soluble and water insoluble polymers that are generally linear, not crosslinked, nor strongly hydrogen bonded to adjacent polymer chains. Examples of suitable thermoplastic materials include: thermoplastic water swellable cellulose derivatives, thermoplastic water insoluble cellulose derivatives, thermoplastic vinyl polymers, thermoplastic starches, thermoplastic polyalkalene glycols, thermoplastic polyalkalene oxides, and amorphous sugar-glass, and the like, and derivatives, copolymers, and combinations thereof. Examples of suitable thermoplastic water swellable cellulose derivatives include hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC). Examples of suitable water insoluble cellulose derivatives include cellulose acetate (CA), ethyl cellulose (EC), cellulose acetate butyrate (CAB), cellulose propionate. Examples of suitable thermoplastic vinyl polymers include polyvinyl alcohol (PVA) and polyvinyl pyrrolidone (PVP). Examples of suitable thermoplastic starches are disclosed for example in U.S. Pat. No. 5,427,614. Examples of suitable thermoplastic polyalkalene glycols include polyethylene glycol. Examples of suitable thermoplastic polyalkalene oxides include polyethylene oxide having a molecular weight from about 100,000 to about 900,000 Daltons. Other suitable thermoplastic materials include sugar in the form on an amorphous glass such as that used to make hard candy forms.
- Any film former known in the art is suitable for use in the flowable material of the present invention. Examples of suitable film formers include, but are not limited to, film-forming water soluble polymers, film-forming proteins, film-forming water insoluble polymers, and film-forming pH-dependent polymers. In one embodiment, the film-former for making the core or shell or portion thereof by molding may be selected from cellulose acetate, ammonio methacrylate copolymer type B, shellac, hydroxypropylmethylcellulose, and polyethylene oxide, and combinations thereof.
- Suitable film-forming water soluble polymers include water soluble vinyl polymers such as polyvinylalcohol (PVA); water soluble polycarbohydrates such as hydroxypropyl starch, hydroxyethyl starch, pullulan, methylethyl starch, carboxymethyl starch, pre-gelatinized starches, and film-forming modified starches; water swellable cellulose derivatives such as hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC), hydroxyethylmethylcellulose (HEMC), hydroxybutylmethylcellulose (HBMC), hydroxyethylethylcellulose (HEEC), and hydroxyethylhydroxypropylmethyl cellulose (HEMPMC); water soluble copolymers such as methacrylic acid and methacrylate ester copolymers, polyvinyl alcohol and polyethylene glycol copolymers, polyethylene oxide and polyvinylpyrrolidone copolymers; and derivatives and combinations thereof.
- Suitable film-forming proteins may be natural or chemically modified, and include gelatin, whey protein, myofibrillar proteins, coaggulatable proteins such as albumin, casein, caseinates and casein isolates, soy protein and soy protein isolates, zein; and polymers, derivatives and mixtures thereof.
- Suitable film-forming water insoluble polymers, include for example ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers; and the like and derivatives, copolymers, and combinations thereof.
- Suitable film-forming pH-dependent polymers include enteric cellulose derivatives, such as for example hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate; natural resins, such as shellac and zein; enteric acetate derivatives such as for example polyvinylacetate phthalate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate; and enteric acrylate derivatives such as for example polymethacrylate-based polymers such as poly(methacrylic acid, methyl methacrylate) 1:2, which is commercially available from Rohm Pharma GmbH under the tradename, EUDRAGIT S, and poly(methacrylic acid, methyl methacrylate) 1:1, which is commercially available from Rohm Pharma GmbH under the tradename, EUDRAGIT L, and the like, and derivatives, salts, copolymers, and combinations thereof.
- One suitable hydroxypropylmethylcellulose compound for use as a thermoplastic film-forming water soluble polymer is “HPMC 2910”, which is a cellulose ether having a degree of substitution of about 1.9 and a hydroxypropyl molar substitution of 0.23, and containing, based upon the total weight of the compound, from about 29% to about 30% methoxyl groups and from about 7% to about 12% hydroxylpropyl groups. HPMC 2910 is commercially available from the Dow Chemical Company under the tradename METHOCEL E. METHOCEL E5, which is one grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 4 to 6 cps (4 to 6 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer. Similarly, METHOCEL E6 which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 5 to 7 cps (5 to 7 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer. METHOCEL E15, which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 15000 cps (15 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer. As used herein, “degree of substitution” shall mean the average number of substituent groups attached to a anhydroglucose ring, and “hydroxypropyl molar substitution” shall mean the number of moles of hydroxypropyl per mole anhydroglucose.
- One suitable polyvinyl alcohol and polyethylene glycol copolymer is commercially available from BASF Corporation under the tradename KOLLICOAT IR.
- As used herein, “modified starches” include starches that have been modified by crosslinking, chemically modified for improved stability or optimized performance, or physically modified for improved solubility properties or optimized performance. Examples of chemically-modified starches are well known in the art and typically include those starches that have been chemically treated to cause replacement of some of its hydroxyl groups with either ester or ether groups. Crosslinking, as used herein, may occur in modified starches when two hydroxyl groups on neighboring starch molecules are chemically linked. As used herein, “pre-gelatinized starches” or “instantized starches” refers to modified starches that have been pre-wetted, then dried to enhance their cold-water solubility. Suitable modified starches are commercially available from several suppliers such as, for example, A. E. Staley Manufacturing Company, and National Starch & Chemical Company. One suitable film forming modified starch includes the pre-gelatinized waxy maize derivative starches that are commercially available from National Starch & Chemical Company under the tradenames PURITY GUM and FILMSET, and derivatives, copolymers, and mixtures thereof. Such waxy maize starches typically contain, based upon the total weight of the starch, from about 0 percent to about 18 percent of amylose and from about 100% to about 88% of amylopectin.
- Another suitable film forming modified starch includes the hydroxypropylated starches, in which some of the hydroxyl groups of the starch have been etherified with hydroxypropyl groups, usually via treatment with propylene oxide. One example of a suitable hydroxypropyl starch that possesses film-forming properties is available from Grain Processing Company under the tradename, PURE-COTE B790.
- Suitable tapioca dextrins for use as film formers include those available from National Starch & Chemical Company under the tradenames CRYSTAL GUM or K-4484, and derivatives thereof such as modified food starch derived from tapioca, which is available from National Starch and Chemical under the
tradename PURITY GUM 40, and copolymers and mixtures thereof. - Any thickener known in the art is suitable for use in the flowable material of the present invention. Examples of such thickeners include but are not limited to hydrocolloids (also referred to herein as gelling polymers), clays, gelling starches, and crystallizable carbohydrates, and derivatives, copolymers and mixtures thereof.
- Examples of suitable hydrocolloids (also referred to herein as gelling polymers) such as alginates, agar, guar gum, locust bean, carrageenan, tara, gum arabic, tragacanth, pectin, xanthan, gellan, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan. Examples of suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof. Examples of suitable gelling starches include acid hydrolyzed starches, and derivatives and mixtures thereof. Additional suitable thickening hydrocolloids include low-moisture polymer solutions such as mixtures of gelatin and other hydrocolloids at water contents up to about 30%, such as for example those used to make “gummi” confection forms.
- Additional suitable thickeners include crystallizable carbohydrates, and the like, and derivatives and combinations thereof. Suitable crystallizable carbohydrates include the monosaccharides and the oligosaccharides. Of the monosaccharides, the aldohexoses e.g., the D and L isomers of allose, altrose, glucose, mannose, gulose, idose, galactose, talose, and the ketohexoses e.g., the D and L isomers of fructose and sorbose along with their hydrogenated analogs: e.g., glucitol (sorbitol), and mannitol are preferred. Of the oligosaccharides, the 1,2-disaccharides sucrose and trehalose, the 1,4-disaccharides maltose, lactose, and cellobiose, and the 1,6-disaccharides gentiobiose and melibiose, as well as the trisaccharide raffinose are preferred along with the isomerized form of sucrose known as isomaltulose and its hydrogenated analog isomalt. Other hydrogenated forms of reducing disaccharides (such as maltose and lactose), for example, maltitol and lactitol are also preferred. Additionally, the hydrogenated forms of the aldopentoses: e.g., D and L ribose, arabinose, xylose, and lyxose and the hydrogenated forms of the aldotetroses: e.g., D and L erythrose and threose are preferred and are exemplified by xylitol and erythritol, respectively.
- In one embodiment of the invention, the flowable material comprises gelatin as a gelling polymer. Gelatin is a natural, thermogelling polymer. It is a tasteless and colorless mixture of derived proteins of the albuminous class which is ordinarily soluble in warm water. Two types of gelatin—Type A and Type B—are commonly used. Type A gelatin is a derivative of acid-treated raw materials. Type B gelatin is a derivative of alkali-treated raw materials. The moisture content of gelatin, as well as its Bloom strength, composition and original gelatin processing conditions, determine its transition temperature between liquid and solid. Bloom is a standard measure of the strength of a gelatin gel, and is roughly correlated with molecular weight. Bloom is defined as the weight in grams required to move a half-inch diameter
plastic plunger 4 mm into a 6.67% gelatin gel that has been held at 10° C. for 17 hours. In a preferred embodiment, the flowable material is an aqueous solution comprising 20% 275 Bloom pork skin gelatin, 20% 250 Bloom Bone Gelatin, and approximately 60% water. - Suitable xanthan gums include those available from C. P. Kelco Company under the tradenames KELTROL 1000, XANTROL 180, or K9B310
- Suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof.
- “Acid-hydrolyzed starch,” as used herein, is one type of modified starch that results from treating a starch suspension with dilute acid at a temperature below the gelatinization point of the starch. During the acid hydrolysis, the granular form of the starch is maintained in the starch suspension, and the hydrolysis reaction is ended by neutralization, filtration and drying once the desired degree of hydrolysis is reached. As a result, the average molecular size of the starch polymers is reduced. Acid-hydrolyzed starches (also known as “thin boiling starches”) tend to have a much lower hot viscosity than the same native starch as well as a strong tendency to gel when cooled.
- “Gelling starches,” as used herein, include those starches that, when combined with water and heated to a temperature sufficient to form a solution, thereafter form a gel upon cooling to a temperature below the gelation point of the starch. Examples of gelling starches include, but are not limited to, acid hydrolyzed starches such as that available from Grain Processing Corporation under the tradename PURE-SET B950; hydroxypropyl distarch phosphate such as that available from Grain Processing Corporation under the tradename, PURE-GEL B990, and mixtures thereof.
- Suitable low-melting hydrophobic materials include fats, fatty acid esters, phospholipids, and waxes. Examples of suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts. Examples of suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GLYCOWAX-932, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides. Examples of suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid. Examples of suitable waxes include camauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; and the like.
- Suitable non-crystallizable carbohydrates include non-crystallizable sugars such as polydextrose, and starch hydrolysates, e.g. glucose syrup, corn syrup, and high fructose corn syrup; and non-crystallizable sugar-alcohols such as maltitol syrup.
- Suitable solvents for optional use as components of the flowable material for making the core, or the shell, or a portion thereof by molding include water; polar organic solvents such as methanol, ethanol, isopropanol, acetone, and the like; and non-polar organic solvents such as methylene chloride, and the like; and mixtures thereof.
- The flowable material for making the core or the shell or a portion thereof by molding may optionally comprise adjuvants or excipients, which may comprise up to about 30% by weight of the flowable material. Examples of suitable adjuvants or excipients include plasticizers, detackifiers, humectants, surfactants, anti-foaming agents, colorants, flavorants, sweeteners, opacifiers, and the like. Suitable plasticizers for making the core, the shell, or a portion thereof, by molding include, but not be limited to polyethylene glycol; propylene glycol; glycerin; sorbitol; triethyl citrate; tribuyl citrate; dibutyl sebecate; vegetable oils such as castor oil, rape oil, olive oil, and sesame oil; surfactants such as polysorbates, sodium lauryl sulfates, and dioctyl-sodium sulfosuccinates; mono acetate of glycerol; diacetate of glycerol; triacetate of glycerol; natural gums; triacetin; acetyltributyl citrate; diethyloxalate; diethylmalate; diethyl fumarate; diethylmalonate; dioctylphthalate; dibutylsuccinate; glyceroltributyrate; hydrogenated castor oil; fatty acids; substituted triglycerides and glycerides; and the like and/or mixtures thereof. In one embodiment, the plasticizer is triethyl citrate. In certain embodiments, the shell is substantially free of plasticizers, i.e. contains less than about 1%, say less than about 0.01% of plasticizers.
- In one preferred embodiment, the flowable material comprises less than 5% humectants, or alternately is substantially free of humectants, such as glycerin, sorbitol, maltitol, xylitol, or propylene glycol. Humectants have traditionally been included in pre-formed films employed in enrobing processes, such as that disclosed in U.S. Pat. Nos. 5,146,730 and 5,459,983, assigned to Banner Gelatin Products Corp., to ensure adequate flexibility or plasticity and bondability of the film during processing. Humectants function by binding water and retaining it in the film. Pre-formed films used in enrobing processes can typically comprise up to 45% water. Disadvantageously, the presence of humectant prolongs the drying process, and can adversely affect the stability of the finished dosage form.
- In certain embodiments in which the core, the shell, or portions thereof are prepared using solvent-free molding, the core, shell, or portions thereof may comprise active ingredient contained within an excipient matrix. The matrix, or the core, or the shell, or portions thereof typically comprises at least about 30 percent, e.g. at least about 45 weight percent of a thermal-reversible carrier, and optionally up to about 30 weight percent of various adjuvants such as for example plasticizers, gelling agents, strengthening agents, colorants, stabilizers, preservatives, and the like as known in the art. The matrix or the core, or the shell, or portions thereof may optionally further comprise up to about 55 weight percent of one or more release-modifying moldable excipients as described below. Solvent-free molding may be used to obtain semipermeable, impermeable, or diffusible shells or shell portions.
- The core may be in a variety of different shapes. For example, the core may be shaped as a polyhedron, such as a cube, pyramid, prism, or the like; or may have the geometry of a space figure with some non-flat faces, such as a cone, truncated cone, cylinder, sphere, torus, or the like. In certain embodiments, the core has one or more major faces. For example in embodiments wherein the core is a compressed tablet, the core surface typically has two opposing major faces formed by contact with the upper and lower punch faces in the compression machine. In such embodiments the core surface typically further comprises a “belly-band” located between the two major faces, and formed by contact with the die walls in the compression machine. Exemplary core shapes which may be employed include tablet shapes formed from compression tooling shapes described by “The Elizabeth Companies Tablet Design Training Manual” (Elizabeth Carbide Die Co., Inc., p. 7 (McKeesport, Pa.) (incorporated herein by reference) as follows (the tablet shape corresponds inversely to the shape of the compression tooling):
- 1. Shallow Concave.
- 2. Standard Concave.
- 3. Deep Concave.
- 4. Extra Deep Concave.
- 5. Modified Ball Concave.
- 6. Standard Concave Bisect.
- 7. Standard Concave Double Bisect.
- 8. Standard Concave European Bisect.
- 9. Standard Concave Partial Bisect.
- 10. Double Radius.
- 11. Bevel & Concave.
- 12. Flat Plain.
- 13. Flat-Faced-Beveled Edge (F.F.B.E.).
- 14. F.F.B.E. Bisect.
- 15. F.F.B.E. Double Bisect.
- 16. Ring.
- 17. Dimple.
- 18. Ellipse.
- 19. Oval.
- 20. Capsule.
- 21. Rectangle.
- 22. Square.
- 23. Triangle.
- 24. Hexagon.
- 25. Pentagon.
- 26. Octagon.
- 27. Diamond.
- 28. Arrowhead.
- 29. Bullet.
- 30. Shallow Concave.
- 31. Standard Concave.
- 32. Deep Concave.
- 33. Extra Deep Concave.
- 34. Modified Ball Concave.
- 35. Standard Concave Bisect.
- 36. Standard Concave Double Bisect.
- 37. Standard Concave European Bisect.
- 38. Standard Concave Partial Bisect.
- 39. Double Radius.
- 40. Bevel & Concave.
- 41. Flat Plain.
- 42. Flat-Faced-Beveled Edge (F.F.B.E.).
- 43. F.F.B.E. Bisect.
- 44. F.F.B.E. Double Bisect.
- 45. Ring.
- 46. Dimple.
- 47. Ellipse.
- 48. Oval.
- 49. Capsule.
- 50. Rectangle.
- 51. Square.
- 52. Triangle.
- 53. Hexagon.
- 54. Pentagon.
- 55. Octagon.
- 56. Diamond.
- 57. Arrowhead.
- 58. Bullet.
- 59. Barrel.
- 60. Half Moon.
- 61. Shield.
- 62. Heart.
- 63. Almond.
- 64. House/Home Plate.
- 65. Parallelogram.
- 66. Trapezoid.
- 67. FIG. 8/Bar Bell.
- 68. Bow Tie.
- 69. Uneven Triangle.
- In one embodiment of the invention, the core comprises multiple portions, for example a first portion and a second portion. The portions may be prepared by the same or different methods, such as the thermal cycle molding or thermal setting molding methods described herein, and mated using various techniques. For example, the first and second portions may both be made by compression, or both may be made by molding. Or one portion may be made by compression and the other by molding. The same or different active ingredient may be present in the first and second portions of the core. Alternately, one or more core portions may be substantially free of active ingredients.
- In another embodiment of this invention, the core comprises first, second and third portions, each comprising the same or different active ingredient. In another embodiment, the core comprises first, second and third portions, and the third portion (located between the first and second portions) has a higher concentration of active ingredient, thereby causing a particularly desired release profile for at least one active ingredient from the dosage form. In this embodiment, release of at least one active ingredient from the dosage form may have a substantially constant release rate, substantially non-constant release rate, or an ascending release rate. In another embodiment the core comprises first, second, and third portions, and the third portion (located between the first and second portions) is substantially free of active ingredient, and may contain osmagent or osmopolymer, or may serve as a barrier to the passage of active ingredient between the first and second core portions.
- In certain embodiments of the invention, the core or a portion thereof may function to confer modified release properties to at least one active ingredient contained therein. In such embodiments, wherein the core or core portion is made by compression, as previously noted, the core preferably comprises a release-modifying compressible excipient. In such embodiments, wherein the core or core portion is made by molding, as previously noted, the core preferably comprises a release-modifying moldable excipient. In embodiments in which one or more core portions function as an eroding matrix from which dispersed active ingredient is liberated in a sustained, extended, prolonged, or retarded manner, the core portion preferably comprises a release-modifying compressible or moldable excipient selected from swellable erodible hydrophilic agents, pH-dependent polymers, and combinations thereof.
- In embodiments in which one or more core portions function as a diffusional matrix through which active ingredient is liberated in a sustained, extended, prolonged, or retarded manner, the core portion preferably comprises a release-modifying excipient selected from combinations of insoluble edible materials and pore formers. Alternately, in such embodiments in which the core portion is prepared by molding, a thermal-reversible carrier may be included in the core portion and may function by dissolving and forming pores or channels through which the active ingredient may be liberated.
- As described herein, at least a portion of the shell is semipermeable to a liquid medium. As used herein, the term “semipermeable” means permeable to the passage of water but not permeable to the passage of active ingredient therethrough. The semipermeable shell or shell portion allows water to be absorbed therethrough and into the core of the dosage form from the environment, such as the dissolution media or gastro-intestinal fluids. The semipermeable shell portion functions as a barrier to the passage of active ingredient from the underlying core portion, forcing the active ingredient to be released from the dosage form via a different avenue, such as an orifice or passageway, or through a diffusible shell portion. The semipermeable shell or shell portions are non-erodible, and they are insoluble in fluids.
- In one embodiment of this invention, the semipermeable shell or shell portion is made using a flowable material. Suitable dissolved or molten components for the flowable material for forming the semi-permeable shell or shell portion may include thermoplastic film-formers selected from cellulose esters, cellulose ethers, and cellulose ester-ethers. These cellulosic polymers have a degree of substitution (D.S.) on the anhydroglucose unit, from greater than 0 up to 3 inclusive. By “degree of substitution” as used herein it is meant the average number of hydroxyl groups originally present on the anhydroglucose unit comprising the cellulose polymer that are replaced by a substituting group. Representative materials include those selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, mono-, di-, and tricellulose alkanylates, nono-, di-, and tricellulose aroylates, and the like. Exemplary polymers include cellulose acetate having a D.S. up to 1 and an acetyl content up to 21%; cellulose acetate having an acetyl content of 32 to 39.8%; cellulose acetate having a D.S. of 1 to 2 and an acetyl content of 21 to 35%; cellulose acetate having a D.S. of 2 to 3 and an acetyl content of 35 to 44.8%, and the like. More specific cellulosic polymers include cellulose propionate having a D.S. of 1.8 and a propyl content of 39.2 to 45% and a hydroxyl content of 2.8 to 5.4%; cellulose acetate butyrate having a D.S. of 1.8, an acetyl content of 13 to 15% and a butyryl content of 34 to 39%; cellulose acetate butyrate having an acetyl content of 2 to 29%, a butyryl content of 17 to 53% and a hydroxyl content of 0.5 to 4.7%; cellulose triacylates having a D.S. of 2.9 to 3, such as cellulose trivalerate, cellulose trilaurate, cellulose tripalmitate, cellulose trisuccinate, and cellulose trioctanoate; cellulose diacylates having a D.S. of 2.2 to 2.6, such as cellulose disuccinate, cellulose dipalmitate, cellulose dioctanoate, cellulose dipentanoate, co-esters of cellulose, such as cellulose acetate butyrate and cellulose acetate propionate.
- Additional polymers useful for manufacturing the semipermeable shell or shell portion include ethyl cellulose of various degree of etherification with ethoxy content of from about 40 to 55%, acetaldehyde demethylcellulose acetate, cellulose acetate ethyl carbamate, cellulose acetate methyl carbamate, cellulose acetate diethyl aminoacetate, semipermeable polyamides; semipermeable polyurethanes; semipermeable sulfonated polystyrenes; semipermeable cross-linked selective polymers formed by the coprecipitation of a polyanion and a polycation as disclosed in U.S. Pat. Nos. 3,173,876; 3,276,586; 4,541,005; 3,541,006, and 3,546,142; semipermeable polymers as disclosed in U.S. Pat. No. 3,133,132; semipermeable lightly cross-linked poly(-sodium styrene sulfonate); semipermeable cross-linked poly(vinylbenzyltrimethyl ammonium chloride); semipermeable polymers exhibiting a fluid permeability of 2.5×10−8 to 2.5×10−4(cm2/hr atm) expressed per atmosphere of hydrostatic or osmotic pressure difference across the semipermeable wall. The polymers are known to those skilled in the art, as set forth in U.S. Pat. Nos. 3,845,770; 3,916,899; and 4,160,020.
- In one embodiment, wherein the semipermeable shell or shell portion functions to slow or delay the rate of passage of a fluid, such as water or a biological fluid therethrough, the dissolved or molten components for the flowable material for forming the semi-permeable shell or shell portion comprise a polymer exhibiting a 8,500 to 4,000,000 molecular weight, and is present in the shell portion at a level from about 15 to about 85 weight percent of the shell portion. Polymeric materials, which may be used include non-ionic water-soluble polymers, cellulose ether nonionic with its solutions unaffected by cations, hydroxyalkylcellulose, hydroxyalkylalkylcellulose, hydroxypropylcellulose, phenylellulose, benzylcellulose, nonionic cellulose ester with its solutions unaffected by cations, benzhydrylcellulose, hydroxyethyloctylcellulose, diphenylmethylcellulose, hydroxyethylcellulose, tritylcellulose and polymercompositions that delay water flux up to 7.0 hours, and more preferably, up to 4.5 hours.
- In one embodiment, at least about 30% of the cross-sectional area of the semipermeable shell or semipermeable shell portion used in dosage forms of this invention is non-striated. In other embodiments, at least about 50% of the cross-sectional area of the semipermeable shell or semipermeable shell portion is non-striated. In yet other embodiments, at least about 80% of the cross-sectional area of the semipermeable shell or semipermeable shell portion is non-striated. As used herein, “non-striated” means homogeneous with respect to appearance, and with respect to the internal structure of the shell or shell portion when viewed under any magnification and lighting conditions. For example a cross-section of the shell or shell portion is free of striations, and uniform with respect to refractive properties when observed utilizing a light microscope at a magnification of about 50 to about 400 times.
- The costly and lengthy prior art method for building up a semi-permeable coating on tablets and pharmaceutical dosage forms by spray-coating techniques gives rise to a characteristic striated pattern, which is visible in the cross section of such dosage forms or their semi-permeable coatings (see for example FIGS. 7A and 7B). These characteristic striations are indicative of the spray-coating process consisting of multiple repetitions of the steps consisting of: (a) application via spraying of coating solution; followed by (b) warm air drying, to a tumbling bed of dosage forms in a revolving coating pan such that numerous layers of coating material are built up as each application of coating material dries to form a layer. The thickness of typical sprayed semi-permeable coatings is about 60 to about 150 microns. The thickness of an individual layer is typically in the range of about 10 microns to about 13 microns.
- In contrast, the shell or shell portion of the present invention may advantageously be applied to a core directly by a molding process, yielding a uniform and homogeneous layer in 5 minutes or less, e.g. 60 seconds or less, or 30 seconds or less, or 10 seconds or less, and in certain embodiments, say 1 second or less. As such, at least about 30% of the cross-sectional area of the shell or shell portion in certain embodiments of the present invention is non-striated.
- FIGS. 7A and 7B show prior art spray coated compositions having striations which are thus distinguishable from certain embodiments of the present invention. FIG. 7A is a micrographic cross-section (121× magnification) of a prior art PROCARDIA XL tablet (commercially available from Pfizer Labs) and FIG. 7B is a micrographic cross-section (800× magnification) of the same tablet. This prior art product clearly had striations. In contrast, FIGS. 8A and 8B show a dosage form of this invention (at 124× and 800× magnifications, respectively). As shown, this embodiment of the invention had no striations.
- The shell or shell portion of the present invention has a cross-sectional area in the range of about 1 to 900 sq. mm, preferably about 25 to 600 sq. mm, most preferably about 50 to about 500 sq. mm.
- In one particular embodiment, the shell comprises two parts that abut one another, thereby forming a shell that completely surrounds the core.
- In certain embodiments of this invention, a portion of the shell contains active ingredient which is released essentially immediately upon ingestion of the dosage form. In these embodiments, the shell or shell portion preferably comprises materials which exhibit rapid dissolution in gastro-intestinal fluids.
- The shell or shell portion employed in this invention also provides for delivery of active ingredient from the core or core portion to the liquid medium outside the dosage form after the dosage form is contacted with the liquid medium. In one embodiment, this is accomplished by having at least one aperture or passageway within the shell or shell portion to permit liquid medium containing active ingredient within the dosage form to pass through the shell or shell portion and out of the dosage form. In another embodiment, the shell comprises a diffusible shell or shell portion, and active ingredient diffuses therethrough to the liquid medium outside of the dosage form. In yet another embodiment, the shell or shell portion has at least a portion which is extremely thin (e.g. less than about 50 microns), and internal pressure within the shell or shell portion causes a breach or mechanical failure of the thin shell portion, thereby delivering active ingredient from the core to the liquid medium outside of the dosage form. In yet another embodiment, the shell or shell portion has a seam, and internal pressure within the shell or shell portion causes a breach or mechanical failure of the seam, thereby delivering active ingredient from the core to the liquid medium outside of the dosage form.
- In certain other embodiments, a portion of the shell functions as a diffusional membrane which contains pores through which liquid medium containing active ingredient within the dosage form can be released through the diffusible shell portion in a sustained, extended, prolonged or retarded manner. In these embodiments, the rate of release of active ingredient from the underlying core or core portion will depend upon the total pore area in the shell or shell portion, the pathlength of the pores, and the solubility and diffusivity of the active ingredient (in addition to its rate of release from the core or core portion itself). In preferred embodiments in which the shell or shell portion functions as a diffusional membrane, the release of the active ingredient from the dosage form may be described as controlled, prolonged, sustained or extended. In these embodiments, the contribution to active ingredient dissolution from the shell or shell portion may follow zero-order, first-order, or square-root of time kinetics. In certain such embodiments, the diffusional membrane shell or shell portion preferably comprises a release-modifying excipient such as a combination of a pore former and an insoluble edible material such as for example a film forming water insoluble polymer. Alternately, in such embodiments in which the shell or shell portion is prepared by solvent-free molding using a thermal reversible carrier, the thermal-reversible carrier may function by dissolving and forming pores or channels through which the active ingredient may be liberated.
- In certain other embodiments, a portion of the shell functions as an eroding matrix from which active ingredient dispersed in the shell portion is liberated by the dissolution of successive layers of the shell or shell portion surface. In these embodiments, the rate of active ingredient release will depend on the dissolution rate of the matrix material in the shell or shell portion. Particularly useful matrix materials for providing surface erosion include those which first absorb liquid, then swell and/or gel prior to dissolving. In certain such embodiments, the eroding matrix shell or shell portion preferably comprises a swellable erodible hydrophilic material.
- In certain other embodiments, one or more shell portions function as a barrier to prevent release therethrough of an active ingredient contained in the underlying core or core portion. In such embodiments, active ingredient is typically released from a portion of the core which is not covered by the barrier shell portion. Typically, this is achieved by having at least one passageway in the shell or shell portion to permit active ingredient to reach the liquid medium outside the dosage form. Such embodiments advantageously allow for control of the surface area for release of the active ingredient. In certain particular embodiments, for example, the surface area for release of active ingredient can be maintained substantially constant over time. In a particularly preferred embodiment, the release of at least one active ingredient follows substantially zero-order kinetics. In certain such embodiments, the barrier shell portion preferably comprises a water insoluble material such as for example a water insoluble polymer.
- In certain other embodiments, the shell or portion thereof functions as a delayed release coating to delay release of an active ingredient which is contained in the core or a portion thereof. In these embodiments, the lag-time for onset of active ingredient release may be governed by erosion of the coating or diffusion through the coating or a combination thereof. In certain such embodiments, the eroding matrix shell or shell portion preferably comprises a swellable erodible hydrophilic material.
- In embodiments in which the shell or portion thereof functions to modify the release of an active ingredient which is contained in the core or the subject shell or shell portion, the thickness of the shell or shell portion is critical to the release properties of the dosage form. Advantageously the dosage forms of the invention can be made with precise control over shell thickness. In a preferred embodiment in which the shell or one or more shell portions function to modify the release of an active ingredient which is contained in the core or the subject shell or shell portion, the shell or shell portion is made by the thermal cycle or thermal setting molding methods and apparatus described below.
- In certain other embodiments of the invention, a further degree of flexibility in designing the dosage forms of the present invention can be achieved through the use of an additional outer coating overlaying the shell or one or more portions thereof. The additional outer coating may be applied for example by compression, or by molding. In such embodiments, the dosage form of the invention comprises at least one active ingredient; a core; a shell or shell portion which resides upon at least a portion of the core; and an outer coating which covers at least a portion of the shell or shell portion. The outer coating may for example cover a portion of the first shell portion, or the second shell portion, or both, or may surround the entire shell. In one particularly preferred embodiment, the outer coating comprises an active ingredient, which is released immediately (i.e. the dissolution of the active ingredient from the outer coating conforms to USP specifications for immediate release dosage forms of the particular active ingredient employed). In one such particularly preferred embodiment, the dosage form is a pulsatile drug delivery system, in which one or more shell portions provides for delayed release of a second dose of active ingredient, which is contained in an underlying core portion.
- In one embodiment of the present invention, in which the shell comprises first and second shell portions, the first and second shell portions may comprise different levels of the same ingredients, e.g. colorants, opacifiers, film-formers, etc. In one such embodiment, the first and second shell portions may be visually distinct from one another, for example the visually distinct portions may be of different colors, hues, glosses, reflective qualities, brightness, depth, shades, chroma, opacity, etc. For example, the shell may have a red portion and a yellow portion, or a flat finish portion and a glossy portion, or an opaque portion and a translucent portion. Alternatively, the first and second shell portions may have different thickness. The first and second shell portions may have different functionalities. For example, the first and second shell portions may confer different release properties to an active ingredient contained in either the subject shell portion, or in a corresponding underlying core portion. In one particular embodiment, the first shell portion may function as a diffusional membrane which contains pores through which fluids can enter the dosage form, and dissolved active ingredient can be released from an underlying core portion; and the second shell portion, may function as an eroding matrix from which active ingredient dispersed in the second shell portion is liberated by the dissolution of successive layers of the shell portion surface.
- In embodiments in which the shell or shell portion or portions are prepared using a solvent-free molding process, the shell or shell portions will typically comprise at least about 30 percent, e.g. at least about 45 percent by weight of a thermal-reversible carrier. The shell or shell portion or portions may optionally further comprise up to about 55 weight percent of a release-modifying excipient. The shell or shell portion or portions may optionally further comprise up to about 30 weight percent total of various plasticizers, adjuvants and excipients. In certain embodiments in which the shell or shell portions are prepared by solvent-free molding, and function to delay the release of one or more active ingredients from an underlying core or core portion, the release modifying excipient is preferably selected from swellable, erodible hydrophilic materials.
- In embodiments in which the shell or shell portion or portions are prepared using a solvent-based molding process, the shell or shell portion or portions will typically comprise at least about 10 weight percent, e.g. at least about 12 weight percent or at least about 15 weight percent or at least about 20 weight percent or at least about 25 weight percent of a film-former. Here, the solvent-molded shell or shell portion or portions may optionally further comprise up to about 55 weight percent of a release-modifying excipient. The solvent-molded shell or shell portion or portions may again also optionally further comprise up to about 30 weight percent total of various plasticizers, adjuvants, and excipients.
- In one embodiment of this invention, the shell or shell portion or portions of the present invention, whether prepared by a solvent-free molding process, or by a solvent-based molding process, are substantially free of pores having a diameter of 0.5-5.0 microns. As used herein, “substantially free” means that the shell or shell portion or portions have a pore volume of less than about 0.02 cc/g, preferably less than about 0.01 cc/g, more preferably less than about 0.005 cc/g in the pore diameter range of 0.5 to 5.0 microns. In contrast, typical compressed materials have pore volumes of more than about 0.02 cc/g in this diameter range. In another embodiment of this invention, the core is a molded core and the core or core portions are substantially free of pores having a diameter of 0.5-5.0 microns.
- Shell or shell portions may be tested for surface gloss using an instrument available from TriCor Systems Inc. (Elgin, IL) under the tradename TRI-COR MODEL 805A/806H SURFACE ANALYSIS SYSTEM and generally in accordance with the procedure described in “TriCor Systems WGLOSS 3.4 Model 805A/806H Surface Analysis System Reference Manual” (1996), which is incorporated by reference herein, except as modified below.
- This instrument uses a CCD camera detector, a flat diffuse light source, compares tablet samples to a reference standard, and determines average gloss values at a 60 degree incident angle. During its operation, the instrument generates a gray-scale image, wherein the occurrence of brighter pixels indicates the presence of more gloss at that given location.
- The instrument also incorporates software that uses a grouping method to quantify gloss: i.e., pixels with similar brightness which are grouped together for averaging purposes.
- The “percent full scale” or “percent ideal” setting (also referred to as the “percent sample group” setting), is specified by the user to designate the portion of the brightest pixels above the threshold that will be considered as one group and averaged within that group. “Threshold,” as used herein, is defined as the maximum gloss value that will not be included in the average gloss value calculation. Thus, the background, or the non-glossy areas of a sample are excluded from the average gloss value calculations. The method disclosed in K. Fegley and C. Vesey, “The Effect of Tablet Shape on the Perception of High Gloss Film Coating Systems,” which is available at www.colorcon.com as of Mar. 18, 2002 and incorporated by reference herein, is used to minimize the effects resulting from different tablet shapes, and to report a metric that was comparable across the industry. (The 50% sample group setting is selected as the setting which best approximates analogous data from tablet surface roughness measurements.)
- After initially calibrating the instrument using a calibration reference plate (190-228; 294 degree standard; no mask,
rotation 0, depth 0), a standard surface gloss measurement is created. For example, a standard surface gloss was obtained using gel-coated caplets available from McNEIL-PPC, Inc. under the tradename, EXTRA STRENGTH TYLENOL GELCAPS. The average gloss value for a sample of 112 of such gel-coated caplets was then determined, while employing the 25 mm full view mask (190-280), and configuring the instrument to the following settings: - Rotation: 0
- Depth: 0.25 inches
- Gloss Threshold: 95
- % Full Scale: 50%
- Index of Refraction: 1.57
- The average surface gloss value for the reference standard was determined to be 269.
- The total weight of the shell or shell portion or portions is preferably about 20 percent to about 400 percent of the weight of the core. In embodiments wherein the shell or shell portion or portions prepared by a solvent-free molding process, the total weight of the shell or shell portion or portions is typically from about 50 percent to about 400 percent, e.g. from about 75 percent to about 400 percent, or about 100 percent to about 200 percent of the weight of the core. In embodiments wherein the shell portion or portions are prepared by a solvent-based molding process, the total weight of the shell or shell portion or portions is typically from about 20 percent to about 100 percent of the weight of the core.
- Typical shell or shell portion thicknesses which may be employed in this invention are about 10 to about 1000 microns. In certain preferred embodiments, the shell or shell portion has a thickness of less than 800 microns. In embodiments wherein the shell or shell portion is prepared by a solvent-free molding process, the shell or shell portion typically has a thickness of about 500 to about 4000 microns, e.g. about 500 to about 2000 microns, say about 500 to about 800 microns, or about 800 to about 1200 microns. In embodiments wherein the shell or shell portion is prepared by a solvent-based molding process, the shell or shell portion typically has a thickness of less than about 800 microns, e.g. about 20 to about 600 microns, say about 40 to about 200 microns. The semi-permeable shell or shell portion typically has a thickness from about 20 to about 400 microns, e.g. about 20 to about 200 microns, say about 40 to about 100 microns.
- In those embodiments in which solvent-free molding is employed, the flowable material may comprise a thermal-reversible carrier. Suitable thermal-reversible carriers are thermoplastic materials typically having a melting point below about 110° C., more preferably between about 20 and about 100° C. Examples of suitable thermal-reversible carriers for solvent-free molding include thermoplastic polyalkalene glycols, thermoplastic polyalkalene oxides, low melting hydrophobic materials, thermoplastic polymers, thermoplastic starches, and the like. Preferred thermal-reversible carriers include polyethylene glycol and polyethylene oxide. Suitable thermoplastic polyalkylene glycols for use as thermal-reversible carriers include polyethylene glycol having molecular weight from about 100 to about 20,000, e.g. from about 100 to about 8,000 Daltons. Suitable thermoplastic polyalkalene oxides include polyethylene oxide having a molecular weight from about 100,000 to about 900,000 Daltons. Suitable low-melting hydrophobic materials for use as thermal-reversible carriers include fats, fatty acid esters, phospholipids, and waxes which are solid at room temperature, fat-containing mixtures such as chocolate; and the like. Examples of suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts. Examples of suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GLYCOWAX-932, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides. Examples of suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid. Examples of suitable waxes which are solid at room temperature include carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax. Suitable thermoplastic polymers for use as thermal-reversible carriers include thermoplastic water swellable cellulose derivatives, thermoplastic water insoluble polymers, thermoplastic vinyl polymers, thermoplastic starches, and thermoplastic resins, and combinations thereof. Suitable thermoplastic water swellable cellulose derivatives include hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC), carboxymethylcellulose (CMC), cross-linked hydroxypropylcellulose, hydroxypropyl cellulose (HPC), hydroxybutylcellulose (HBC), hydroxyethylcellulose (HEC), hydroxypropylethylcellulose, hydroxypropylbutylcellulose, hydroxypropylethylcellulose, and salts, derivatives, copolymers, and combinations thereof. Suitable thermoplastic water insoluble polymers include ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers, and the like and derivatives, copolymers, and combinations thereof. Suitable thermoplastic vinyl polymers include polyvinylacetate, polyvinyl alcohol, and polyvinyl pyrrolidone (PVP). Examples of suitable thermoplastic starches for use as thermal-reversible carriers are disclosed for example in U.S. Pat. No. 5,427,614. Examples of suitable thermoplastic resins for use as thermal-reversible carriers include dammars, mastic, rosin, shellac, sandarac, and glcerol ester of rosin. In one embodiment, the thermal-reversible carrier for making the core, or a portion thereof, by molding is selected from polyalkylene glycols, polyalkaline oxides, and combinations thereof.
- Suitable release-modifying excipients for making the core, or the shell, or a portion thereof, by solvent free or solvent based molding include but are not limited to swellable erodible hydrophilic materials, pH-dependent polymers, pore formers, and insoluble edible materials. In one embodiment, suitable release-modifying excipients for making the core, or the shell, or a portion thereof, by molding include hydroxypropylmethylcellulose, polyethylene oxide, ammonio methacrylate copolymer type B, and shellac, and combinations thereof.
- Suitable swellable erodible hydrophilic materials for use as release-modifying excipients for making the core, or the shell, or a portion thereof by a solvent-free molding process include water swellable cellulose derivatives, polyalkalene glycols, thermoplastic polyalkalene oxides, acrylic polymers, hydrocolloids, clays, gelling starches, and swelling cross-linked polymers, and derivatives, copolymers, and combinations thereof. Examples of suitable water swellable cellulose derivatives include sodium carboxymethylcellulose, cross-linked hydroxypropylcellulose, hydroxypropyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyisopropylcellulose, hydroxybutylcellulose, hydroxyphenylcellulose, hydroxyethylcellulose (HEC), hydroxypentylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, hydroxypropylethylcellulose. Examples of suitable polyalkalene glycols include polyethylene glycol. Examples of suitable thermoplastic polyalkalene oxides include poly (ethylene oxide). Examples of suitable acrylic polymers include potassium methacrylatedivinylbenzene copolymer, polymethylmethacrylate, CARBOPOL (high-molecular weight cross-linked acrylic acid homopolymers and copolymers), and the like. Examples of suitable hydrocolloids include alginates, agar, guar gum, locust bean gum, kappa carrageenan, iota carrageenan, tara, gum arabic, tragacanth, pectin, xanthan gum, gellan gum, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, gelatin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan. Examples of suitable clays include smectites such as bentonite, kaolin, and laponite; magnesium trisilicate, magnesium aluminum silicate, and the like, and derivatives and mixtures thereof. Examples of suitable gelling starches include acid hydrolyzed starches, swelling starches such as sodium starch glycolate, and derivatives thereof. Examples of suitable swelling cross-linked polymers include cross-linked polyvinyl pyrrolidone, cross-linked agar, and cross-linked carboxymethylcellose sodium.
- Suitable pH-dependent polymers for use as release-modifying moldable excipients for making the molded core or molded shell or a portion thereof by molding include enteric cellulose derivatives, for example hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate; natural resins such as shellac and zein; enteric acetate derivatives such as for example polyvinylacetate phthalate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate; and enteric acrylate derivatives such as for example polymethacrylate-based polymers such as poly(methacrylic acid, methyl methacrylate) 1:2, which is commercially available from Rohm Pharma GmbH under the tradename EUDRAGIT S, and poly(methacrylic acid, methyl methacrylate) 1:1, which is commercially available from Rohm Pharma GmbH under the tradename EUDRAGIT L, and the like, and derivatives, salts, copolymers, and combinations thereof.
- Suitable insoluble edible materials for use as release-modifying excipients making the core, or the shell, or a portion thereof by molding, include water-insoluble polymers, and low-melting hydrophobic materials. Examples of suitable water-insoluble polymers include ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers; and the like and derivatives, copolymers, and combinations thereof. Suitable low-melting hydrophobic materials include fats, fatty acid esters, phospholipids, and waxes. Examples of suitable fats include hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts. Examples of suitable fatty acid esters include sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, GLYCOWAX-932, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides. Examples of suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, and phosphotidic acid. Examples of suitable waxes include carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; and the like.
- Suitable pore formers for use as release-modifying excipients for making the molded core, the shell, or a portion thereof by molding include water-soluble organic and inorganic materials. In one embodiment the pore former is hydroxypropylmethylcellulose. Examples of suitable water-soluble organic materials include water soluble polymers including water soluble cellulose derivatives such as hydroxypropylmethylcellulose, and hydroxypropylcellulose; water soluble carbohydrates such as sugars, and starches; water soluble polymers such as polyvinylpyrrolidone and polyethylene glycol, and insoluble swelling polymers such as microcrystalline cellulose. Examples of suitable water soluble inorganic materials include salts such as sodium chloride and potassium chloride and the like and/or mixtures thereof.
- In embodiments in which the shell or portions thereof comprise an active ingredient intended to have immediate release from the dosage form, the shell or shell portion is preferably prepared via the solvent-free molding method described above. In such embodiments the thermal-reversible carrier is preferably selected from polyethylene glycol with weight average molecular weight from about 1450 to about 20000, polyethylene oxide with weight average molecular weight from about 100,000 to about 900,000, and the like.
- In embodiments in which the shell or shell portion functions to confer modified release properties to at least one active ingredient contained within the dosage form, in the core, the shell or both, the shell or shell portion typically comprises at least one release modifying agent as described above.
- In embodiments of the invention in which the core or portion thereof and shell or portion thereof each comprise a dose of active ingredient, the dosage form may function for example as a multi-compartment, e.g. a four-compartment pulsatile release delivery system. In one such embodiment, each of the compartments may comprise a dose of the same active ingredient, to be release at a desired time or rate. In another such embodiment, the corresponding first core portion and first shell portions may comprise a dose of the same first active ingredient to be released at a desired time or rate, while the second core portion and second shell portion may comprise a dose of the same second active ingredient to be released at a desired time or rate. In such embodiments, each compartment comprises inactive materials which enable the desired functionality of that particular core portion or shell portion.
- In certain such embodiments, the dosage form may further comprise a water-impermeable barrier layer between the first and second core portions. The water-impermeable barrier layer may be made by any method, for example compression or molding, and preferably comprises at least one water-insoluble material selected from water-insoluble polymers, insoluble edible materials, pH-dependent polymers, and mixtures thereof.
- In one particular embodiment of this invention, at least one active ingredient contained within the dosage form exhibits a non-constant release rate.
- In another particular embodiment of this invention, at least one active ingredient contained within the dosage form exhibits a delayed burst release profile. By “delayed burst release profile” it is meant that the release of that particular active ingredient from the dosage form is delayed for a pre-determined time after ingestion by the patient, and the delay period (“lag time”) is followed by prompt (immediate) release of that active ingredient. At least one shell portion of the present invention provides for the delay period and is preferably substantially free of the active ingredient to be released in a delayed burst manner. In such embodiments, the delayed burst active ingredient is typically contained within the corresponding underlying core portion. In these embodiments, the core portion may be prepared by compression or molding, and is formulated for immediate release, as is known in the art, so that the core portion is readily soluble upon contact with the dissolution medium. In such embodiments the core portion preferably comprises a disintegrant, and optionally comprises additional excipients such as fillers or thermoplastic materials selected from water-soluble or low-melting materials, and surfactants or wetting agents. In these embodiments, the dissolution of the burst release active ingredient, after the delay period, meets USP specifications for immediate release tablets containing that active ingredient. For example, for acetaminophen tablets,
USP 24 specifies that in pH 5.8 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released therefrom within 30 minutes after dosing, and for ibuprofen tablets,USP 24 specifies that in pH 7.2 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the ibuprofen contained in the dosage form is released therefrom within 60 minutes after dosing. (SeeUSP 24, 2000 Version, 19-20 and 856 (1999)). - In another particular embodiment of this invention at least one active ingredient contained within the dosage form exhibits a delayed and sustained release profile. By “delayed then sustained release profile” it is meant that the release of that particular active ingredient from the dosage form is delayed for a pre-determined time after ingestion by the patient, and the delay period (“lag time”) is followed by sustained (prolonged, extended, or retarded) release of that active ingredient. At least one shell portion of the present invention provides for the delay period, and is preferably substantially free of the active ingredient to be released in a delayed then sustained manner. In such embodiments, the delayed then sustained release active ingredient is preferably contained within the corresponding underlying core portion. In such embodiments the core portion may function for example as an eroding matrix or a diffusional matrix, or an osmotic pump. In embodiments in which the core portion functions as a diffusional matrix through which active ingredient is liberated in a sustained, extended, prolonged, or retarded manner, the core portion preferably comprises a release-modifying excipient selected from combinations of insoluble edible materials and pore-formers. Alternately, in such embodiments in which the core portion is prepared by molding, the thermal-reversible carrier may function by dissolving and forming pores or channels through which the active ingredient may be liberated. In embodiments in which the core portion functions as an eroding matrix from which dispersed active ingredient is liberated in a sustained, extended, prolonged, or retarded manner, the core portion preferably comprises a release-modifying compressible or moldable excipient selected from swellable erodible hydrophilic materials, pH-dependent polymers, and combinations thereof.
- In embodiments in which one or more core portions function as a diffusional matrix through which active ingredient contained therein is liberated in a sustained, extended, prolonged, or retarded manner, the core portion preferably comprises a release-modifying excipient selected from combinations of insoluble edible materials and pore formers. Alternately, in such embodiments in which the core portion is prepared by solvent-free molding, the thermal-reversible carrier may function by dissolving and forming pores or channels through which the active ingredient may be liberated.
- In embodiments in which a shell or shell portion functions by an erosion-based mechanism to provide a time delay for the release of an active ingredient from an underlying core portion, the release-delaying shell or shell portion preferably comprises a release modifying excipient selected from swellable erodible hydrophilic materials, insoluble edible materials, and combinations thereof.
- In embodiments in which a shell or shell portion functions as an eroding matrix from which active ingredient dispersed therein is liberated in a sustained, extended, prolonged, or retarded manner, the shell or shell portion preferably comprises a release-modifying compressible or moldable excipient selected from swellable erodible hydrophilic materials, pH-dependent polymers, insoluble edible materials, and combinations thereof.
- In embodiments of the invention in which a shell or shell portion functions to confer a delay to the release of one or more active ingredients contained in an underlying core portion, the release-delaying shell or shell portion preferably provides a delay of greater than one hour, for example at least about 3 hours, or at least about 4 hours, or at least about 6 hours, or at least about 12 hours to the onset of dissolution of the active ingredient upon contacting of the dosage form with a liquid medium such as water, gastrointestinal fluid or the like. The delay period is typically controlled by the shell or shell portion thickness, composition, or a combination thereof. In one embodiment the delay period is independent of the pH of the dissolution media or fluid environment. For example, the average lag-time for dissolution of active ingredient in 0.1 N HCl is not substantially different (i.e. within about 30 minutes, preferably within about 15 minutes) from the average lag-time for the dissolution of active ingredient in pH 5.6 buffer system. In certain such embodiments, the release-delaying shell or shell portion preferably comprises a release modifying excipient selected from swellable erodible hydrophilic materials, insoluble edible materials, and combinations thereof.
- In embodiments in which the shell or portions thereof contain active ingredient which is released essentially immediately upon ingestion of the dosage form, the shell or shell portion preferably comprises materials which exhibit rapid dissolution in gastro-intestinal fluids. For example the immediate release shell or shell portion or portions may comprise readily soluble materials selected from water soluble or water swellable thermoplastic film formers, water soluble or water swellable thickeners, crystallizable and non-crystallizable carbohydrates. In certain such embodiments, suitable water soluble or water swellable thermoplastic film formers may be selected from water swellable cellulose derivatives, thermoplastic starches, polyalkalene glycols, polyalkalene oxides, and amorphous sugar glass, and combinations thereof. In certain other such embodiments, suitable film formers may be selected from film forming water soluble polymers such as for example water soluble vinyl polymers, water soluble polycarbohydrates, water swellable cellulose derivatives, and water soluble copolymers; film-forming proteins, and combinations thereof. In certain other such embodiments, suitable thickeners may be selected from gelling polymers or hydrocolloids; gelling starches, and crystallizable carbohydrates. In certain other such embodiments, suitable non-crystallizable carbohydrates may be selected from polydextrose, starch hydrolysates, and non-crystallizable sugar alcohols. In such embodiments, the immediate release shell or shell portion will preferably be breached or dissolved within 30 minutes in 900 ml water or 0.1 N HCl, or phosphate buffer solution at 37° C. with stirring by a USP type 2 (Paddle method) at 50 or 100 rpm.
- In one embodiment of this invention, the shell or portion thereof additionally comprises at least one active ingredient which may be the same or different than the active ingredient contained in the core.
- In embodiments in which the shell or portion thereof confers sustained, extended, or retarded release of an active ingredient contained in an underlying core or core portion, the release-modifying agent in the shell or shell portion preferably comprises a pore-former, and optionally a film-former. In a particularly preferred embodiment, the shell or shell portion functions as a diffusional membrane. In some such embodiments, the dissolution of the active ingredient may follow “diffusion-controlled” release kinetics, as described for example in Example 1 of U.S. Pat. No. 5,286,497. Shells or shell portions which confer sustained, extended, or retarded release and/or function as diffusional membranes can be prepared by a solvent-free method, or a solvent-based method, as described above.
- In embodiments in which the shell or portion thereof confers sustained, extended, or retarded release of an active ingredient contained in the shell or first or second shell portion, the release-modifying agent in the shell or shell portion preferably comprises a swellable erodible hydrophilic material, and may optionally comprise a secondary gelling agent such as for example cross-linked carboxymethylcellulose, cross-linked polyvinylpyrrolidone, or sodium starch glycolate.
- In embodiments in which the shell or portion thereof confers a delayed release to an active ingredient contained in an underlying core or core portion, the release-modifying agent is preferably selected from swellable erodible hydrophilic materials. The shell or shell portions which confer delayed release can be prepared by a solvent-free method, or a solvent-based method, as described above.
- In embodiments in which the shell or portion thereof provides a barrier to prevent release therethrough of an active ingredient contained in the underlying core or core portion, the shell or shell portion is preferably prepared via a solvent-free molding method, as described above. In such embodiments, the thermal-reversible carrier is preferably selected from waxes, such as for example camuba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; hydrogenated vegetable oils such as for example cocoa butter, hydrogenated castor oil; other waxy materials such as for example glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate; thermal-reversible polymers such as for example polycaprolactones and polyvinyl acetate. In certain embodiments, an impermeable barrier can be formed which consists essentially of the thermal reversible carrier. In such embodiments, an additional release-modifying agent is not necessary. In certain other embodiments, the release-modifying agent is preferably selected from water insoluble polymers such as cellulose acetate, acrylates, acrylic acid copolymers, cellulose acetate, cellulose acetate propionate, cellulose acetate propionate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate, cellulose acetate ethyl carbamate, cellulose acetate methyl carbamate, cellulose acetate diethyl aminoacetate, ethylcellulose, methacrylates, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, and the like, and mixtures thereof. In such embodiments, the shell or shell portion may optionally further comprise a liquid carrier such as for example mineral oil, propylene glycol, low molecular weight polyethylene glycol, glycerin, and the like.
- This invention will be illustrated by the following examples, which are not meant to limit the invention in any way.
- Dosage forms according to the invention comprising a core having a first core portion and a second core portion within a shell having a first shell portion and a second shell portion were prepared as follows.
- The following ingredients were used to make the first core portion (Osmotic layer):
Mg/Dosage Ingredient Trade Name Manufacturer Weight % Form Polyethylene Oxide Polyox ® WSR 303Union Carbide 69 128.3 (MW = 7,000,000) Corporation, Danbury, CT Sodium Chloride Sigma Chemical Co. 25 46.5 St Louis, MO Hydroxypropyl Methocel E5 Dow Chemical 5.8 10.8 Methylcellulose Company, Midland, MI Magnesium Stearate Mallinckrodt Inc., 0.2 0.4 St. Louis, MO FD&C Yellow # 6Trace Amount Ethanol Anhydrous (dried as solvent) - Sodium chloride, hydroxypropyl methylcellulose, polyethylene oxide (PEO) (MW=7,000,000), and FD&C
yellow # 6 were mixed in a plastic bag for 5 minutes. This powder mixture was added into a 5 qt. bowl of a planetary mixer (available from Hobart Corp., Dayton, Ohio). The alcohol was added to the powder mixture while mixing at low speed. The ingredients were mixed for 3 minutes. The resulting granulation was removed from the bowl and dried at room temperature for 12 to 16 hours to remove all residual solvent. The granulation was screened through a #20 mesh screen and put into a plastic bag. Magnesium stearate was added to the dry granules, followed by mixing for 5 minutes to form the first core portion. - The following ingredients were used to make the second core portion:
Mg/Dosage Ingredient Trade Name Manufacturer Weight % Form Pseudoephedrine BASF 15.0 65.1 HCI Crystal PharmaChemikalien GmbH & Co. Polyethylene Oxide Polyox ® WSR N-750 Union Carbide 75.0 325.5 (MW = 300,000) Corporation, Danbury, CT Hydroxypropyl Methocel ES Dow Chemical 8.5 36.9 Methylcellulose Company, Midland, MI Magnesium Stearate Mallinckrodt Inc., 1.5 6.5 St. Louis, MO Alcohol USP (dried as solvent) - The pseudoephedrine HCl crystal, hydroxypropyl methylcellulose, and PEO (MW=300,000) were first mixed in a plastic bag for 1-2 minutes. This powder mixture was added into the 5 qt. bowl of a planetary mixer (available from Hobart Corp., Dayton, Ohio). The alcohol was added to the powder mixture while mixing at low speed. The ingredients were mixed for 10 minutes. The resulting granulation was removed from the bowl and dried at room temperature for 12 to 16 hours to remove all residual solvent. The granulation was screened through a #20 mesh screen and put into a plastic bag. Magnesium stearate was added to the dry granules, followed by mixing for 3 minutes to form the second core portion.
- Cores were made from two different portions (by weight) of the first and second core portions as follows. A model M hydraulic Carver Laboratory Press (available from Fred S. Carver, Inc., Hydraulic Equipment, Summit, N.J.) was employed. A round, concave punch and die unit having a 0.4375″ diameter was used for compression. The osmotic layer granulation (186 mg) for the first core portion was fed into the cavity mold of the press and was gently tapped. Then the pseudoephedrine HCl granulation (434 mg) for the second core portion was fed into the cavity overlying the osmotic granulation. The granulations were pressed into a solid two-portion core using 1600 lb/sq. in. of compression force.
- The shell portion was made using the following ingredients:
Mg/Dosage Ingredient Trade Name Manufacturer Weight % Form Cellulose Acetate 398-10 Eastman Chemical 80.0 27.4 Company, Kingsport, TN Polyethylene Oxide Polyox ® WSR N-80 Union Carbide 20.0 6.8 (MW = 200,000) Corporation, Danbury, CT Acetone (dried as solvent) - The cellulose acetate was added to a beaker containing acetone and mixed using a mixer until all powder was dissolved. An agitating speed of 500 rpm was used. PEO, which was screened through a #40 mesh screen, was added to the cellulose acetate solution, which was again mixed until all powder was dispersed. The shell portion material was provided in flowable form.
- A laboratory scale thermal cycle molding unit was used to apply the first and second shell portions to the core, and comprised a single mold assembly made from an upper mold assembly portion comprising an upper mold cavity, and a lower mold assembly portion comprising a lower mold cavity. The lower mold assembly portion was first cycled to a cold stage at 5° C. for 30 seconds. The shell portion material was added to the lower mold cavity. A two-portion core as described above was inserted into the lower mold cavity such that the first core portion, containing osmotic layer granules, was inserted into the lower mold cavity. A blank upper mold assembly portion was mated the lower mold assembly portion. The mold assembly was then cycled to a hot stage at 85° C. for 2 minutes. Next, the assembly was cycled to a cold stage at 5° C. for 1 minute to harden the first shell portion. The blank upper mold assembly portion was then removed from the lower mold assembly portion.
- The upper mold assembly portion was next cycled to a cold stage at 5° C. for 30 seconds. The shell portion material was added to the upper mold cavity. The half-coated core, with the first shell portion, was inserted into the upper mold cavity such that the uncoated core portion containing pseudoephedrine HCl sustained release granules rested within the upper mold cavity. The lower mold assembly portion, which had been maintained at 5° C., was then mated with the upper mold assembly portion. The upper mold assembly portion was then cycled to a hot stage at 85° C. for 2 minutes, followed by a cold stage at 5° C. for 1 minute to harden the second shell portion. The lower mold assembly portion was removed and the finished dosage form, a two-portion core coated with the same shell portion, was ejected form the upper mold cavity. The weight gain due to the shell portion, i.e. the difference in weights of the finished dosage form and the uncoated core, was recorded. The finished dosage form was dried at room temperature for 12 hours to remove all residual solvent. A 0.55 mm aperture was manually drilled on the pseudophedrine HCl layer side of the dosage form by using a pin of diameter of 0.55 mm.
- The release profile for the active ingredient contained in the dosage form of this example is given as follow. The results are shown in FIG. 9, which depicts the percent release of active ingredient versus hours for the dosage form of Example 1. The curve depicts the dissolution profile of the pseudoephedrine HCl contained in the second core portion of the finished dosage form of this example.
- All curves were obtained using the following dissolution apparatus: USP Type II apparatus (paddles, 50 RPM). Media: pH 6.8 phosphate buffer at 37° C. Time points: Samples were removed at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours to be analyzed for pseudoephedrine HCl. Dissolution samples were analyzed for pseudoephedrine HCl versus a standard prepared at the theoretical concentration for 100% released of the compound. Samples were assayed spectrophotometrically using a
Cary 50 UV-Visible spectrophotometer at 257 nm for pseudoephedrine HCl content. - Although this invention has been illustrated by reference to specific embodiments, it will be apparent to those skilled in the art that various changes and modifications may be made which clearly fall within the scope of the invention.
Claims (44)
1. A dosage form comprising:
(a) at least one active ingredient;
(b) a core having an outer surface; and
(c) a shell which resides upon at least a portion of the core outer surface, wherein at least a portion of the shell is semipermeable, at least about 30% of the cross-sectional area of the semipermeable shell portion is non-striated, and the shell comprises means for providing the active ingredient to a liquid medium outside the shell after contacting of the dosage form with the liquid medium.
2. The dosage form of claim 1 , in which substantially all of the shell is semipermeable, and the shell additionally comprises at least one passageway therein extending to the core outer surface.
3. The dosage form of claim 1 , in which at least about 50% of the cross sectional area of the shell is non-striated.
4. The dosage form of claim 1 , in which at least about 80% of the cross sectional area of the shell is non-striated.
5. The dosage form of claim 1 , in which the core comprises at least one active ingredient.
6. The dosage form of claim 1 , in which the shell comprises at least one active ingredient.
7. The dosage form of claim 1 , in which the core and the shell each comprise at least one active ingredient.
8. The dosage form of claim 1 , in which the core comprises an osmagent.
9. The dosage form of claim 1 , in which the core comprises a first core portion and a second core portion.
10. The dosage form of claim 9 , in which the shell comprises a plurality of passageways therein extending to the core.
11. A dosage form comprising:
(a) at least one active ingredient;
(b) a core having an outer surface; and
(c) a shell which resides upon at least a portion of the core outer surface,
wherein the shell comprises a first shell portion which is semipermeable to the liquid medium, and a second shell portion which is compositionally different than the first shell portion, the first and second shell portions each are substantially in contact with the core outer surface, and the shell comprises means for providing the active ingredient to a liquid medium outside the shell after contacting of the dosage form with the liquid medium.
12. The dosage form of claim 11 , in which at least one of the first or second shell portions has at least one passageway therein extending to the core outer surface.
13. The dosage form of claim 11 , in which the second shell portion is diffusible.
14. The dosage form of claim 11 , in which the first shell portion has at least one passageway therein extending to the core, and the second shell portion is impermeable to the liquid medium.
15. The dosage form of claim 11 , in which the second shell portion has at least one passageway therein extending to the core.
16. The dosage form of claim 11 , in which the core comprises at least one active ingredient.
17. The dosage form of claim 11 , in which the first shell portion comprises at least one active ingredient.
18. The dosage form of claim 11 , in which the second shell portion comprises at least one active ingredient.
19. The dosage form of claim 11 , in which the core, the first shell portion and the second shell portion each comprises at least one active ingredient.
20. The dosage form of claim 11 , in which the first shell portion has a first thickness, and the second shell portion has a second thickness which is different than the first shell portion thickness.
21. The dosage form of claim 11 , in which the first shell portion has a first thickness, and the second shell portion has a second thickness which is substantially the same as the first shell portion thickness.
22. The dosage form of claim 11 , in which the core comprises a first core portion and a second core portion.
23. The dosage form of claim 22 , in which at least one of the first or second core portions comprises at least one active ingredient.
24. The dosage form of claim 22 , in which the first core portion comprises a first active ingredient and the second core portion comprises a second active ingredient which may be the same or different than the first active ingredient.
25. A dosage form comprising:
(a) at least one active ingredient;
(b) a core having an outer surface, a first core portion, a second core portion, and a third core portion located between the first and second core portions, wherein the third core portion comprises an osmopolymer; and
(c) a shell which resides upon at least a portion of the core outer surface, in which the shell comprises a first shell portion which is semipermeable to the liquid medium, and a second shell portion which is compositionally different than the first shell portion, the first and second shell portions each are substantially in contact with the core outer surface, and at least one of the first or second shell portions has at least one passageway therein extending to the core outer surface.
26. The dosage form of claim 25 , in which at least one of the first or second core portions comprises at least one active ingredient.
27. The dosage form of claim 25 , in which the first core portion comprises a first active ingredient and the second core portion comprises a second active ingredient which may be the same or different than the first active ingredient.
28. A dosage form comprising:
(a) at least one active ingredient;
(b) a core having an outer surface; and
(c) a shell which resides upon at least a portion of the core outer surface, in which the shell comprises a first shell portion which is semipermeable to the liquid medium, and a second shell portion which is compositionally different than the first shell portion, the first and second shell portions each are substantially in contact with the core outer surface, and the shell and core have a continuous cavity therein defining an interior surface, wherein neither the first shell portion nor the second shell portion extend substantially upon the interior surface.
29. The dosage form of claim 28 , in which the core comprises at least one active ingredient.
30. A dosage form comprising:
(a) at least one active ingredient;
(b) a core having an outer surface, a first core portion, a second core portion, and a third core portion located between the first and second core portions, wherein the third core portion comprises a osmopolymer; and
(c) a shell which resides upon at least a portion of the core outer surface, in which the shell comprises a first shell portion which is semipermeable to the liquid medium, and a second shell portion which is compositionally different than the first shell portion, the first and second shell portions each are substantially in contact with the core outer surface, and the shell and core have a continuous cavity therein defining an interior surface, wherein neither the first shell portion nor the second shell portion extend substantially upon the interior surface.
31. The dosage form of claim 30 , in which at least one of the first or second core portions comprises at least one active ingredient.
32. The dosage form of claim 30 , in which the first core portion comprises a first active ingredient and the second core portion comprises a second active ingredient which may be the same or different than the first active ingredient.
33. The dosage form of claims 28 or 30, in which the core erodes upon contacting of the interior surface with a liquid medium.
34. The dosage form of claims 28 or 30, in which the diameter of the continuous cavity is in the range of about 15 to about 90 percent of the thickness of the dosage form.
35. The dosage form of any of claims 1, 11, 25, 28 or 30, wherein the providing of at least one active ingredient follows substantially zero-order kinetics over a specified time interval.
36. The dosage form of any of claims 1, 11, 25, 28 or 30, wherein the providing of at least one active ingredient follows square-root-of-time kinetics over a specified time interval.
37. The dosage form of any of claims 1, 11, 25, 28 or 30, wherein the providing of at least one active ingredient follows substantially first-order kinetics over a specified time interval.
38. The dosage form of any of claims 9, 22, 25 or 30, wherein at least one of the first or second core portions functions as an eroding matrix.
39. The dosage form of claim 38 , wherein the eroding matrix core portion comprises a release-modifying compressible or moldable excipient selected from swellable erodible hydrophilic agents, pH-dependent polymers, and combinations thereof.
40. The dosage form of any of claims 1, 11, 25, 28 or 30, in which the release rate of at least one active ingredient is non-constant.
41. The dosage form of any of claims 1, 11, 25, 28 or 30, in which the release of at least one dose of at least one active ingredient is a burst release.
42. The dosage form of any of claims 1, 11, 25, 28 or 30, in which the release rate of at least one active ingredient is an ascending release rate.
43. The dosage form of any of claim 1 , 11, 25, 28, or 30, which provides an ascending blood level PK profile for at least one active ingredient after administration to a mammal.
44. The dosage form of any of claims 1, 11, 25, 28 or 30, in which the shell contains greater than 90 mg of at least one active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/393,638 US20030232082A1 (en) | 2001-09-28 | 2003-03-21 | Modified release dosage forms |
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/966,939 US6837696B2 (en) | 2001-09-28 | 2001-09-28 | Apparatus for manufacturing dosage forms |
US09/966,509 US6767200B2 (en) | 2001-09-28 | 2001-09-28 | Systems, methods and apparatuses for manufacturing dosage forms |
US09/967,414 US6742646B2 (en) | 2001-09-28 | 2001-09-28 | Systems, methods and apparatuses for manufacturing dosage forms |
US09/966,450 US6982094B2 (en) | 2001-09-28 | 2001-09-28 | Systems, methods and apparatuses for manufacturing dosage forms |
US09/966,497 US7122143B2 (en) | 2001-09-28 | 2001-09-28 | Methods for manufacturing dosage forms |
PCT/US2002/031163 WO2003026627A1 (en) | 2001-09-28 | 2002-09-28 | Composite dosage forms |
PCT/US2002/031024 WO2003026625A1 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
PCT/US2002/031129 WO2003026630A1 (en) | 2001-09-28 | 2002-09-28 | Dosage forms having an inner core and outer shell with different shapes |
PCT/US2002/031062 WO2003026626A2 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
PCT/US2002/031117 WO2003026629A2 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
US10/393,638 US20030232082A1 (en) | 2001-09-28 | 2003-03-21 | Modified release dosage forms |
Related Parent Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/031062 Continuation-In-Part WO2003026626A2 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
PCT/US2002/031163 Continuation-In-Part WO2003026627A1 (en) | 2001-09-28 | 2002-09-28 | Composite dosage forms |
PCT/US2002/031129 Continuation-In-Part WO2003026630A1 (en) | 2001-09-28 | 2002-09-28 | Dosage forms having an inner core and outer shell with different shapes |
PCT/US2002/031024 Continuation-In-Part WO2003026625A1 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
PCT/US2002/031117 Continuation-In-Part WO2003026629A2 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030232082A1 true US20030232082A1 (en) | 2003-12-18 |
Family
ID=27542311
Family Applications (15)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/476,529 Abandoned US20050019407A1 (en) | 2001-09-28 | 2002-09-28 | Composite dosage forms |
US10/476,504 Abandoned US20040213848A1 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
US10/432,488 Abandoned US20040062804A1 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
US10/476,530 Expired - Fee Related US8545887B2 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
US10/484,485 Abandoned US20040241208A1 (en) | 2001-09-28 | 2002-09-28 | Fondant-based pharmaceutical composition |
US10/476,238 Abandoned US20040241236A1 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
US10/476,514 Abandoned US20040170750A1 (en) | 2001-09-28 | 2002-09-28 | Edible composition and dosage form comprising an edible shell |
US10/477,334 Expired - Fee Related US7968120B2 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
US10/393,610 Abandoned US20030219484A1 (en) | 2001-09-28 | 2003-03-21 | Immediate release dosage form comprising shell having openings therein |
US10/393,638 Abandoned US20030232082A1 (en) | 2001-09-28 | 2003-03-21 | Modified release dosage forms |
US10/393,752 Expired - Fee Related US7635490B2 (en) | 2001-09-28 | 2003-03-21 | Modified release dosage form |
US10/393,765 Abandoned US20040018327A1 (en) | 2001-09-28 | 2003-03-21 | Delayed release dosage forms |
US10/393,871 Expired - Fee Related US7416738B2 (en) | 2001-09-28 | 2003-03-21 | Modified release dosage form |
US12/049,628 Abandoned US20080305150A1 (en) | 2001-09-28 | 2008-03-17 | Polymer Composition And Dosage Forms Comprising The Same |
US12/391,475 Expired - Fee Related US7972624B2 (en) | 2001-09-28 | 2009-02-24 | Method of manufacturing modified release dosage forms |
Family Applications Before (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/476,529 Abandoned US20050019407A1 (en) | 2001-09-28 | 2002-09-28 | Composite dosage forms |
US10/476,504 Abandoned US20040213848A1 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
US10/432,488 Abandoned US20040062804A1 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
US10/476,530 Expired - Fee Related US8545887B2 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
US10/484,485 Abandoned US20040241208A1 (en) | 2001-09-28 | 2002-09-28 | Fondant-based pharmaceutical composition |
US10/476,238 Abandoned US20040241236A1 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
US10/476,514 Abandoned US20040170750A1 (en) | 2001-09-28 | 2002-09-28 | Edible composition and dosage form comprising an edible shell |
US10/477,334 Expired - Fee Related US7968120B2 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
US10/393,610 Abandoned US20030219484A1 (en) | 2001-09-28 | 2003-03-21 | Immediate release dosage form comprising shell having openings therein |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/393,752 Expired - Fee Related US7635490B2 (en) | 2001-09-28 | 2003-03-21 | Modified release dosage form |
US10/393,765 Abandoned US20040018327A1 (en) | 2001-09-28 | 2003-03-21 | Delayed release dosage forms |
US10/393,871 Expired - Fee Related US7416738B2 (en) | 2001-09-28 | 2003-03-21 | Modified release dosage form |
US12/049,628 Abandoned US20080305150A1 (en) | 2001-09-28 | 2008-03-17 | Polymer Composition And Dosage Forms Comprising The Same |
US12/391,475 Expired - Fee Related US7972624B2 (en) | 2001-09-28 | 2009-02-24 | Method of manufacturing modified release dosage forms |
Country Status (20)
Country | Link |
---|---|
US (15) | US20050019407A1 (en) |
EP (12) | EP1438028A1 (en) |
JP (11) | JP2005535558A (en) |
KR (11) | KR20040045034A (en) |
CN (10) | CN1592612A (en) |
AT (4) | ATE476957T1 (en) |
AU (1) | AU2002330164A1 (en) |
BR (11) | BR0213593A (en) |
CA (12) | CA2461870A1 (en) |
CO (1) | CO5570655A2 (en) |
DE (4) | DE60223269T2 (en) |
ES (3) | ES2295427T3 (en) |
HK (1) | HK1072902A1 (en) |
HU (1) | HUP0401686A3 (en) |
MX (12) | MXPA04002891A (en) |
NO (4) | NO20032363L (en) |
NZ (3) | NZ532097A (en) |
PL (1) | PL369134A1 (en) |
PT (1) | PT1429738E (en) |
WO (12) | WO2003026626A2 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050196447A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20050196446A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20050196442A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20050196448A1 (en) * | 2004-03-05 | 2005-09-08 | Hai Yong Huang | Polymeric compositions and dosage forms comprising the same |
US20060233882A1 (en) * | 2005-04-15 | 2006-10-19 | Sowden Harry S | Osmotic dosage form |
US20070184111A1 (en) * | 2006-02-03 | 2007-08-09 | Pharmavite Llc | Hybrid tablet |
US20080299199A1 (en) * | 2004-05-11 | 2008-12-04 | Egalet A/S | Swellable Dosage Form Comprising Gellan Gum |
US20100291159A1 (en) * | 2009-05-12 | 2010-11-18 | Bpsi Holdings, Llc. | Film coatings containing fine particle size detackifiers and substrates coated therewith |
US7968120B2 (en) | 2001-09-28 | 2011-06-28 | Mcneil-Ppc, Inc. | Modified release dosage forms |
US8062672B2 (en) * | 2003-08-12 | 2011-11-22 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
WO2011161666A2 (en) * | 2010-06-21 | 2011-12-29 | White Innovation Ltd. | Enclosed liquid capsules |
US20120258171A1 (en) * | 2009-10-30 | 2012-10-11 | Ratiopharm Gmbh | Composition comprising fesoterodine and fiber |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US20130074855A1 (en) * | 2011-09-22 | 2013-03-28 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
WO2013149056A1 (en) * | 2012-03-30 | 2013-10-03 | Elwha Llc | Device, system, and method for delivery of sugar glass stabilized compositions |
US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US20160151542A1 (en) * | 2010-02-05 | 2016-06-02 | Allergan, Inc. | Porogen compositions, methods of making and uses |
US9375033B2 (en) | 2014-02-14 | 2016-06-28 | R.J. Reynolds Tobacco Company | Tobacco-containing gel composition |
US9474303B2 (en) | 2011-09-22 | 2016-10-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9629392B2 (en) | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US10391199B2 (en) | 2010-02-05 | 2019-08-27 | Allergan, Inc. | Porous materials, methods of making and uses |
US11000471B2 (en) * | 2018-03-05 | 2021-05-11 | Kashiv Specialty Pharmaceuticals, Llc | Programmable pharmaceutical compositions for chrono drug release |
US11129898B2 (en) | 2011-09-22 | 2021-09-28 | Modoral Brands Inc. | Nicotine-containing pharmaceutical composition |
US11202853B2 (en) * | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
Families Citing this family (289)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
US6607751B1 (en) * | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
AU3024399A (en) * | 1998-04-03 | 1999-10-25 | Bm Research A/S | Controlled release composition |
US20090149479A1 (en) * | 1998-11-02 | 2009-06-11 | Elan Pharma International Limited | Dosing regimen |
DE10026698A1 (en) | 2000-05-30 | 2001-12-06 | Basf Ag | Self-emulsifying active ingredient formulation and use of this formulation |
US20040234602A1 (en) * | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8323692B2 (en) | 2002-02-21 | 2012-12-04 | Valeant International Bermuda | Controlled release dosage forms |
PT1476138E (en) * | 2002-02-21 | 2012-02-14 | Valeant Internat Barbados Srl | Modified release formulations of at least one form of tramadol |
US7169450B2 (en) | 2002-05-15 | 2007-01-30 | Mcneil-Ppc, Inc. | Enrobed core |
US20040161474A1 (en) * | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
US20060083791A1 (en) | 2002-05-24 | 2006-04-20 | Moerck Rudi E | Rare earth metal compounds methods of making, and methods of using the same |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
WO2004052345A1 (en) * | 2002-12-11 | 2004-06-24 | Ranbaxy Laboratories Limited | Coating composition for taste masking coating and methods for their application and use |
GB0229258D0 (en) * | 2002-12-16 | 2003-01-22 | Boots Healthcare Int Ltd | Medicinal compositions |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
US8298581B2 (en) * | 2003-03-26 | 2012-10-30 | Egalet A/S | Matrix compositions for controlled delivery of drug substances |
DE602004031096D1 (en) | 2003-03-26 | 2011-03-03 | Egalet As | MORPHINE SYSTEM WITH CONTROLLED RELEASE |
SI1631251T1 (en) | 2003-04-24 | 2011-10-28 | Jagotec Ag | Delayed release tablet with defined core geometry |
DK1615626T3 (en) * | 2003-04-24 | 2010-02-08 | Jagotec Ag | Colored core tablet |
CN1829499A (en) * | 2003-05-29 | 2006-09-06 | 格利康科技集团有限责任公司 | Method and composition for stable and controlled delivery of (-)-hydroxycitric acid |
US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
TW200514579A (en) * | 2003-07-24 | 2005-05-01 | Smithkline Beecham Corp | Orally dissolving films |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE102004032051A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
JP2005075826A (en) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Internatl Gmbh | Controlled release preparation comprising porous silica support |
GB0320854D0 (en) | 2003-09-05 | 2003-10-08 | Arrow No 7 Ltd | Buccal drug delivery |
US8469036B2 (en) | 2003-11-07 | 2013-06-25 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
US8627828B2 (en) | 2003-11-07 | 2014-01-14 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
US7879354B2 (en) * | 2004-01-13 | 2011-02-01 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
US8067029B2 (en) | 2004-01-13 | 2011-11-29 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
CA2558219C (en) * | 2004-03-10 | 2014-04-08 | Taisho Pharmaceutical Co., Ltd. | Poorly water-soluble drug-containing solid formulation |
US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
US7622137B2 (en) * | 2004-05-21 | 2009-11-24 | Accu-Break Technologies, Inc. | Dosage forms contained within a capsule or sachet |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20060002986A1 (en) * | 2004-06-09 | 2006-01-05 | Smithkline Beecham Corporation | Pharmaceutical product |
TWI428271B (en) * | 2004-06-09 | 2014-03-01 | Smithkline Beecham Corp | Apparatus and method for pharmaceutical production |
US20050281876A1 (en) * | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
US8609198B2 (en) * | 2004-07-21 | 2013-12-17 | Hewlett-Packard Development Company, L.P. | Pharmaceutical dose form with a patterned coating and method of making the same |
AU2005266882A1 (en) * | 2004-07-26 | 2006-02-02 | Teva Pharmaceutical Indudstries, Ltd. | Dosage forms with an enterically coated core tablet |
US7621734B2 (en) | 2004-07-28 | 2009-11-24 | Mars, Incorporated | Apparatus and process for preparing confectionery having an inclusion therein using forming rolls and a forming pin |
US20060024361A1 (en) * | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
US20060024368A1 (en) * | 2004-07-30 | 2006-02-02 | Reza Fassihi | Compressed composite delivery system for release-rate modulation of bioactives |
EP1639899A1 (en) * | 2004-08-23 | 2006-03-29 | Friesland Brands B.V. | Powdered, cold-water soluble/dispersible, foamable composition |
US10624858B2 (en) * | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
EP1944008A3 (en) * | 2004-09-24 | 2008-07-23 | BioProgress Technology Limited | Additional improvements in powder compaction and enrobing |
CN101065091A (en) * | 2004-09-24 | 2007-10-31 | 生物进展技术有限公司 | Additional improvements in powder compaction and enrobing |
AU2005292271A1 (en) * | 2004-09-30 | 2006-04-13 | Monosol Rx, Llc | Multi-layer films having uniform content |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
CA2583548A1 (en) * | 2004-10-15 | 2006-04-27 | Altairnano, Inc. | Phosphate binder with reduced pill burden |
ES2409347T3 (en) | 2004-10-21 | 2013-06-26 | Aptalis Pharmatech, Inc. | Pharmaceutical compositions of masked flavor with gastro-soluble porogenic agents |
US20060087051A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060088586A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060088593A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20070190133A1 (en) * | 2004-10-27 | 2007-08-16 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US8383159B2 (en) | 2004-10-27 | 2013-02-26 | Mcneil-Ppc, Inc. | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20070281022A1 (en) * | 2004-10-27 | 2007-12-06 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
US20060088587A1 (en) * | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
GB0423964D0 (en) * | 2004-10-28 | 2004-12-01 | Jagotec Ag | Dosage form |
US20060093560A1 (en) * | 2004-10-29 | 2006-05-04 | Jen-Chi Chen | Immediate release film coating |
AR051654A1 (en) * | 2004-11-04 | 2007-01-31 | Astrazeneca Ab | NEW FORMULATIONS OF MODIFIED RELEASE PELLETS FOR PROTON PUMP INHIBITORS |
AR052225A1 (en) * | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | FORMULATIONS OF MODIFIED RELEASE TABLETS FOR INHIBITORS OF THE PUMP OF PROTONS |
PL1836665T3 (en) | 2004-11-19 | 2013-06-28 | Glaxosmithkline Llc | Method for customized dispensing of variable dose drug combination products for individualizing of therapies |
US7530804B2 (en) * | 2004-12-07 | 2009-05-12 | Mcneil-Ppc, Inc. | System and process for providing at least one opening in dosage forms |
US7404708B2 (en) * | 2004-12-07 | 2008-07-29 | Mcneil-Ppc, Inc. | System and process for providing at least one opening in dosage forms |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
MX2007007836A (en) | 2004-12-27 | 2007-08-20 | Eisai R&D Man Co Ltd | Method for stabilizing anti-dementia drug. |
EP1838287B1 (en) * | 2005-01-07 | 2012-05-23 | Sandoz Ag | Process for preparing granulates comprising amoxicillin |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
EP1858483A4 (en) * | 2005-03-16 | 2009-07-15 | Reddys Lab Ltd Dr | Delivery system for multiple drugs |
MX2007012220A (en) * | 2005-04-06 | 2007-12-06 | Mallinckrodt Inc | Matrix-based pulse release pharmaceutical formulation. |
AU2006235483B2 (en) * | 2005-04-12 | 2010-11-25 | Elan Pharma International Limited | Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection |
US20090023778A1 (en) * | 2005-04-28 | 2009-01-22 | Eisai R&D Management Co., Ltd. | Composition Containing Anti-Dementia Drug |
AU2006239221C1 (en) | 2005-04-28 | 2012-08-16 | Otsuka Pharmaceutical Co., Ltd. | Pharma-informatics system |
US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
DE602006020133D1 (en) * | 2005-05-18 | 2011-03-31 | Goemar Lab Sa | LAMINARIN-CONTAINING FOODS |
JP5161075B2 (en) * | 2005-06-03 | 2013-03-13 | エガレット エイ/エス | Solid pharmaceutical composition having a first fraction of a dispersion medium and a second fraction of a matrix, wherein the second fraction is first at least partially exposed to gastrointestinal fluid |
JP5095615B2 (en) | 2005-06-27 | 2012-12-12 | バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ | Modified release of bupropion salt |
US20070009573A1 (en) * | 2005-07-07 | 2007-01-11 | L N K International | Method of forming immediate release dosage form |
US20070015834A1 (en) * | 2005-07-18 | 2007-01-18 | Moshe Flashner-Barak | Formulations of fenofibrate containing PEG/Poloxamer |
DE102005034043B4 (en) * | 2005-07-18 | 2019-12-12 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Mixture containing L-carnitine and trehalulose and product containing the mixture |
US20080058250A1 (en) * | 2005-08-17 | 2008-03-06 | Allison Wren | Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods |
TWI274889B (en) * | 2005-10-06 | 2007-03-01 | Elan Microelectronics Corp | Resistive touch screen measurement system |
AU2006304889A1 (en) * | 2005-10-14 | 2007-04-26 | H. Lundbeck A/S | Stable pharmaceutical formulations containing escitalopram and bupropion |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
WO2007086846A1 (en) * | 2006-01-24 | 2007-08-02 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
JP2007224012A (en) * | 2006-01-30 | 2007-09-06 | Fujifilm Corp | Enzymatically crosslinked protein nanoparticle |
US20070190131A1 (en) * | 2006-02-10 | 2007-08-16 | Perry Ronald L | Press-fit rapid release medicament and method and apparatus of manufacturing |
US20070224258A1 (en) * | 2006-03-22 | 2007-09-27 | Bunick Frank J | Dosage forms having a randomized coating |
BRPI0710029A2 (en) * | 2006-03-28 | 2011-08-02 | Mcneil Ppc Inc | inhomogeneous dosage form coatings |
CN104825397A (en) | 2006-04-03 | 2015-08-12 | 伊萨·奥迪迪 | Controlled release delivery device comprising an organosol coat |
JP5349290B2 (en) * | 2006-04-03 | 2013-11-20 | オディディ,イサ | Drug delivery composition, pharmaceutical comprising the same, and method for producing the same |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
WO2007139661A1 (en) * | 2006-05-23 | 2007-12-06 | Haley Jeffrey T | Xylitol troches and methods of use |
US20070293587A1 (en) * | 2006-05-23 | 2007-12-20 | Haley Jeffrey T | Combating sinus, throat, and blood infections with xylitol delivered in the mouth |
US20100239668A1 (en) * | 2006-06-19 | 2010-09-23 | Kaplan Allan S | Segmented pharmaceutical dosage forms |
SG10201503411QA (en) | 2006-08-03 | 2015-06-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
US8399230B2 (en) * | 2006-10-12 | 2013-03-19 | Kemin Industries, Inc. | Heat-stable enzyme compositions |
EP1916006A1 (en) * | 2006-10-19 | 2008-04-30 | Albert Schömig | Implant coated with a wax or a resin |
BRPI0718171A2 (en) | 2006-10-20 | 2013-11-26 | Mcneil Ppc Inc | Acetaminophen / IBUPROPHEN COMBINATIONS AND METHOD FOR USE |
CA2667207A1 (en) * | 2006-10-25 | 2008-05-02 | Mcneil-Ppc, Inc. | Ibuprofen composition |
WO2008086804A2 (en) * | 2007-01-16 | 2008-07-24 | Egalet A/S | Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
US7767248B2 (en) | 2007-02-02 | 2010-08-03 | Overly Iii Harry J | Soft chew confectionary with high fiber and sugar content and method for making same |
GB0702974D0 (en) * | 2007-02-15 | 2007-03-28 | Jagotec Ag | Method and apparatus for producing a tablet |
JP5224790B2 (en) * | 2007-03-02 | 2013-07-03 | 株式会社明治 | Solid food and method for producing the same |
CA2677076C (en) * | 2007-03-02 | 2017-09-12 | Meda Pharmaceuticals Inc. | Compositions comprising carisoprodol and methods of use thereof |
DE102007011485A1 (en) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
US20080292692A1 (en) * | 2007-05-21 | 2008-11-27 | Shira Pilch | Impermeable Capsules |
US20080300322A1 (en) * | 2007-06-01 | 2008-12-04 | Atlantic Pharmaceuticals, Inc. | Delivery vehicles containing rosin resins |
EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
MX2009013494A (en) * | 2007-06-11 | 2010-01-18 | Procter & Gamble | Benefit agent containing delivery particle. |
US20080317678A1 (en) * | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
US20080317677A1 (en) * | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
US20090004248A1 (en) * | 2007-06-29 | 2009-01-01 | Frank Bunick | Dual portion dosage lozenge form |
CA2923102C (en) * | 2007-08-13 | 2019-10-15 | Abuse Deterrent Pharmaceutical Llc | Abuse resistant drugs, method of use and method of making |
US20090060983A1 (en) * | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
CA2697189A1 (en) * | 2007-09-12 | 2009-03-19 | Elan Pharma International Limited | Dosing regimen |
US8741329B2 (en) * | 2007-09-21 | 2014-06-03 | Merck Sharp & Dohme B.V. | Drug delivery system |
FR2921835B1 (en) * | 2007-10-05 | 2012-05-04 | Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic | COATING COMPOSITION COMPRISING POLYDEXTROSE, PROCESS FOR PREPARING THE SAME, AND USE FOR COATING INFRINGABLE SOLID FORMS |
US8789536B2 (en) | 2007-10-17 | 2014-07-29 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US20090105561A1 (en) * | 2007-10-17 | 2009-04-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Medical or veterinary digestive tract utilization systems and methods |
US8303573B2 (en) | 2007-10-17 | 2012-11-06 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US8707964B2 (en) * | 2007-10-31 | 2014-04-29 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
JP4879351B2 (en) † | 2007-10-19 | 2012-02-22 | 大塚製薬株式会社 | Pharmaceutical solid formulation |
US8808276B2 (en) * | 2007-10-23 | 2014-08-19 | The Invention Science Fund I, Llc | Adaptive dispensation in a digestive tract |
US8808271B2 (en) * | 2007-10-31 | 2014-08-19 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US8109920B2 (en) * | 2007-10-31 | 2012-02-07 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US20090163894A1 (en) * | 2007-10-31 | 2009-06-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Medical or veterinary digestive tract utilization systems and methods |
WO2009058798A2 (en) * | 2007-10-31 | 2009-05-07 | Mcneil-Ppc, Inc. | Orally disintegrated dosage form |
US8333754B2 (en) * | 2007-10-31 | 2012-12-18 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US20090137866A1 (en) * | 2007-11-28 | 2009-05-28 | Searete Llc, A Limited Liability Corporation Of The State Delaware | Medical or veterinary digestive tract utilization systems and methods |
EP3090739A1 (en) | 2008-01-04 | 2016-11-09 | Schabar Research Associates LLC | Compositions composed of naproxen sodium and nizatidine |
RU2493830C2 (en) | 2008-01-25 | 2013-09-27 | Грюненталь Гмбх | Drug form |
WO2009154810A2 (en) * | 2008-02-25 | 2009-12-23 | Dr. Reddy's Laboratories Ltd. | Delivery systems for multiple active agents |
CA2720108C (en) | 2008-03-11 | 2016-06-07 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
WO2009137648A1 (en) * | 2008-05-09 | 2009-11-12 | Aptapharma, Inc. | Multilayer proton pump inhibitor tablets |
BRPI0912014A2 (en) | 2008-05-09 | 2019-03-06 | Grünenthal GmbH | A process for preparing an intermediate powder formulation and a final solid dosage form using a spray freeze step |
WO2009140351A2 (en) * | 2008-05-14 | 2009-11-19 | Cadbury Adams Usa Llc | Confectionery with enzymatically manipulated texture |
WO2009146537A1 (en) * | 2008-06-02 | 2009-12-10 | Pharmascience Inc. | Multilayer control-release drug delivery system |
KR200452140Y1 (en) * | 2008-06-20 | 2011-02-08 | 주식회사 부성시스템 | Control device for nonwoven open/closed device of vinyl house |
JP5681626B2 (en) * | 2008-07-14 | 2015-03-11 | ポリーペイド リミテッドPolypid Ltd. | Sustained release drug carrier composition |
KR200450450Y1 (en) * | 2008-07-16 | 2010-10-04 | 이봉석 | The case of position limit switch |
EP2326316A1 (en) * | 2008-08-07 | 2011-06-01 | Avantor Performance Materials, Inc. | Sustained release compositions comprising gums and sugar alcohols |
US8038424B2 (en) * | 2008-09-22 | 2011-10-18 | Xerox Corporation | System and method for manufacturing sold ink sticks with an injection molding process |
FR2936952A1 (en) * | 2008-10-09 | 2010-04-16 | Monique Bellec | Product, useful as nutritional supplements, comprises a composition in powder/anhydrous liquid form, having active ingredient and gelling agent e.g. lecithin and alginic acid, where composition is enclosed in edible water-soluble envelope |
IT1394597B1 (en) * | 2008-11-05 | 2012-07-05 | Politi | DRY GRANULATION IN GAS FLOW. |
WO2010067478A1 (en) * | 2008-12-12 | 2010-06-17 | 株式会社ミツヤコーポレーション | Food and method for processing the same |
AU2010207740B2 (en) * | 2009-01-26 | 2016-06-16 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
NZ594208A (en) * | 2009-02-06 | 2012-10-26 | Egalet Ltd | Pharmaceutical compositions resistant to abuse |
WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
DK2395840T3 (en) * | 2009-02-13 | 2020-06-08 | Romark Laboratories Lc | Controlled release nitazoxanide pharmaceutical formulations |
WO2010129288A2 (en) | 2009-04-28 | 2010-11-11 | Proteus Biomedical, Inc. | Highly reliable ingestible event markers and methods for using the same |
WO2010133961A1 (en) | 2009-05-22 | 2010-11-25 | Inventia Healthcare Private Limited | Extended release compositions of cyclobenzaprine |
WO2010149169A2 (en) | 2009-06-24 | 2010-12-29 | Egalet A/S | Controlled release formulations |
AU2010272167B2 (en) * | 2009-07-14 | 2016-11-17 | Polypid Ltd. | Sustained-release drug carrier composition |
BR112012001547A2 (en) | 2009-07-22 | 2016-03-08 | Gruenenthal Gmbh | hot melt extruded pharmaceutical dosage form |
JP2012533585A (en) | 2009-07-22 | 2012-12-27 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper-resistant dosage forms for oxidation-sensitive opioids |
CN102469806A (en) * | 2009-07-24 | 2012-05-23 | 日本卡夫食品株式会社 | Multiple-region candy and manufacturing method therefor |
TW201117812A (en) | 2009-08-05 | 2011-06-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
WO2011025673A1 (en) * | 2009-08-26 | 2011-03-03 | Aptapharma, Inc. | Multilayer minitablets |
US20110052685A1 (en) * | 2009-08-31 | 2011-03-03 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
WO2011028286A1 (en) * | 2009-09-01 | 2011-03-10 | Rhodia Operations | Polymer compositions |
US20110070286A1 (en) * | 2009-09-24 | 2011-03-24 | Andreas Hugerth | Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process |
US8313768B2 (en) * | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
US8343533B2 (en) * | 2009-09-24 | 2013-01-01 | Mcneil-Ppc, Inc. | Manufacture of lozenge product with radiofrequency |
US20110318411A1 (en) | 2010-06-24 | 2011-12-29 | Luber Joseph R | Multi-layered orally disintegrating tablet and the manufacture thereof |
WO2011056764A1 (en) | 2009-11-05 | 2011-05-12 | Ambit Biosciences Corp. | Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles |
EP2506836B1 (en) | 2009-12-02 | 2018-02-14 | Adare Pharmaceuticals S.R.L. | Fexofenadine microcapsules and compositions containing them |
UA109424C2 (en) * | 2009-12-02 | 2015-08-25 | PHARMACEUTICAL PRODUCT, PHARMACEUTICAL TABLE WITH ELECTRONIC MARKER AND METHOD OF MANUFACTURING PHARMACEUTICAL TABLETS | |
CA2780347A1 (en) * | 2009-12-07 | 2011-06-16 | Mcneil-Ppc, Inc. | Partial dip coating of dosage forms for modified release |
MY159958A (en) | 2009-12-18 | 2017-02-15 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
US10485770B2 (en) | 2009-12-21 | 2019-11-26 | Aptapharma, Inc. | Functionally-coated multilayer tablets |
CN102892406B (en) | 2010-01-19 | 2015-04-08 | 波利皮得有限公司 | Sustained-release nucleic acid matrix compositions |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
CN102821757B (en) | 2010-02-03 | 2016-01-20 | 格吕伦塔尔有限公司 | By extrusion mechanism for powdery medicine compositions |
GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
GB201003731D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
GB201003766D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
EP2544887A1 (en) * | 2010-03-11 | 2013-01-16 | Wockhardt Limited | A device for the manufacture of a dosage form with a hole and method of manufacture |
WO2011112689A2 (en) | 2010-03-11 | 2011-09-15 | Ambit Biosciences Corp. | Saltz of an indazolylpyrrolotriazine |
US8486013B2 (en) * | 2010-03-18 | 2013-07-16 | Biotronik Ag | Balloon catheter having coating |
US9743688B2 (en) | 2010-03-26 | 2017-08-29 | Philip Morris Usa Inc. | Emulsion/colloid mediated flavor encapsulation and delivery with tobacco-derived lipids |
CA2795746C (en) | 2010-04-07 | 2019-10-01 | Timothy Robertson | Miniature ingestible device |
KR101940207B1 (en) | 2010-05-12 | 2019-01-18 | 스펙트럼 파마슈티컬즈 인크 | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
US20110280936A1 (en) * | 2010-05-17 | 2011-11-17 | Aptapharma, Inc. | Self Breaking Tablets |
WO2012030885A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Hydrobromide salts of a pyrazolylaminoquinazoline |
US8703943B2 (en) | 2010-09-01 | 2014-04-22 | Ambit Biosciences Corporation | Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
WO2012028319A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
WO2012028318A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
EP2642983A4 (en) | 2010-11-22 | 2014-03-12 | Proteus Digital Health Inc | Ingestible device with pharmaceutical product |
AU2011338530B2 (en) | 2010-12-06 | 2017-06-15 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
US10821085B2 (en) * | 2010-12-07 | 2020-11-03 | Kimberly-Clark Worldwide, Inc. | Wipe coated with a botanical composition having antimicrobial properties |
US9233076B2 (en) | 2010-12-13 | 2016-01-12 | Purdue Pharma L.P. | Controlled release dosage forms |
WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
CN103338753A (en) | 2011-01-31 | 2013-10-02 | 细胞基因公司 | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
KR102059698B1 (en) | 2011-06-06 | 2019-12-26 | 오크 크레스트 인스티튜트 오브 사이언스 | Drug delivery device employing wicking release window |
USD723766S1 (en) | 2011-06-30 | 2015-03-10 | Intercontinental Great Brands Llc | Confectionary article |
US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
BR112014002022A2 (en) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | tamper-resistant tablet providing immediate drug release |
CN103857386A (en) | 2011-07-29 | 2014-06-11 | 格吕伦塔尔有限公司 | Tamper-resistant tablet providing immediate drug release |
CA2851544C (en) | 2011-10-14 | 2016-08-09 | Hill's Pet Nutrition, Inc. | Process for preparing a pet food composition |
KR101384055B1 (en) * | 2012-02-02 | 2014-04-14 | 한국원자력연구원 | Burst type lagged-release controlled composition and preparation method thereof |
US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
AU2013205306B2 (en) | 2012-03-16 | 2015-09-17 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
AU2013248351B2 (en) | 2012-04-18 | 2018-04-26 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US9985320B2 (en) * | 2012-04-30 | 2018-05-29 | Carnegie Mellon University | Water-activated, ingestible battery |
US9445971B2 (en) * | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
US9233491B2 (en) | 2012-05-01 | 2016-01-12 | Johnson & Johnson Consumer Inc. | Machine for production of solid dosage forms |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
WO2013183497A1 (en) * | 2012-06-05 | 2013-12-12 | 武田薬品工業株式会社 | Dry-coated tablet |
KR20150059167A (en) | 2012-07-06 | 2015-05-29 | 에갈렛 리미티드 | Abuse deterrent pharmaceutical compositions for controlled release |
CN102824640A (en) * | 2012-08-06 | 2012-12-19 | 济南圣泉唐和唐生物科技有限公司 | Capsule shell and preparation method thereof |
US20140193543A1 (en) * | 2013-01-09 | 2014-07-10 | Alexander Vigneri | Decorative hollow chocolate confection with improved writability |
JP2016508529A (en) | 2013-01-29 | 2016-03-22 | プロテウス デジタル ヘルス, インコーポレイテッド | Highly expandable polymer film and composition containing the same |
DE102013004263A1 (en) | 2013-03-13 | 2014-09-18 | Martin Lipsdorf | Fast-dissolving oral dosage form and method of making the same |
JP6395800B2 (en) * | 2013-03-15 | 2018-09-26 | インキューブ ラブズ, エルエルシー | Multi-stage biodegradable drug delivery platform |
MX2015013231A (en) | 2013-03-15 | 2016-06-07 | Inspirion Delivery Technologies Llc | Abuse deterrent compositions and methods of use. |
JP5941240B2 (en) | 2013-03-15 | 2016-06-29 | プロテウス デジタル ヘルス, インコーポレイテッド | Metal detector device, system and method |
US9470489B2 (en) * | 2013-05-14 | 2016-10-18 | Kerry Thaddeus Bowden | Airsoft marking round |
MX2015016254A (en) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Tamper resistant dosage form with bimodal release profile. |
BR112015026549A2 (en) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | tamper-proof dosage form containing one or more particles |
AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US10596103B2 (en) | 2013-12-11 | 2020-03-24 | Merek Sharp & Dohme B.V. | Drug delivery system for delivery of anti-virals |
US10413504B2 (en) | 2013-12-11 | 2019-09-17 | Merck Sharp & Dohme Corp. | Intravaginal ring drug delivery system |
WO2015095230A1 (en) * | 2013-12-16 | 2015-06-25 | Massachusetts Institute Of Technology | Micromolded or 3-d printed pulsatile release vaccine formulations |
DK3087980T3 (en) * | 2013-12-23 | 2019-02-18 | Xiaoguang Wen | DOUBLE LAYER TABLE AND METHOD OF PRODUCING THEREOF |
CA2936216C (en) | 2014-01-10 | 2021-10-26 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
TWI683813B (en) | 2014-03-20 | 2020-02-01 | 美商卡佩拉醫療公司 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof |
JP6568926B2 (en) | 2014-03-20 | 2019-08-28 | カペラ セラピューティクス,インコーポレーテッド | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
MX2016014738A (en) | 2014-05-12 | 2017-03-06 | Gruenenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol. |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
EA032473B1 (en) | 2014-12-23 | 2019-05-31 | Аксикин Фармасьютикалз, Инк. | 3,5-diaminopyrazole kinase inhibitors |
DE202016008309U1 (en) * | 2015-01-22 | 2017-07-14 | Pfeifer & Langen GmbH & Co. KG | Cellobiose-containing sugar mass |
US10174275B2 (en) * | 2015-01-30 | 2019-01-08 | Follmann Gmbh & Co. Kg | Thermally opening stable core/shell microcapsules |
USD765828S1 (en) | 2015-02-19 | 2016-09-06 | Crossford International, Llc | Chemical tablet |
US9839212B2 (en) | 2015-04-16 | 2017-12-12 | Bio-Lab, Inc. | Multicomponent and multilayer compacted tablets |
AU2016251854A1 (en) | 2015-04-24 | 2017-10-19 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
JP2018526414A (en) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Protection against oral overdose with abuse-inhibiting immediate release formulations |
US20190022013A1 (en) | 2015-12-19 | 2019-01-24 | First Time Us Generics Llc | Soft-chew tablet pharmaceutical formulations |
CN108712900A (en) | 2015-12-19 | 2018-10-26 | 第时间美国泛型药物有限公司 | Soft chewable tablet pharmaceutical preparation |
JP2017158534A (en) * | 2016-03-07 | 2017-09-14 | 焼津水産化学工業株式会社 | Manufacturing method of chip-like foods and chip-like foods |
EP3431079B1 (en) * | 2016-03-15 | 2023-06-07 | Astellas Pharma Inc. | Tablet |
EP3487393A4 (en) | 2016-07-22 | 2020-01-15 | Proteus Digital Health, Inc. | Electromagnetic sensing and detection of ingestible event markers |
EP4091796A1 (en) * | 2016-09-09 | 2022-11-23 | Merck Patent GmbH | Process for the manufacture of a solid pharmaceutical administration form |
MX2019003039A (en) | 2016-09-26 | 2019-07-08 | Procter & Gamble | Extended relief dosage form. |
CN109963499B (en) | 2016-10-26 | 2022-02-25 | 大冢制药株式会社 | Method for manufacturing capsules with ingestible event markers |
CN106945323B (en) * | 2017-03-14 | 2018-11-02 | 常熟市双月机械有限公司 | A kind of efficient metal powder hydraulic press |
US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
CN110382229A (en) * | 2017-04-07 | 2019-10-25 | 宝洁公司 | Water-solubility membrane |
DE102017107845A1 (en) | 2017-04-11 | 2018-10-11 | Gelita Ag | Gelatin product with a core component and process for its preparation |
CN110719968A (en) | 2017-06-22 | 2020-01-21 | 宝洁公司 | Film comprising a water-soluble layer and a vapor-deposited inorganic coating |
WO2018237212A1 (en) | 2017-06-22 | 2018-12-27 | The Procter & Gamble Company | Films including a water-soluble layer and a vapor-deposited organic coating |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
EP3587467A1 (en) * | 2018-06-25 | 2020-01-01 | Rudolf GmbH | Functional multi-walled core-shell particle |
EP3813540A4 (en) * | 2018-06-28 | 2022-04-06 | Mars, Incorporated | Improved edible ink formulations including calcium carbonate |
KR102151342B1 (en) * | 2019-03-18 | 2020-09-02 | 박문수 | Oral capsule and manufacturing method of the same |
CN110006918B (en) * | 2019-04-17 | 2021-04-30 | 湖北三环锻造有限公司 | Penetrant flaw detection agent for penetrant flaw detection process |
US10945953B1 (en) * | 2019-09-12 | 2021-03-16 | Nulixir Inc. | Controlled release core-shell particles and suspensions including the same |
IL299845A (en) | 2020-07-15 | 2023-03-01 | Schabar Res Associates Llc | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
CA3124579A1 (en) | 2020-07-15 | 2022-01-15 | Schabar Research Associates Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
Citations (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133132A (en) * | 1960-11-29 | 1964-05-12 | Univ California | High flow porous membranes for separating water from saline solutions |
US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3546142A (en) * | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
US3604417A (en) * | 1970-03-31 | 1971-09-14 | Wayne Henry Linkenheimer | Osmotic fluid reservoir for osmotically activated long-term continuous injector device |
US3760804A (en) * | 1971-01-13 | 1973-09-25 | Alza Corp | Improved osmotic dispenser employing magnesium sulphate and magnesium chloride |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3855770A (en) * | 1971-12-09 | 1974-12-24 | Howorth Air Conditioning Ltd | Machines acting on continuously running textile yarns |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3995631A (en) * | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4160020A (en) * | 1975-11-24 | 1979-07-03 | Alza Corporation | Therapeutic device for osmotically dosing at controlled rate |
US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
US4304232A (en) * | 1979-03-14 | 1981-12-08 | Alza Corporation | Unit system having multiplicity of means for dispensing useful agent |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4340054A (en) * | 1980-12-29 | 1982-07-20 | Alza Corporation | Dispenser for delivering fluids and solids |
US4627971A (en) * | 1985-04-22 | 1986-12-09 | Alza Corporation | Osmotic device with self-sealing passageway |
US4816262A (en) * | 1986-08-28 | 1989-03-28 | Universite De Montreal | Controlled release tablet |
US4871549A (en) * | 1985-07-19 | 1989-10-03 | Fujisawa Pharmaceutical Co., Ltd. | Time-controlled explosion systems and processes for preparing the same |
US4960416A (en) * | 1986-04-30 | 1990-10-02 | Alza Corporation | Dosage form with improved delivery capability |
US5200196A (en) * | 1986-05-09 | 1993-04-06 | Alza Corporation | Improvement in pulsed drug therapy |
US5209746A (en) * | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5221278A (en) * | 1992-03-12 | 1993-06-22 | Alza Corporation | Osmotically driven delivery device with expandable orifice for pulsatile delivery effect |
US5458887A (en) * | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5508040A (en) * | 1992-05-04 | 1996-04-16 | Andrx Pharmaceuticals, Inc. | Multiparticulate pulsatile drug delivery system |
US5558879A (en) * | 1995-04-28 | 1996-09-24 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
US5654005A (en) * | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
US5736159A (en) * | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
US5830502A (en) * | 1994-10-28 | 1998-11-03 | Alza Corporation | Injection-molded dosage form |
US5861173A (en) * | 1995-11-28 | 1999-01-19 | Bayer Aktiengesellschaft | Long-lasting release nifedipine preparation |
US6110499A (en) * | 1997-07-24 | 2000-08-29 | Alza Corporation | Phenytoin therapy |
US6210712B1 (en) * | 1997-12-05 | 2001-04-03 | Alza Corporation | Dosage form having first and second coats |
US20020028240A1 (en) * | 2000-04-17 | 2002-03-07 | Toyohiro Sawada | Timed-release compression-coated solid composition for oral administration |
US6365185B1 (en) * | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
US20020051807A1 (en) * | 2000-01-13 | 2002-05-02 | Joaquina Faour | Osmotic device containing alprazolam and an antipsychotic agent |
US6485748B1 (en) * | 1997-12-12 | 2002-11-26 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
Family Cites Families (402)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US599865A (en) | 1898-03-01 | Emanuel l | ||
US231024A (en) * | 1880-08-10 | Machine for lining sheets of straw-board | ||
US231117A (en) * | 1880-08-10 | Folding boat | ||
US542614A (en) * | 1895-07-09 | Office | ||
US3371136A (en) * | 1968-02-27 | United States Borax Chem | Detergent tablet forming machine | |
US582438A (en) * | 1897-05-11 | John scheidler | ||
US231062A (en) * | 1880-08-10 | Felt hat | ||
US231129A (en) * | 1880-08-10 | wiesebrook | ||
US231163A (en) * | 1880-08-17 | hamlin | ||
US966450A (en) * | 1909-06-18 | 1910-08-09 | John W S Jones | Couch or bed. |
US966509A (en) * | 1909-06-25 | 1910-08-09 | Charles A Wulf | Flushing-valve. |
US967414A (en) * | 1910-02-11 | 1910-08-16 | William W Hallam | Railway-rail. |
US966939A (en) * | 1910-05-02 | 1910-08-09 | James V Mitchell | Sash-lock. |
US996497A (en) * | 1911-03-30 | 1911-06-27 | Kokomo Sanitary Mfg Co | Tank-cover fastener. |
US1036647A (en) | 1911-06-19 | 1912-08-27 | St Louis Briquette Machine Company | Briquet-machine. |
US1437816A (en) | 1922-07-26 | 1922-12-05 | Howard S Paine | Process for preparing fondant or chocolate soft cream centers |
US1505827A (en) * | 1923-04-25 | 1924-08-19 | Villasenor Eduardo | Tablet-making machine |
US1900012A (en) * | 1925-09-04 | 1933-03-07 | Western Cartridge Co | Process of and apparatus for making wads |
US2307371A (en) | 1941-08-13 | 1943-01-05 | Ray O Vac Co | Molding process |
US2415997A (en) * | 1946-01-12 | 1947-02-18 | John W Eldred | Article handling apparatus |
US2823789A (en) * | 1952-05-06 | 1958-02-18 | Gilman Engineering & Mfg Corp | Parts feeder ribbon |
US2996431A (en) | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
GB759081A (en) | 1954-04-15 | 1956-10-10 | John Holroyd And Company Ltd | Improvements relating to machines for the production of coated tablets and the like |
US2849965A (en) | 1954-04-15 | 1958-09-02 | John Holroyd & Company Ltd | Machines for use in the production of coated tablets and the like |
US2966431A (en) | 1956-03-24 | 1960-12-27 | Basf Ag | Separation of filter material from carbon black |
US2946298A (en) | 1957-11-13 | 1960-07-26 | Arthur Colton Company | Compression coating tablet press |
US2931276A (en) * | 1958-02-10 | 1960-04-05 | Jagenberg Werke Ag | Methods of and means for producing, processing, and for treating articles |
GB866681A (en) | 1958-05-22 | 1961-04-26 | May & Baker Ltd | N-substituted piperidines |
GB888038A (en) * | 1959-12-16 | 1962-01-24 | William Warren Triggs C B E | Medicinal tablet |
GB936386A (en) | 1959-01-16 | 1963-09-11 | Wellcome Found | Pellets for supplying biologically active substances to ruminants |
US2963993A (en) | 1959-01-20 | 1960-12-13 | John Holroyd & Company Ltd | Machines for making coated tablets by compression |
US3096248A (en) | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
US3029752A (en) * | 1959-07-20 | 1962-04-17 | Stokes F J Corp | Tablet making machine |
GB972128A (en) * | 1960-01-21 | 1964-10-07 | Wellcome Found | Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets |
GB990784A (en) * | 1960-05-23 | 1965-05-05 | Dunlop Rubber Co | Improvements in or relating to balls |
GB994742A (en) * | 1960-09-09 | 1965-06-10 | Wellcome Found | Pharmaceutical tablets containing anthelmintics, and the manufacture thereof |
US3108046A (en) | 1960-11-25 | 1963-10-22 | Smith Kline French Lab | Method of preparing high dosage sustained release tablet and product of this method |
NL272604A (en) * | 1960-12-28 | |||
US3430535A (en) * | 1961-08-25 | 1969-03-04 | Independent Lock Co | Key cutter |
BE636865A (en) * | 1962-08-31 | |||
US3185626A (en) * | 1963-03-06 | 1965-05-25 | Sterling Drug Inc | Tablet coating method |
US3279995A (en) | 1963-05-31 | 1966-10-18 | Allen F Reid | Shaped pellets |
US3300063A (en) * | 1965-01-25 | 1967-01-24 | Mayer & Co Inc O | Vacuum gripping apparatus |
FR1603314A (en) * | 1965-02-23 | 1971-04-05 | Pharmaceutical tablets - having a core and a matrix material | |
US3328840A (en) * | 1965-04-23 | 1967-07-04 | Pentronix Inc | Powder compacting press |
US3279360A (en) | 1965-09-13 | 1966-10-18 | Miehle Goss Dexter Inc | Machine for printing on cylindrical articles |
US3330400A (en) | 1966-03-08 | 1967-07-11 | Miehle Goss Dexter Inc | Mechanism for transferring cylindrical articles |
GB1212535A (en) * | 1966-10-12 | 1970-11-18 | Shionogi & Co | Method and apparatus for producing molded article |
US3458968A (en) | 1966-11-16 | 1969-08-05 | Lester Gregory Jr | Dispensing and feed mechanism |
GB1144915A (en) | 1966-11-24 | 1969-03-12 | Armour Pharma | Improvements in or relating to pastille formulations |
US3656518A (en) * | 1967-03-27 | 1972-04-18 | Perry Ind Inc | Method and apparatus for measuring and dispensing predetermined equal amounts of powdered material |
US3563170A (en) * | 1968-04-16 | 1971-02-16 | Reynolds Metals Co | Machine for marking the exterior cylindrical surfaces of cans in a continous nonidexing manner |
US3605479A (en) | 1968-05-08 | 1971-09-20 | Textron Inc | Forming press |
US3584114A (en) | 1968-05-22 | 1971-06-08 | Hoffmann La Roche | Free-flowing powders |
NL6808619A (en) * | 1968-06-19 | 1969-12-23 | ||
FR1581088A (en) | 1968-07-17 | 1969-09-12 | ||
US3567043A (en) * | 1968-08-05 | 1971-03-02 | Sun Chemical Corp | Transfer assembly for use with container printing machines |
US3627583A (en) | 1969-04-29 | 1971-12-14 | Sucrest Corp | Direct compression vehicles |
US3640654A (en) * | 1970-06-25 | 1972-02-08 | Wolverine Pentronix | Die and punch assembly for compacting powder and method of assembly |
US3832252A (en) | 1970-09-29 | 1974-08-27 | T Higuchi | Method of making a drug-delivery device |
CH569482A5 (en) | 1970-12-23 | 1975-11-28 | Boehringer Sohn Ingelheim | |
US3811552A (en) * | 1971-01-11 | 1974-05-21 | Lilly Co Eli | Capsule inspection apparatus and method |
US3726622A (en) * | 1971-08-20 | 1973-04-10 | Wolverine Pentronix | Compacting apparatus |
DE2157465C3 (en) * | 1971-11-19 | 1975-04-24 | Werner & Pfleiderer, 7000 Stuttgart | Filling device for a hydraulic block press |
BE794951A (en) * | 1972-02-03 | 1973-05-29 | Parke Davis & Co | WATER SOLUBLE PACKAGING |
US3851751A (en) | 1972-04-26 | 1974-12-03 | Jones & Co Inc R A | Method and apparatus for forming, filling and sealing packages |
US3975888A (en) | 1972-04-26 | 1976-08-24 | R. A. Jones & Company, Inc. | Method and apparatus for forming, filling and sealing packages |
US3912441A (en) | 1972-12-13 | 1975-10-14 | Yasuo Shimada | Compressing roll in rotary power compression molding machine |
US3851638A (en) | 1973-02-02 | 1974-12-03 | Kam Act Enterprises Inc | Force multiplying type archery bow |
DE2309202A1 (en) * | 1973-02-21 | 1974-08-29 | Schering Ag | MEDICINAL FORMS WITH MICRO-ENCAPSULATED MEDICINAL ACTIVE |
US3832525A (en) * | 1973-03-26 | 1974-08-27 | Raymond Lee Organization Inc | Automatic heating device to prevent freezing of water supply lines |
US3884143A (en) * | 1973-09-04 | 1975-05-20 | Hartnett Co R W | Conveyor link for tablet printing apparatus |
DE2401419A1 (en) | 1974-01-12 | 1975-07-17 | Bosch Gmbh Robert | VEHICLE WITH A HYDROSTATIC AND MECHANICAL DRIVE |
US3891375A (en) | 1974-01-21 | 1975-06-24 | Vector Corp | Tablet press |
GB1497044A (en) * | 1974-03-07 | 1978-01-05 | Prodotti Antibiotici Spa | Salts of phenyl-alkanoic acids |
US3988403A (en) * | 1974-07-09 | 1976-10-26 | Union Carbide Corporation | Process for producing molded structural foam article having a surface that reproducibly and faithfully replicates the surface of the mold |
US4139589A (en) * | 1975-02-26 | 1979-02-13 | Monique Beringer | Process for the manufacture of a multi-zone tablet and tablet manufactured by this process |
US4230693A (en) | 1975-04-21 | 1980-10-28 | Armour-Dial, Inc. | Antacid tablets and processes for their preparation |
FR2312247A1 (en) * | 1975-05-30 | 1976-12-24 | Parcor | THIENO-PYRIDINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS |
US4097606A (en) | 1975-10-08 | 1978-06-27 | Bristol-Myers Company | APAP Tablet containing an alkali metal carboxymethylated starch and processes for manufacturing same |
SE414386B (en) | 1976-03-10 | 1980-07-28 | Aco Laekemedel Ab | VIEW TO PREPARE AND AT THE SAME PACKAGE PHARMACEUTICAL DOSAGE UNITS |
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US4218433A (en) * | 1977-03-03 | 1980-08-19 | Nippon Kayaku Kabushiki Kaisha | Constant-rate eluting tablet and method of producing same |
US4139627A (en) * | 1977-10-06 | 1979-02-13 | Beecham Inc. | Anesthetic lozenges |
DE2752971C2 (en) * | 1977-11-28 | 1982-08-19 | Lev Nikolaevič Moskva Koškin | Injection molding machine for the production of injection molded parts from thermoplastic materials |
GB2030042A (en) * | 1978-09-21 | 1980-04-02 | Beecham Group Ltd | Antacid fondant |
DE2849494A1 (en) | 1978-11-15 | 1980-05-29 | Voss Gunter M | METHOD FOR THE PRODUCTION OF MEDICINAL FORMS |
US4198390A (en) * | 1979-01-31 | 1980-04-15 | Rider Joseph A | Simethicone antacid tablet |
US4271142A (en) * | 1979-06-18 | 1981-06-02 | Life Savers, Inc. | Portable liquid antacids |
US4286497A (en) * | 1979-06-18 | 1981-09-01 | Shamah Alfred A | Ratchet-securable toggle retainer |
JPS5827162B2 (en) | 1979-08-24 | 1983-06-08 | 株式会社ヤクルト本社 | Constant speed transport mechanism |
NL7906689A (en) * | 1979-09-06 | 1981-03-10 | Dawsonville Corp Nv | TATTOO. |
DE2936040C2 (en) * | 1979-09-06 | 1982-05-19 | Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring | Coating process and means for carrying out the process, consisting essentially of sucrose, at least one other sugar and water |
US4271206A (en) | 1979-10-26 | 1981-06-02 | General Foods Corporation | Gasified candy having a predetermined shape |
US4273793A (en) * | 1979-10-26 | 1981-06-16 | General Foods Corporation | Apparatus and process for the preparation of gasified confectionaries by pressurized injection molding |
US4543370A (en) | 1979-11-29 | 1985-09-24 | Colorcon, Inc. | Dry edible film coating composition, method and coating form |
US4318746A (en) * | 1980-01-08 | 1982-03-09 | Ipco Corporation | Highly stable gel, its use and manufacture |
US4473526A (en) | 1980-01-23 | 1984-09-25 | Eugen Buhler | Method of manufacturing dry-pressed molded articles |
US4292017A (en) | 1980-07-09 | 1981-09-29 | Doepel Wallace A | Apparatus for compressing tablets |
US4362757A (en) | 1980-10-22 | 1982-12-07 | Amstar Corporation | Crystallized, readily water dispersible sugar product containing heat sensitive, acidic or high invert sugar substances |
FR2492661A1 (en) * | 1980-10-28 | 1982-04-30 | Laruelle Claude | NOVEL GALENIC FORM OF ADMINISTRATION OF METOCLOPRAMIDE, ITS PREPARATION METHOD AND MEDICINAL PRODUCT COMPRISING THIS NOVEL FORM |
US4683256A (en) * | 1980-11-06 | 1987-07-28 | Colorcon, Inc. | Dry edible film coating composition, method and coating form |
US4327076A (en) * | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US5002970A (en) * | 1981-07-31 | 1991-03-26 | Eby Iii George A | Flavor masked ionizable zinc compositions for oral absorption |
IE53102B1 (en) * | 1981-05-12 | 1988-06-22 | Ici Plc | Pharmaceutical spiro-succinimide derivatives |
US4372942A (en) * | 1981-08-13 | 1983-02-08 | Beecham Inc. | Candy base and liquid center hard candy made therefrom |
DE3144678A1 (en) | 1981-11-10 | 1983-05-19 | Eugen Dipl.-Ing. 8871 Burtenbach Bühler | METHOD AND DEVICE FOR THE PRODUCTION OF MOLDINGS FROM A GIANT CAPABILITY |
JPS58152813A (en) | 1982-03-08 | 1983-09-10 | Sumitomo Chem Co Ltd | Tablet having clear carved seal and its preparation |
US4449983A (en) * | 1982-03-22 | 1984-05-22 | Alza Corporation | Simultaneous delivery of two drugs from unit delivery device |
DK151608C (en) * | 1982-08-13 | 1988-06-20 | Benzon As Alfred | PROCEDURE FOR PREPARING A PHARMACEUTICAL PERORAL POLYDEPOT PREPARATION WITH CONTROLLED RELEASE |
US4517205A (en) * | 1983-01-03 | 1985-05-14 | Nabisco Brands, Inc. | Co-deposited two-component hard candy |
US4576604A (en) * | 1983-03-04 | 1986-03-18 | Alza Corporation | Osmotic system with instant drug availability |
US4882167A (en) * | 1983-05-31 | 1989-11-21 | Jang Choong Gook | Dry direct compression compositions for controlled release dosage forms |
US4533345A (en) * | 1983-06-14 | 1985-08-06 | Fertility & Genetics Associates | Uterine catheter |
FR2548675B1 (en) * | 1983-07-06 | 1987-01-09 | Seppic Sa | FILM-FORMING COMPOSITIONS FOR COATING SOLID FORMS OF PHARMACEUTICAL OR FOOD PRODUCTS AND PRODUCTS OBTAINED COATED WITH SUCH COMPOSITIONS |
US4749575A (en) | 1983-10-03 | 1988-06-07 | Bio-Dar Ltd. | Microencapsulated medicament in sweet matrix |
AU591171B2 (en) | 1983-11-02 | 1989-11-30 | Alza Corporation | Dispenser for delivering thermo-responsive composition |
US4781714A (en) * | 1983-11-02 | 1988-11-01 | Alza Corporation | Dispenser for delivering thermo-responsive composition |
NL194820C (en) | 1983-11-02 | 2003-04-03 | Alza Corp | Preparation for the release of a heat-reacting composition. |
DE3404108A1 (en) * | 1984-02-07 | 1985-08-14 | Kilian & Co GmbH, 5000 Köln | TABLET PRESS |
US4518335A (en) * | 1984-03-14 | 1985-05-21 | Allied Corporation | Dilatant mold and dilatant molding apparatus |
US4564525A (en) * | 1984-03-30 | 1986-01-14 | Mitchell Cheryl R | Confection products |
JPS60217106A (en) | 1984-04-12 | 1985-10-30 | 高橋 信之 | Inorganic-powder freezing molding method |
US4661521A (en) | 1984-04-30 | 1987-04-28 | Mallinckrodt, Inc. | Direct tableting acetaminophen compositions |
US4528335A (en) * | 1984-05-18 | 1985-07-09 | Phillips Petroleum Company | Polymer blends |
US4666212A (en) * | 1984-06-15 | 1987-05-19 | Crucible S.A. | Metal value recovery |
US4610884A (en) | 1984-06-29 | 1986-09-09 | The Procter & Gamble Company | Confectionery cremes |
US4643894A (en) * | 1984-07-24 | 1987-02-17 | Colorcon, Inc. | Maltodextrin coating |
US4828841A (en) * | 1984-07-24 | 1989-05-09 | Colorcon, Inc. | Maltodextrin coating |
US4894234A (en) * | 1984-10-05 | 1990-01-16 | Sharma Shri C | Novel drug delivery system for antiarrhythmics |
JPS61100519A (en) * | 1984-10-23 | 1986-05-19 | Shin Etsu Chem Co Ltd | Hard capsule for drug |
US4684534A (en) * | 1985-02-19 | 1987-08-04 | Dynagram Corporation Of America | Quick-liquifying, chewable tablet |
US4874614A (en) * | 1985-03-25 | 1989-10-17 | Abbott Laboratories | Pharmaceutical tableting method |
CA1234717A (en) * | 1985-06-28 | 1988-04-05 | Leslie F. Knebl | Moist chewing gum composition |
GB8517073D0 (en) | 1985-07-05 | 1985-08-14 | Hepworth Iron Co Ltd | Pipe pipe couplings &c |
DK8603837A (en) * | 1985-08-13 | 1987-02-14 | ||
US4665116A (en) | 1985-08-28 | 1987-05-12 | Turtle Wax, Inc. | Clear cleaner/polish composition |
US4663147A (en) * | 1985-09-03 | 1987-05-05 | International Minerals & Chemical Corp. | Disc-like sustained release formulation |
US5188840A (en) * | 1985-09-26 | 1993-02-23 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
US4898733A (en) * | 1985-11-04 | 1990-02-06 | International Minerals & Chemical Corp. | Layered, compression molded device for the sustained release of a beneficial agent |
US4853249A (en) | 1985-11-15 | 1989-08-01 | Taisho Pharmaceutical Co., Ltd. | Method of preparing sustained-release pharmaceutical/preparation |
US5229164A (en) * | 1985-12-19 | 1993-07-20 | Capsoid Pharma Gmbh | Process for producing individually dosed administration forms |
DE3601516A1 (en) * | 1986-01-20 | 1987-07-23 | Agie Ag Ind Elektronik | PHOTOELECTRIC BARRIER |
JPS62230600A (en) | 1986-03-31 | 1987-10-09 | 東洋ゴム工業株式会社 | Forklift with expansible fork |
DE3610878A1 (en) | 1986-04-01 | 1987-10-08 | Boehringer Ingelheim Kg | PELLET SHAPES |
US4873231A (en) | 1986-04-08 | 1989-10-10 | Smith Walton J | Decreasing the toxicity of an ibuprofen salt |
SE8601624D0 (en) * | 1986-04-11 | 1986-04-11 | Haessle Ab | NEW PHARMACEUTICAL PREPARATIONS |
US4857330A (en) * | 1986-04-17 | 1989-08-15 | Alza Corporation | Chlorpheniramine therapy |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
US4802924A (en) * | 1986-06-19 | 1989-02-07 | Colorcon, Inc. | Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products |
IE58401B1 (en) | 1986-06-20 | 1993-09-08 | Elan Corp Plc | Controlled absorption pharmaceutical composition |
US4757090A (en) * | 1986-07-14 | 1988-07-12 | Mallinckrodt, Inc. | Direct tableting acetaminophen compositions |
US4762719A (en) | 1986-08-07 | 1988-08-09 | Mark Forester | Powder filled cough product |
DE3629994A1 (en) | 1986-09-03 | 1988-03-17 | Weissenbacher Ernst Rainer Pro | Device for administration of medicaments in body cavities or on body surfaces |
US4803076A (en) * | 1986-09-04 | 1989-02-07 | Pfizer Inc. | Controlled release device for an active substance |
CA1290526C (en) | 1986-11-07 | 1991-10-15 | Marianne Wieser | Mold and die operation |
DE3640574A1 (en) | 1986-11-27 | 1988-06-09 | Katjes Fassin Gmbh & Co Kg | METHOD FOR PRODUCING AN EDIBLE PRALINE-SHAPED PRODUCT AND DEVICE FOR IMPLEMENTING THE METHOD |
US4828845A (en) * | 1986-12-16 | 1989-05-09 | Warner-Lambert Company | Xylitol coated comestible and method of preparation |
IT1201136B (en) | 1987-01-13 | 1989-01-27 | Resa Farma | TABLET FOR PHARMACEUTICAL USE SUITABLE FOR THE RELEASE OF SUBSTANCES OF ACTIVE SUBSTANCES |
US4801461A (en) * | 1987-01-28 | 1989-01-31 | Alza Corporation | Pseudoephedrine dosage form |
US4820524A (en) | 1987-02-20 | 1989-04-11 | Mcneilab, Inc. | Gelatin coated caplets and process for making same |
US5200193A (en) | 1987-04-22 | 1993-04-06 | Mcneilab, Inc. | Pharmaceutical sustained release matrix and process |
US4808413A (en) * | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
US4792448A (en) | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
US4813818A (en) * | 1987-08-25 | 1989-03-21 | Michael Sanzone | Apparatus and method for feeding powdered materials |
US4978483A (en) | 1987-09-28 | 1990-12-18 | Redding Bruce K | Apparatus and method for making microcapsules |
US4996061A (en) * | 1987-10-07 | 1991-02-26 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol-decongestant combination |
US4851226A (en) * | 1987-11-16 | 1989-07-25 | Mcneil Consumer Products Company | Chewable medicament tablet containing means for taste masking |
US4894236A (en) * | 1988-01-12 | 1990-01-16 | Choong-Gook Jang | Direct compression tablet binders for acetaminophen |
CA1330886C (en) | 1988-01-22 | 1994-07-26 | Bend Research Inc. | Osmotic system for delivery of dilute solutions |
CH676470A5 (en) * | 1988-02-03 | 1991-01-31 | Nestle Sa | |
US4929446A (en) * | 1988-04-19 | 1990-05-29 | American Cyanamid Company | Unit dosage form |
US5279660A (en) * | 1988-05-24 | 1994-01-18 | Berol Nobel Stenungsund Ab | Use of viscosity-adjusting agent to counteract viscosity decrease upon temperature increase of a water-based system |
US4999226A (en) * | 1988-06-01 | 1991-03-12 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination |
DE3822095A1 (en) | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | NEW MEDICAMENT FORMULATION AND METHOD FOR THE PRODUCTION THEREOF |
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
WO1990002546A1 (en) * | 1988-09-09 | 1990-03-22 | The Ronald T. Dodge Company | Pharmaceuticals microencapsulated by vapor deposited polymers and method |
US5194464A (en) * | 1988-09-27 | 1993-03-16 | Takeda Chemical Industries, Ltd. | Enteric film and preparatoin thereof |
JPH0816051B2 (en) | 1988-12-07 | 1996-02-21 | エスエス製薬株式会社 | Sustained release suppositories |
US4906478A (en) * | 1988-12-12 | 1990-03-06 | Valentine Enterprises, Inc. | Simethicone/calcium silicate composition |
US4984240A (en) * | 1988-12-22 | 1991-01-08 | Codex Corporation | Distributed switching architecture for communication module redundancy |
US5610214A (en) * | 1988-12-29 | 1997-03-11 | Deknatel Technology Corporation, Inc. | Method for increasing the rate of absorption of polycaprolactone |
US5030452A (en) * | 1989-01-12 | 1991-07-09 | Pfizer Inc. | Dispensing devices powered by lyotropic liquid crystals |
IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
US5032406A (en) * | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
US5006297A (en) * | 1989-02-22 | 1991-04-09 | Acushnet Company | Method of molding polyurethane covered golf balls |
US4956182A (en) | 1989-03-16 | 1990-09-11 | Bristol-Myers Company | Direct compression cholestyramine tablet and solvent-free coating therefor |
US4931286A (en) * | 1989-04-19 | 1990-06-05 | Aqualon Company | High gloss cellulose tablet coating |
NZ233403A (en) * | 1989-04-28 | 1992-09-25 | Mcneil Ppc Inc | Simulated capsule-like medicament |
US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
US4960169A (en) * | 1989-06-20 | 1990-10-02 | Modien Manufacturing Co. | Baffle for tubular heat exchanger header |
US4992277A (en) * | 1989-08-25 | 1991-02-12 | Schering Corporation | Immediate release diltiazem formulation |
EP0419410A3 (en) | 1989-09-19 | 1991-08-14 | Ciba-Geigy Ag | Alkanophenones |
US5146730A (en) * | 1989-09-20 | 1992-09-15 | Banner Gelatin Products Corp. | Film-enrobed unitary-core medicament and the like |
DK469989D0 (en) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | PHARMACEUTICAL PREPARATION |
US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
US5275822A (en) * | 1989-10-19 | 1994-01-04 | Valentine Enterprises, Inc. | Defoaming composition |
JPH03139496A (en) * | 1989-10-25 | 1991-06-13 | Sanshin Ind Co Ltd | Ship propulsion machinery |
US5169645A (en) | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
FR2655266B1 (en) * | 1989-12-05 | 1992-04-03 | Smith Kline French Lab | CIMETIDINE PHARMACEUTICAL COMPOSITIONS. |
US5223266A (en) * | 1990-01-24 | 1993-06-29 | Alza Corporation | Long-term delivery device with early startup |
US5100676A (en) * | 1990-02-02 | 1992-03-31 | Biosurface Technology, Inc. | Cool storage of cultured epithelial sheets |
US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
US4983394A (en) * | 1990-05-03 | 1991-01-08 | Warner-Lambert Company | Flavor enhancing and medicinal taste masking agent |
US4980169A (en) | 1990-05-03 | 1990-12-25 | Warner-Lambert Company | Flavor enhancing and increasing efficacy of cough drops |
US5213738A (en) * | 1990-05-15 | 1993-05-25 | L. Perrigo Company | Method for making a capsule-shaped tablet |
US5089270A (en) * | 1990-05-15 | 1992-02-18 | L. Perrigo Company | Capsule-shaped tablet |
US5075114A (en) | 1990-05-23 | 1991-12-24 | Mcneil-Ppc, Inc. | Taste masking and sustained release coatings for pharmaceuticals |
US5464631A (en) | 1990-06-27 | 1995-11-07 | Warner-Lambert Company | Encapsulated dosage forms |
US5133892A (en) * | 1990-10-17 | 1992-07-28 | Lever Brothers Company, Division Of Conopco, Inc. | Machine dishwashing detergent tablets |
US5503673A (en) * | 1990-11-05 | 1996-04-02 | Mcneil-Ppc, Inc | Apparatus for dip coating product |
US5228916A (en) | 1990-11-05 | 1993-07-20 | Mcneil-Ppc, Inc. | Apparatus for creating a gelatin coating |
US5436026A (en) * | 1990-11-05 | 1995-07-25 | Mcneil-Ppc, Inc. | Discharge and transfer system for apparatus for gelatin coating tablets |
US5538125A (en) * | 1990-11-05 | 1996-07-23 | Mcneil-Ppc, Inc. | Indexing and feeding systems for apparatus for gelatin coating tablets |
US5683719A (en) | 1990-11-22 | 1997-11-04 | British Technology Group Limited | Controlled release compositions |
US5098715A (en) * | 1990-12-20 | 1992-03-24 | Burroughs Wellcome Co. | Flavored film-coated tablet |
US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
DE4101873C2 (en) * | 1991-01-23 | 1993-12-09 | Isis Pharma Gmbh | Orally administrable drug form for the treatment of central dopamine deficiency states |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
NZ241613A (en) * | 1991-02-27 | 1993-06-25 | Janssen Pharmaceutica Nv | Highlighting intagliations in tablets |
CA2061520C (en) * | 1991-03-27 | 2003-04-22 | Lawrence J. Daher | Delivery system for enhanced onset and increased potency |
US5286497A (en) * | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
CA2068402C (en) * | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
YU48263B (en) | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | PROCEDURE FOR OBTAINING PANTOPRAZOLE PHARMACEUTICAL PRODUCT |
US5252338A (en) * | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
US5314696A (en) * | 1991-06-27 | 1994-05-24 | Paulos Manley A | Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor |
US5190927A (en) * | 1991-07-09 | 1993-03-02 | Merck & Co., Inc. | High-glyceryl, low-acetyl gellan gum for non-brittle gels |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
US5200191A (en) * | 1991-09-11 | 1993-04-06 | Banner Gelatin Products Corp. | Softgel manufacturing process |
US5405617A (en) | 1991-11-07 | 1995-04-11 | Mcneil-Ppc, Inc. | Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals |
US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5200195A (en) * | 1991-12-06 | 1993-04-06 | Alza Corporation | Process for improving dosage form delivery kinetics |
DK171536B1 (en) | 1991-12-06 | 1996-12-23 | Rasmussen Kann Ind As | Window with frame of extruded profile items |
US5200194A (en) * | 1991-12-18 | 1993-04-06 | Alza Corporation | Oral osmotic device |
GB2284760B (en) | 1993-11-23 | 1998-06-24 | Euro Celtique Sa | A method of preparing pharmaceutical compositions by melt pelletisation |
AU674840B2 (en) * | 1992-01-17 | 1997-01-16 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on cellulosic polymers and lactose |
US5427614A (en) * | 1992-02-14 | 1995-06-27 | Warner-Lambert Company | Starch based formulations |
US5656296A (en) * | 1992-04-29 | 1997-08-12 | Warner-Lambert Company | Dual control sustained release drug delivery systems and methods for preparing same |
GR1002332B (en) | 1992-05-21 | 1996-05-16 | Mcneil-Ppc Inc. | Novel simethicone containing pharmaceutical compositions. |
EP0572731A1 (en) | 1992-06-01 | 1993-12-08 | The Procter & Gamble Company | Chewable preparation containing a decongestant |
US5317849A (en) * | 1992-08-07 | 1994-06-07 | Sauter Manufacturing Corporation | Encapsulation equipment and method |
IT1255522B (en) | 1992-09-24 | 1995-11-09 | Ubaldo Conte | COMPRESSED FOR THERAPEUTIC USE SUITABLE FOR SELLING ONE OR MORE ACTIVE SUBSTANCES WITH DIFFERENT SPEEDS |
JPH07507564A (en) | 1992-09-30 | 1995-08-24 | ファイザー・インク. | Articles containing a core and a coating of variable thickness |
AU5681294A (en) * | 1992-11-30 | 1994-06-22 | Kv Pharmaceutical Company | Tastemasked pharmaceutical materials |
US5375963A (en) | 1993-01-19 | 1994-12-27 | Wohlwend; Clayton E. | Multipurpose lifting apparatus |
TW272942B (en) * | 1993-02-10 | 1996-03-21 | Takeda Pharm Industry Co Ltd | |
US5391378A (en) | 1993-02-22 | 1995-02-21 | Elizabeth-Hata International, Inc. | Two-part medicinal tablet and method of manufacture |
JP2524955B2 (en) | 1993-04-22 | 1996-08-14 | トーワ株式会社 | Method and apparatus for resin sealing molding of electronic parts |
DE69425453T2 (en) * | 1993-04-23 | 2001-04-12 | Novartis Ag | Drug delivery device with controlled release |
NZ260408A (en) | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
US5415868A (en) * | 1993-06-09 | 1995-05-16 | L. Perrigo Company | Caplets with gelatin cover and process for making same |
JP3054989B2 (en) * | 1993-06-19 | 2000-06-19 | 八幡 貞男 | Insulated expression container |
IT1264855B1 (en) * | 1993-06-21 | 1996-10-17 | Zambon Spa | PHARMACEUTICAL COMPOSITIONS CONTAINING S (+) - 2- (4-ISOBUTYLPHENYL) PROPIONIC ACID SALTS WITH BASIC AMINO ACIDS |
ZA944949B (en) | 1993-07-12 | 1995-04-05 | Smithkline Beecham Corp | Matrix-entrapped beadlet preparation |
EP0716597A1 (en) * | 1993-08-30 | 1996-06-19 | Warner-Lambert Company | Tablet coating based on a melt-spun mixture of a saccharide and apolymer |
US5622719A (en) | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5518551A (en) * | 1993-09-10 | 1996-05-21 | Fuisz Technologies Ltd. | Spheroidal crystal sugar and method of making |
US5397574A (en) * | 1993-10-04 | 1995-03-14 | Andrx Pharmaceuticals, Inc. | Controlled release potassium dosage form |
US5433951A (en) * | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
DE4341442C2 (en) * | 1993-12-04 | 1998-11-05 | Lohmann Therapie Syst Lts | Device for the controlled release of active substances and their use |
US6060639A (en) * | 1994-03-04 | 2000-05-09 | Mentor Corporation | Testicular prosthesis and method of manufacturing and filling |
US5453920A (en) * | 1994-03-08 | 1995-09-26 | Eubanks; William W. | Trouble light having a shroud with see-through opening |
US5559110A (en) | 1994-03-09 | 1996-09-24 | The Dupont Merck Pharmaceutical Company | Pharmaceutical formulations of cyclic urea type compounds |
JPH07281423A (en) * | 1994-04-07 | 1995-10-27 | Konica Corp | Plate making method of printing plate |
US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
US6020002A (en) * | 1994-06-14 | 2000-02-01 | Fuisz Technologies Ltd. | Delivery of controlled-release system(s) |
SE9402431D0 (en) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
DE69535889D1 (en) | 1994-07-08 | 2009-01-02 | Astrazeneca Ab | Tableted dosage form composed of many individual units |
US5788979A (en) * | 1994-07-22 | 1998-08-04 | Inflow Dynamics Inc. | Biodegradable coating with inhibitory properties for application to biocompatible materials |
IT1274034B (en) | 1994-07-26 | 1997-07-14 | Applied Pharma Res | PHARMACEUTICAL COMPOSITIONS BASED ON RUBBER TO BE CHEWED AND PROCEDURE FOR THEIR PREPARATION |
US5849327A (en) | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
EP0773866B1 (en) * | 1994-08-03 | 1998-04-08 | Gunter Meinhardt Voss | Method or producing coated tablets |
DE9414065U1 (en) * | 1994-08-31 | 1994-11-03 | Roehm Gmbh | Thermoplastic plastic for pharmaceutical casings soluble in intestinal juice |
DE4431653C2 (en) * | 1994-09-06 | 2000-01-20 | Lohmann Therapie Syst Lts | Coated tablet for the controlled release of active substances, a process for their preparation and their use |
US5733575A (en) * | 1994-10-07 | 1998-03-31 | Bpsi Holdings, Inc. | Enteric film coating compositions, method of coating therewith, and coated forms |
CA2134611C (en) * | 1994-10-28 | 2002-12-24 | Richard John Yarwood | Process for preparing solid pharmaceutical dosage forms |
US5593696A (en) * | 1994-11-21 | 1997-01-14 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
US5756123A (en) * | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
US5626896A (en) * | 1994-12-09 | 1997-05-06 | A.E. Staley Manufacturing Co. | Method for making liquid-centered jelly candies |
US5582838A (en) * | 1994-12-22 | 1996-12-10 | Merck & Co., Inc. | Controlled release drug suspension delivery device |
DE4446468A1 (en) * | 1994-12-23 | 1996-06-27 | Basf Ag | Process for the production of coated tablets |
US6471994B1 (en) * | 1995-01-09 | 2002-10-29 | Edward Mendell Co., Inc. | Pharmaceutical excipient having improved compressibility |
ES2094694B1 (en) * | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | NEW PHARMACEUTICALLY STABLE FORMULATION OF A COMPOUND OF BENZMIDAZOLE AND ITS PROCESS OF OBTAINING. |
EP0726216B1 (en) * | 1995-02-07 | 1998-09-09 | Hermann Kronseder | Transporting star wheel for vessels |
SE9500478D0 (en) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
US5827874A (en) | 1995-05-05 | 1998-10-27 | Meyer; Hans | Methods of treating pain and inflammation with proline |
JPH11507292A (en) | 1995-05-09 | 1999-06-29 | カラーコン リミテッド | Electrostatic painting |
DE59601245D1 (en) * | 1995-05-13 | 1999-03-18 | Hermann Kronseder | Transport star for vessels |
US5627971A (en) * | 1995-06-01 | 1997-05-06 | Northern Telecom Limited | Machine method for determining the eligibility of links in a network |
US5578336A (en) * | 1995-06-07 | 1996-11-26 | Monte; Woodrow C. | Confection carrier for vitamins, enzymes, phytochemicals and ailmentary vegetable compositions and method of making |
AU718160B2 (en) * | 1995-06-09 | 2000-04-06 | R.P. Scherer Corporation | Soft gelatin capsules containing particulate material |
US5614207A (en) * | 1995-06-30 | 1997-03-25 | Mcneil-Ppc, Inc. | Dry mouth lozenge |
GB9517031D0 (en) | 1995-08-19 | 1995-10-25 | Procter & Gamble | Confection compositions |
JP3463266B2 (en) * | 1995-09-21 | 2003-11-05 | ファーマ パス エルエルシー | Novel composition containing acid-labile omeparazole and method for producing the same |
AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
DE19539361A1 (en) | 1995-10-23 | 1997-04-24 | Basf Ag | Process for the preparation of multilayer, solid pharmaceutical forms for oral or rectal administration |
IT1279673B1 (en) * | 1995-11-07 | 1997-12-16 | Acma Spa | EQUIPMENT AND METHOD FOR THE FORMATION OF ORDERED GROUPS OF PRODUCTS TO BE FOOD BY STEP. |
US5733578A (en) * | 1995-11-15 | 1998-03-31 | Edward Mendell Co., Inc. | Directly compressible high load acetaminophen formulations |
US5807579A (en) * | 1995-11-16 | 1998-09-15 | F.H. Faulding & Co. Limited | Pseudoephedrine combination pharmaceutical compositions |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
SE9600071D0 (en) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
SE9600070D0 (en) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
US5879728A (en) * | 1996-01-29 | 1999-03-09 | Warner-Lambert Company | Chewable confectionary composition and method of preparing same |
IT1282576B1 (en) * | 1996-02-06 | 1998-03-31 | Jagotec Ag | PHARMACEUTICAL TABLET SUITABLE TO GIVE THE ACTIVE SUBSTANCE IN SUBSEQUENT AND PREDETERMINABLE TIMES |
US6245351B1 (en) * | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
US5711691A (en) * | 1996-05-13 | 1998-01-27 | Air Packaging Technologies, Inc. | Self-closing and self-sealing valve device for use with inflatable structures |
US5827535A (en) | 1996-06-21 | 1998-10-27 | Banner Pharmacaps, Inc. | Graphically impressed softgel and method for making same |
US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US5824338A (en) * | 1996-08-19 | 1998-10-20 | L. Perrigo Company | Caplet and gelatin covering therefor |
US5916881A (en) * | 1996-10-07 | 1999-06-29 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | High trehalose content syrup |
US5807580A (en) | 1996-10-30 | 1998-09-15 | Mcneil-Ppc, Inc. | Film coated tablet compositions having enhanced disintegration characteristics |
US6077539A (en) | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
GB9624110D0 (en) * | 1996-11-20 | 1997-01-08 | Molins Plc | Transferring rod like articles |
US5830801A (en) * | 1997-01-02 | 1998-11-03 | Motorola, Inc. | Resistless methods of gate formation in MOS devices |
DE19710213A1 (en) | 1997-03-12 | 1998-09-17 | Basf Ag | Process for the manufacture of solid combination dosage forms |
US6210710B1 (en) * | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
US5837301A (en) | 1997-04-28 | 1998-11-17 | Husky Injection Molding Systems Ltd. | Injection molding machine having a high speed turret |
US6149939A (en) * | 1997-05-09 | 2000-11-21 | Strumor; Mathew A. | Healthful dissolvable oral tablets, and mini-bars |
KR20010012402A (en) * | 1997-05-09 | 2001-02-15 | 세이지 파마슈티칼스, 인크. | Stable oral pharmaceutical dosage forms |
WO1999000122A1 (en) * | 1997-06-25 | 1999-01-07 | Ipr-Institute For Pharmaceutical Research Ag | Method for reducing body weight |
US6517866B1 (en) * | 1997-07-01 | 2003-02-11 | Pfizer Inc. | Sertraline salts and sustained-release dosage forms of sertraline |
DE59812488D1 (en) | 1997-07-09 | 2005-02-17 | Swiss Caps Rechte & Lizenzen | METHOD AND DEVICE FOR PRODUCING A MULTILAYER, PHYSIOLOGICALLY COMPATIBLE PHARMACEUTICAL FORM |
US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
US5942034A (en) * | 1997-07-24 | 1999-08-24 | Bayer Corporation | Apparatus for the gelatin coating of medicaments |
DE19733505A1 (en) * | 1997-08-01 | 1999-02-04 | Knoll Ag | Fast acting analgesic |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6602522B1 (en) | 1997-11-14 | 2003-08-05 | Andrx Pharmaceuticals L.L.C. | Pharmaceutical formulation for acid-labile compounds |
US6174548B1 (en) * | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6022554A (en) * | 1997-12-15 | 2000-02-08 | American Home Products Corporation | Polymeric microporous film coated subcutaneous implant |
KR100775154B1 (en) | 1997-12-19 | 2007-11-12 | 스미스클라인 비참 코포레이션 | Process for Manufacturing Bite-Dispersion Tablets |
US6432442B1 (en) | 1998-02-23 | 2002-08-13 | Mcneil-Ppc, Inc. | Chewable product |
US6110500A (en) | 1998-03-25 | 2000-08-29 | Temple University | Coated tablet with long term parabolic and zero-order release kinetics |
US6372254B1 (en) * | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
US6394094B1 (en) * | 1998-05-01 | 2002-05-28 | Enhance Pharmaceuticals, Inc. | Method for injection molding manufacture of controlled release devices |
US6365183B1 (en) | 1998-05-07 | 2002-04-02 | Alza Corporation | Method of fabricating a banded prolonged release active agent dosage form |
US6544554B1 (en) | 1998-05-15 | 2003-04-08 | Chugai Seiyaku Kabushiki Kaisha | Regulated release preparations |
UA69413C2 (en) * | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Enteric coated pharmaceutical composition, pharmaceutical composition in form of spheroid beads, method for manufacturing pharmaceutical composition |
JP2002516848A (en) | 1998-06-03 | 2002-06-11 | アルザ・コーポレーション | Method and apparatus for providing long-term medication |
US6106267A (en) * | 1998-06-05 | 2000-08-22 | Aylward; John T. | Apparatus for forming a compression-molded product |
US6099865A (en) * | 1998-07-08 | 2000-08-08 | Fmc Corporation | Croscarmellose taste masking |
US6103257A (en) * | 1998-07-17 | 2000-08-15 | Num-Pop, Inc. | System for delivering pharmaceuticals to the buccal mucosa |
UA73092C2 (en) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Tablets with enteric coating and method for their manufacture |
FR2781152B1 (en) * | 1998-07-20 | 2001-07-06 | Permatec Tech Ag | USE OF ACRYLIC-TYPE POLYMER AS A DISAGGREGING AGENT |
DE19834180A1 (en) * | 1998-07-29 | 2000-02-03 | Benckiser Nv | Composition for use in a dishwasher |
US6200590B1 (en) | 1998-08-10 | 2001-03-13 | Naphcare, Inc. | Controlled, phased-release suppository and its method of production |
DE19840256A1 (en) * | 1998-09-03 | 2000-03-09 | Basf Ag | Widely applicable, continuous method for preparing coated solid dosage forms, comprises extruding mixture of drug and thermoplastic binder then applying coating composition in liquid or vapor form |
US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
US6174547B1 (en) * | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
US6602521B1 (en) | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
US6322819B1 (en) * | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
JP3449253B2 (en) * | 1998-10-29 | 2003-09-22 | シオノギクオリカプス株式会社 | Manufacturing method of hard capsule |
US6165512A (en) | 1998-10-30 | 2000-12-26 | Fuisz Technologies Ltd. | Dosage forms containing taste masked active agents |
SE9803772D0 (en) | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
US6270805B1 (en) | 1998-11-06 | 2001-08-07 | Andrx Pharmaceuticals, Inc. | Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate |
US6183681B1 (en) * | 1998-12-07 | 2001-02-06 | Centurion International, Inc. | Multi-stage insert molding method |
EP1029892B1 (en) | 1999-02-10 | 2002-06-05 | Dr. Suwelack Skin & Health Care AG | Freeze-dried product containing beta-1,3-glucan from Euglena, its preparation and use |
US6274162B1 (en) | 2000-01-14 | 2001-08-14 | Bpsi Holdings, Inc. | Elegant film coating system |
US6248361B1 (en) * | 1999-02-26 | 2001-06-19 | Integ, Ltd. | Water-soluble folic acid compositions |
DE19913692A1 (en) * | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanically stable pharmaceutical dosage forms containing liquid or semi-solid surface-active substances |
US6090401A (en) * | 1999-03-31 | 2000-07-18 | Mcneil-Ppc, Inc. | Stable foam composition |
US6248760B1 (en) * | 1999-04-14 | 2001-06-19 | Paul C Wilhelmsen | Tablet giving rapid release of nicotine for transmucosal administration |
JP3716901B2 (en) * | 1999-04-14 | 2005-11-16 | シオノギクオリカプス株式会社 | Cellulose ether film |
DE19925710C2 (en) | 1999-06-07 | 2002-10-10 | Byk Gulden Lomberg Chem Fab | New preparation and dosage form containing an acid labile proton pump inhibitor |
US6375963B1 (en) | 1999-06-16 | 2002-04-23 | Michael A. Repka | Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof |
US6555139B2 (en) * | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
US20020102309A1 (en) * | 1999-09-14 | 2002-08-01 | Jane C. I. Hirsh | Controlled release formulation for administration of an anti-inflammatory naphthalene derivative |
DE19954420A1 (en) | 1999-11-12 | 2001-05-31 | Lohmann Therapie Syst Lts | Preparation consisting of a film, foil or wafer-like dosage form with a two-layer structure and integrated labeling |
DE19960494A1 (en) * | 1999-12-15 | 2001-06-21 | Knoll Ag | Device and method for producing solid active substance-containing forms |
CA2395231C (en) * | 1999-12-23 | 2006-08-15 | Pfizer Products Inc. | Hydrogel-driven layered drug dosage form |
DE19963569B4 (en) * | 1999-12-29 | 2006-11-16 | Reckitt Benckiser N.V. | Composition for use in a dishwasher |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
FR2807034B1 (en) | 2000-03-29 | 2002-06-14 | Roquette Freres | MANNITOL POWDER AND PROCESS FOR PRODUCING THE SAME |
US6372252B1 (en) * | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
GB2362350A (en) | 2000-05-11 | 2001-11-21 | Reckitt Benekiser N V | Process and press for the production of tablets |
US20030086972A1 (en) | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
US6727200B2 (en) * | 2000-08-31 | 2004-04-27 | Mra Laboratories, Inc. | High dielectric constant very low fired X7R ceramic capacitor, and powder for making |
US20020064550A1 (en) | 2000-09-07 | 2002-05-30 | Akpharma, Inc. | Edible candy compositions and methods of using same |
GB0027471D0 (en) * | 2000-11-08 | 2000-12-27 | Smithkline Beecham Plc | Processes |
WO2002066015A1 (en) | 2001-02-16 | 2002-08-29 | Bristol-Myers Squibb Pharma Company | Use of polyalkylamine polymers in controlled release devices |
US20030070584A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
HUP0401941A3 (en) | 2001-07-16 | 2008-04-28 | Astrazeneca Ab | Pharmaceutical formulation comprising a proton pomp inhibitor and antacids and process for its preparation |
US6558722B2 (en) * | 2001-07-18 | 2003-05-06 | Wm. Wrigley Jr. Company | Use of powdered gum in making a coating for a confection |
GB0120835D0 (en) | 2001-08-28 | 2001-10-17 | Smithkline Beecham Plc | Process |
US20030059466A1 (en) * | 2001-09-14 | 2003-03-27 | Pawan Seth | Delayed release tablet of venlafaxin |
US7122143B2 (en) * | 2001-09-28 | 2006-10-17 | Mcneil-Ppc, Inc. | Methods for manufacturing dosage forms |
US6767200B2 (en) * | 2001-09-28 | 2004-07-27 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
US6742646B2 (en) * | 2001-09-28 | 2004-06-01 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
EP1438028A1 (en) | 2001-09-28 | 2004-07-21 | McNEIL-PPC, INC. | Modified release dosage forms |
US7323192B2 (en) * | 2001-09-28 | 2008-01-29 | Mcneil-Ppc, Inc. | Immediate release tablet |
US6837696B2 (en) * | 2001-09-28 | 2005-01-04 | Mcneil-Ppc, Inc. | Apparatus for manufacturing dosage forms |
US20030066068A1 (en) * | 2001-09-28 | 2003-04-03 | Koninklijke Philips Electronics N.V. | Individual recommender database using profiles of others |
US6982094B2 (en) * | 2001-09-28 | 2006-01-03 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
US20040006111A1 (en) | 2002-01-25 | 2004-01-08 | Kenneth Widder | Transmucosal delivery of proton pump inhibitors |
DK1578350T3 (en) | 2002-03-26 | 2009-08-10 | Euro Celtique Sa | Composition with gel coating with depot effect |
EP1764655A3 (en) | 2002-06-11 | 2007-09-19 | ASML Netherlands B.V. | Lithographic apparatus and device manufacturing method |
TW578439B (en) * | 2002-10-25 | 2004-03-01 | Ritdisplay Corp | Organic light emitting diode and material applied in the organic light emitting diode |
US20050008695A1 (en) * | 2003-05-21 | 2005-01-13 | Control Delivery Systems, Inc. | Compositions and methods for delivering a biologically active agent |
US20050074514A1 (en) * | 2003-10-02 | 2005-04-07 | Anderson Oliver B. | Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms |
ES2409347T3 (en) | 2004-10-21 | 2013-06-26 | Aptalis Pharmatech, Inc. | Pharmaceutical compositions of masked flavor with gastro-soluble porogenic agents |
-
2002
- 2002-09-28 EP EP02799682A patent/EP1438028A1/en not_active Withdrawn
- 2002-09-28 ES ES02783988T patent/ES2295427T3/en not_active Expired - Lifetime
- 2002-09-28 PL PL02369134A patent/PL369134A1/en not_active Application Discontinuation
- 2002-09-28 CA CA002461870A patent/CA2461870A1/en not_active Abandoned
- 2002-09-28 BR BR0213593-0A patent/BR0213593A/en not_active Application Discontinuation
- 2002-09-28 MX MXPA04002891A patent/MXPA04002891A/en active IP Right Grant
- 2002-09-28 MX MXPA04002977A patent/MXPA04002977A/en unknown
- 2002-09-28 CA CA2461354A patent/CA2461354C/en not_active Expired - Fee Related
- 2002-09-28 AT AT02799685T patent/ATE476957T1/en not_active IP Right Cessation
- 2002-09-28 WO PCT/US2002/031062 patent/WO2003026626A2/en active IP Right Grant
- 2002-09-28 BR BR0212950-7A patent/BR0212950A/en not_active Application Discontinuation
- 2002-09-28 DE DE60223269T patent/DE60223269T2/en not_active Expired - Lifetime
- 2002-09-28 NZ NZ532097A patent/NZ532097A/en unknown
- 2002-09-28 BR BR0213591-4A patent/BR0213591A/en not_active IP Right Cessation
- 2002-09-28 CA CA002461616A patent/CA2461616A1/en not_active Abandoned
- 2002-09-28 KR KR10-2004-7004663A patent/KR20040045034A/en not_active Application Discontinuation
- 2002-09-28 KR KR10-2004-7004664A patent/KR20040037208A/en not_active Application Discontinuation
- 2002-09-28 CN CNA028233549A patent/CN1592612A/en active Pending
- 2002-09-28 JP JP2003530266A patent/JP2005535558A/en active Pending
- 2002-09-28 US US10/476,529 patent/US20050019407A1/en not_active Abandoned
- 2002-09-28 EP EP02799691A patent/EP1432404A1/en not_active Withdrawn
- 2002-09-28 BR BR0206062-0A patent/BR0206062A/en not_active IP Right Cessation
- 2002-09-28 MX MXPA04002973A patent/MXPA04002973A/en not_active Application Discontinuation
- 2002-09-28 WO PCT/US2002/031115 patent/WO2003026614A1/en active Application Filing
- 2002-09-28 JP JP2003530261A patent/JP2005529059A/en active Pending
- 2002-09-28 EP EP02773665A patent/EP1429737A1/en not_active Withdrawn
- 2002-09-28 KR KR10-2004-7004656A patent/KR20040045030A/en not_active Application Discontinuation
- 2002-09-28 DE DE60239945T patent/DE60239945D1/en not_active Expired - Lifetime
- 2002-09-28 KR KR10-2004-7004658A patent/KR20040045031A/en not_active Application Discontinuation
- 2002-09-28 EP EP02799685A patent/EP1438018B1/en not_active Expired - Lifetime
- 2002-09-28 KR KR10-2004-7004648A patent/KR20040045026A/en not_active Application Discontinuation
- 2002-09-28 AT AT02783988T patent/ATE376826T1/en not_active IP Right Cessation
- 2002-09-28 CN CNA028233611A patent/CN1638740A/en active Pending
- 2002-09-28 EP EP02766426.7A patent/EP1429724B1/en not_active Expired - Lifetime
- 2002-09-28 CA CA002446760A patent/CA2446760A1/en not_active Abandoned
- 2002-09-28 AU AU2002330164A patent/AU2002330164A1/en not_active Abandoned
- 2002-09-28 US US10/476,504 patent/US20040213848A1/en not_active Abandoned
- 2002-09-28 EP EP02799689A patent/EP1438030A2/en not_active Withdrawn
- 2002-09-28 JP JP2003530264A patent/JP2005508329A/en active Pending
- 2002-09-28 AT AT02799684T patent/ATE404179T1/en not_active IP Right Cessation
- 2002-09-28 WO PCT/US2002/031129 patent/WO2003026630A1/en not_active Application Discontinuation
- 2002-09-28 EP EP02766427A patent/EP1429742B1/en not_active Expired - Lifetime
- 2002-09-28 BR BR0212951-5A patent/BR0212951A/en not_active Application Discontinuation
- 2002-09-28 CN CNA028233441A patent/CN1592611A/en active Pending
- 2002-09-28 EP EP02782085A patent/EP1429745A2/en not_active Withdrawn
- 2002-09-28 BR BR0206086-8A patent/BR0206086A/en not_active Application Discontinuation
- 2002-09-28 MX MXPA04002976A patent/MXPA04002976A/en not_active Application Discontinuation
- 2002-09-28 WO PCT/US2002/031066 patent/WO2003026612A2/en active Application Filing
- 2002-09-28 BR BR0212921-3A patent/BR0212921A/en not_active Application Discontinuation
- 2002-09-28 CA CA002446759A patent/CA2446759A1/en not_active Abandoned
- 2002-09-28 WO PCT/US2002/031164 patent/WO2003026616A1/en active Application Filing
- 2002-09-28 CA CA002447984A patent/CA2447984A1/en not_active Abandoned
- 2002-09-28 BR BR0213588-4A patent/BR0213588A/en not_active Application Discontinuation
- 2002-09-28 US US10/432,488 patent/US20040062804A1/en not_active Abandoned
- 2002-09-28 EP EP02799684A patent/EP1429746B1/en not_active Expired - Lifetime
- 2002-09-28 CA CA002461653A patent/CA2461653A1/en not_active Abandoned
- 2002-09-28 DE DE60228281T patent/DE60228281D1/en not_active Expired - Lifetime
- 2002-09-28 MX MXPA04002884A patent/MXPA04002884A/en not_active Application Discontinuation
- 2002-09-28 WO PCT/US2002/031024 patent/WO2003026625A1/en active IP Right Grant
- 2002-09-28 MX MXPA04002980A patent/MXPA04002980A/en unknown
- 2002-09-28 BR BR0213589-2A patent/BR0213589A/en active Search and Examination
- 2002-09-28 KR KR10-2004-7004659A patent/KR20040045032A/en not_active Application Discontinuation
- 2002-09-28 CN CNB028233727A patent/CN100364515C/en not_active Expired - Fee Related
- 2002-09-28 JP JP2003530249A patent/JP2005508325A/en active Pending
- 2002-09-28 CN CNA028233476A patent/CN1592610A/en active Pending
- 2002-09-28 WO PCT/US2002/031163 patent/WO2003026627A1/en active Application Filing
- 2002-09-28 MX MXPA04002992A patent/MXPA04002992A/en unknown
- 2002-09-28 EP EP20020799690 patent/EP1463489A1/en not_active Withdrawn
- 2002-09-28 BR BR0212946-9A patent/BR0212946A/en not_active Application Discontinuation
- 2002-09-28 KR KR10-2004-7004655A patent/KR20040037206A/en not_active Application Discontinuation
- 2002-09-28 CN CNA028235401A patent/CN1596102A/en active Pending
- 2002-09-28 MX MXPA04002978A patent/MXPA04002978A/en unknown
- 2002-09-28 KR KR10-2004-7004642A patent/KR20040037203A/en not_active Application Discontinuation
- 2002-09-28 DE DE60237294T patent/DE60237294D1/en not_active Expired - Lifetime
- 2002-09-28 WO PCT/US2002/031063 patent/WO2003026628A2/en active Application Filing
- 2002-09-28 CA CA002461865A patent/CA2461865A1/en not_active Abandoned
- 2002-09-28 JP JP2003530263A patent/JP2005508328A/en active Pending
- 2002-09-28 EP EP02783988A patent/EP1429738B1/en not_active Expired - Lifetime
- 2002-09-28 JP JP2003530262A patent/JP2005508327A/en active Pending
- 2002-09-28 CA CA002461684A patent/CA2461684A1/en not_active Abandoned
- 2002-09-28 CA CA2461659A patent/CA2461659C/en not_active Expired - Fee Related
- 2002-09-28 WO PCT/US2002/031067 patent/WO2003026613A1/en not_active Application Discontinuation
- 2002-09-28 JP JP2003530253A patent/JP2005509605A/en active Pending
- 2002-09-28 NZ NZ532568A patent/NZ532568A/en unknown
- 2002-09-28 ES ES02799684T patent/ES2311073T3/en not_active Expired - Lifetime
- 2002-09-28 CA CA002461656A patent/CA2461656A1/en not_active Abandoned
- 2002-09-28 CN CNA028236416A patent/CN1596104A/en active Pending
- 2002-09-28 CN CNA028236505A patent/CN1596101A/en active Pending
- 2002-09-28 MX MXPA04002975A patent/MXPA04002975A/en unknown
- 2002-09-28 CN CNB028234308A patent/CN100408029C/en not_active Expired - Fee Related
- 2002-09-28 MX MXPA04002974A patent/MXPA04002974A/en active IP Right Grant
- 2002-09-28 US US10/476,530 patent/US8545887B2/en not_active Expired - Fee Related
- 2002-09-28 KR KR10-2004-7004552A patent/KR20040066094A/en not_active Application Discontinuation
- 2002-09-28 ES ES02766426.7T patent/ES2444549T3/en not_active Expired - Lifetime
- 2002-09-28 CN CNA028236386A patent/CN1596100A/en active Pending
- 2002-09-28 PT PT02783988T patent/PT1429738E/en unknown
- 2002-09-28 JP JP2003530252A patent/JP2005508326A/en active Pending
- 2002-09-28 EP EP02773676A patent/EP1429743A1/en not_active Withdrawn
- 2002-09-28 WO PCT/US2002/031022 patent/WO2003026624A1/en not_active Application Discontinuation
- 2002-09-28 WO PCT/US2002/031117 patent/WO2003026629A2/en active Application Filing
- 2002-09-28 US US10/484,485 patent/US20040241208A1/en not_active Abandoned
- 2002-09-28 US US10/476,238 patent/US20040241236A1/en not_active Abandoned
- 2002-09-28 NZ NZ532096A patent/NZ532096A/en unknown
- 2002-09-28 HU HU0401686A patent/HUP0401686A3/en unknown
- 2002-09-28 MX MXPA04002981A patent/MXPA04002981A/en unknown
- 2002-09-28 CA CA002461682A patent/CA2461682A1/en not_active Abandoned
- 2002-09-28 JP JP2003530251A patent/JP2005509604A/en active Pending
- 2002-09-28 BR BR0206061-2A patent/BR0206061A/en not_active Application Discontinuation
- 2002-09-28 KR KR10-2004-7004657A patent/KR20040037207A/en not_active Application Discontinuation
- 2002-09-28 JP JP2003530265A patent/JP2005508330A/en active Pending
- 2002-09-28 US US10/476,514 patent/US20040170750A1/en not_active Abandoned
- 2002-09-28 MX MXPA04002979A patent/MXPA04002979A/en unknown
- 2002-09-28 WO PCT/US2002/031116 patent/WO2003026615A2/en active Application Filing
- 2002-09-28 KR KR10-2004-7004662A patent/KR20040045033A/en not_active Application Discontinuation
- 2002-09-28 JP JP2003530267A patent/JP2005511515A/en active Pending
- 2002-09-28 US US10/477,334 patent/US7968120B2/en not_active Expired - Fee Related
- 2002-09-28 AT AT02766427T patent/ATE507823T1/en not_active IP Right Cessation
-
2003
- 2003-03-21 US US10/393,610 patent/US20030219484A1/en not_active Abandoned
- 2003-03-21 US US10/393,638 patent/US20030232082A1/en not_active Abandoned
- 2003-03-21 US US10/393,752 patent/US7635490B2/en not_active Expired - Fee Related
- 2003-03-21 US US10/393,765 patent/US20040018327A1/en not_active Abandoned
- 2003-03-21 US US10/393,871 patent/US7416738B2/en not_active Expired - Fee Related
- 2003-05-26 NO NO20032363A patent/NO20032363L/en not_active Application Discontinuation
- 2003-05-26 NO NO20032362A patent/NO20032362L/en not_active Application Discontinuation
- 2003-05-26 NO NO20032364A patent/NO20032364L/en not_active Application Discontinuation
-
2004
- 2004-04-20 NO NO20041613A patent/NO20041613L/en not_active Application Discontinuation
- 2004-04-28 CO CO04038884A patent/CO5570655A2/en unknown
-
2005
- 2005-07-04 HK HK05105590A patent/HK1072902A1/en not_active IP Right Cessation
-
2008
- 2008-03-17 US US12/049,628 patent/US20080305150A1/en not_active Abandoned
-
2009
- 2009-02-24 US US12/391,475 patent/US7972624B2/en not_active Expired - Fee Related
Patent Citations (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
US3133132A (en) * | 1960-11-29 | 1964-05-12 | Univ California | High flow porous membranes for separating water from saline solutions |
US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
US3546142A (en) * | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3604417A (en) * | 1970-03-31 | 1971-09-14 | Wayne Henry Linkenheimer | Osmotic fluid reservoir for osmotically activated long-term continuous injector device |
US3995631A (en) * | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US3760804A (en) * | 1971-01-13 | 1973-09-25 | Alza Corp | Improved osmotic dispenser employing magnesium sulphate and magnesium chloride |
US3855770A (en) * | 1971-12-09 | 1974-12-24 | Howorth Air Conditioning Ltd | Machines acting on continuously running textile yarns |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4160020A (en) * | 1975-11-24 | 1979-07-03 | Alza Corporation | Therapeutic device for osmotically dosing at controlled rate |
US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
US4304232A (en) * | 1979-03-14 | 1981-12-08 | Alza Corporation | Unit system having multiplicity of means for dispensing useful agent |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4340054A (en) * | 1980-12-29 | 1982-07-20 | Alza Corporation | Dispenser for delivering fluids and solids |
US4627971A (en) * | 1985-04-22 | 1986-12-09 | Alza Corporation | Osmotic device with self-sealing passageway |
US4871549A (en) * | 1985-07-19 | 1989-10-03 | Fujisawa Pharmaceutical Co., Ltd. | Time-controlled explosion systems and processes for preparing the same |
US4960416A (en) * | 1986-04-30 | 1990-10-02 | Alza Corporation | Dosage form with improved delivery capability |
US5200196A (en) * | 1986-05-09 | 1993-04-06 | Alza Corporation | Improvement in pulsed drug therapy |
US4816262A (en) * | 1986-08-28 | 1989-03-28 | Universite De Montreal | Controlled release tablet |
US5209746A (en) * | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5221278A (en) * | 1992-03-12 | 1993-06-22 | Alza Corporation | Osmotically driven delivery device with expandable orifice for pulsatile delivery effect |
US5508040A (en) * | 1992-05-04 | 1996-04-16 | Andrx Pharmaceuticals, Inc. | Multiparticulate pulsatile drug delivery system |
US5458887A (en) * | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5830502A (en) * | 1994-10-28 | 1998-11-03 | Alza Corporation | Injection-molded dosage form |
US5736159A (en) * | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
US5558879A (en) * | 1995-04-28 | 1996-09-24 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
US5654005A (en) * | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
US5861173A (en) * | 1995-11-28 | 1999-01-19 | Bayer Aktiengesellschaft | Long-lasting release nifedipine preparation |
US6110499A (en) * | 1997-07-24 | 2000-08-29 | Alza Corporation | Phenytoin therapy |
US6210712B1 (en) * | 1997-12-05 | 2001-04-03 | Alza Corporation | Dosage form having first and second coats |
US6485748B1 (en) * | 1997-12-12 | 2002-11-26 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
US6365185B1 (en) * | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
US20020051807A1 (en) * | 2000-01-13 | 2002-05-02 | Joaquina Faour | Osmotic device containing alprazolam and an antipsychotic agent |
US20020028240A1 (en) * | 2000-04-17 | 2002-03-07 | Toyohiro Sawada | Timed-release compression-coated solid composition for oral administration |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7972624B2 (en) | 2001-09-28 | 2011-07-05 | Shun-Por Li | Method of manufacturing modified release dosage forms |
US8545887B2 (en) | 2001-09-28 | 2013-10-01 | Mcneil-Ppc, Inc. | Modified release dosage forms |
US7968120B2 (en) | 2001-09-28 | 2011-06-28 | Mcneil-Ppc, Inc. | Modified release dosage forms |
US9144548B2 (en) | 2003-08-12 | 2015-09-29 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
US8062672B2 (en) * | 2003-08-12 | 2011-11-22 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
US20050196448A1 (en) * | 2004-03-05 | 2005-09-08 | Hai Yong Huang | Polymeric compositions and dosage forms comprising the same |
US20080206337A1 (en) * | 2004-03-05 | 2008-08-28 | Hai Yong Huang | Method of making dosage forms comprising polymeric compositions |
US20050196447A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20050196442A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20050196446A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
US20080299199A1 (en) * | 2004-05-11 | 2008-12-04 | Egalet A/S | Swellable Dosage Form Comprising Gellan Gum |
US8383155B2 (en) | 2004-05-11 | 2013-02-26 | Egalet A/S | Swellable dosage form comprising gellan gum |
US8383154B2 (en) * | 2004-05-11 | 2013-02-26 | Egalet A/S | Swellable dosage form comprising gellan gum |
US20060233882A1 (en) * | 2005-04-15 | 2006-10-19 | Sowden Harry S | Osmotic dosage form |
US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US20070184111A1 (en) * | 2006-02-03 | 2007-08-09 | Pharmavite Llc | Hybrid tablet |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8388983B2 (en) * | 2009-05-12 | 2013-03-05 | Bpsi Holdings, Llc | Film coatings containing fine particle size detackifiers and substrates coated therewith |
US20100291159A1 (en) * | 2009-05-12 | 2010-11-18 | Bpsi Holdings, Llc. | Film coatings containing fine particle size detackifiers and substrates coated therewith |
US20120258171A1 (en) * | 2009-10-30 | 2012-10-11 | Ratiopharm Gmbh | Composition comprising fesoterodine and fiber |
US10391199B2 (en) | 2010-02-05 | 2019-08-27 | Allergan, Inc. | Porous materials, methods of making and uses |
US10624997B2 (en) * | 2010-02-05 | 2020-04-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
US20160151542A1 (en) * | 2010-02-05 | 2016-06-02 | Allergan, Inc. | Porogen compositions, methods of making and uses |
US11202853B2 (en) * | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
WO2011161666A3 (en) * | 2010-06-21 | 2012-03-29 | White Innovation Ltd. | Enclosed liquid capsules |
WO2011161666A2 (en) * | 2010-06-21 | 2011-12-29 | White Innovation Ltd. | Enclosed liquid capsules |
US9629392B2 (en) | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9474303B2 (en) | 2011-09-22 | 2016-10-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US20130074855A1 (en) * | 2011-09-22 | 2013-03-28 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9901113B2 (en) | 2011-09-22 | 2018-02-27 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US10617143B2 (en) | 2011-09-22 | 2020-04-14 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9084439B2 (en) * | 2011-09-22 | 2015-07-21 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US10952461B2 (en) | 2011-09-22 | 2021-03-23 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US11129898B2 (en) | 2011-09-22 | 2021-09-28 | Modoral Brands Inc. | Nicotine-containing pharmaceutical composition |
US11533944B2 (en) | 2011-09-22 | 2022-12-27 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
WO2013149056A1 (en) * | 2012-03-30 | 2013-10-03 | Elwha Llc | Device, system, and method for delivery of sugar glass stabilized compositions |
US9375033B2 (en) | 2014-02-14 | 2016-06-28 | R.J. Reynolds Tobacco Company | Tobacco-containing gel composition |
US11000471B2 (en) * | 2018-03-05 | 2021-05-11 | Kashiv Specialty Pharmaceuticals, Llc | Programmable pharmaceutical compositions for chrono drug release |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030232082A1 (en) | Modified release dosage forms | |
EP1545452A1 (en) | Modified release dosage forms | |
US20030228368A1 (en) | Edible solid composition and dosage form | |
CA2663871C (en) | Multi-core solid dosage form comprising a transparent coating between said cores | |
US20080206337A1 (en) | Method of making dosage forms comprising polymeric compositions | |
CA2500311A1 (en) | Modified release dosage forms | |
US20050196446A1 (en) | Polymeric compositions and dosage forms comprising the same | |
US20050196447A1 (en) | Polymeric compositions and dosage forms comprising the same | |
US20050196442A1 (en) | Polymeric compositions and dosage forms comprising the same | |
US20060233882A1 (en) | Osmotic dosage form | |
CA2556922C (en) | Polymeric compositions and dosage forms comprising the same | |
CA2612989A1 (en) | Osmotic dosage form | |
AU2002337772A1 (en) | Modified release dosage forms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MCNEIL-PPC, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, SHUN-POR;LEE, DER-YANG;MCNALLY, GERARD P.;AND OTHERS;REEL/FRAME:014360/0140;SIGNING DATES FROM 20030731 TO 20030804 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |